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Summary 
N. meningitidis is a Gram negative, human specific pathogen which is one of the leading 
causes of bacterial meningitis worldwide. Despite the severity of the disease the current 
available vaccines do not provide complete protection against infection therefore 
prompting research into other proteins which have potential as vaccine targets.  A variety 
of possible virulence factors have been found for this pathogen including IgA1 protease 
which has been attributed with immune evasion and causing severe inflammation. It has 
also been noted that natural antibodies to IgA1P persist in the body for five years or longer 
post infection or carriage of N. meningitidis. All of these factors suggest a role in virulence 
determination and the potential for the use of IgA1P and its co-secreted peptides as 
potential vaccine targets. This report outlines how the α and c-γ-α proteins, which are co-
secreted alongside neisserial IgA1P, underwent several trials in order to elucidate 
structural data and cross-linking experiments which have determined a potential binding 
partner in the circulation system.  Further the potential of α as a vaccine carrier protein 
has been evaluated, showing that it boosts immune response to other proteins when 
inoculated alongside them. In parallel with this work neisserial IgA1P protein has 
undergone multiple mutagenesis reactions creating inactive and easier to purify versions 
of the protein which can be used in future structural and functional trials. 
1. Introduction 
1.1 Meningitis overview 
Meningitis is a life threatening disease affecting between 1/100000 and 1/1000000 people 
worldwide with significantly higher incidences in developing countries, in particular the sub-
Saharan Africa “meningitis belt” 1 . Upon infection patients present with inflammation of the 
meninges which surround the brain and the spinal cord, at a later stage septicaemia can also 
develop. The inflammation of the meninges causes pressure to be exerted on the brain which 
can lead to a number of symptoms including vomiting, purpuric rash and septicaemia. 
Ultimately this pressure on the brain and septicaemia, if left untreated is fatal 1 . Despite the 
fact that meningitis can be treated simply if caught early it still is associated with around a 
10% mortality rate in developed countries, this mortality rate rises significantly in those 
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patients who develop septicaemia or in less developed countries 2 . Patients who survive 
meningitis infection are often left with a number of permanent after effects such as 
deafness, brain damage or the loss of limbs due to prolonged pressure on the brain or 
septicaemia 3 . These effects often leave patients needing ongoing support post-infection 
which can decrease their quality of life and burden the healthcare system. As a result work 
into developing a protective vaccine for meningitis, specifically bacterial meningitis as will be 
explained later, is ongoing.   
1.2 Meningitis causes 
Meningitis can be brought about by a number of disease states such as fungal infection, 
cancer, viral infection or bacterial infection 4 . Generally however, meningitis in developed 
countries is associated most commonly with viral or bacterial infection (Figure 1.) 4 , 5 . 
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Figure 1. A breakdown of the number of reported cases of meningitis in the UK between 
2013-2014. This graph shows the relative prevalence of different causes of meningitis, 
highlighting how viral and bacterial meningitis are the leading causes of infectious meningitis 
in the UK 5 . 
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Across all of these causes meningitis incidence peaks in children below 1 year old and in 
adults between 15-39 years old (Figure 2.) 5,6 . The main reasons for these peaks is that 
children under 1 tend to have weaker, developing immune systems, whilst people between 
15-39 tend to live in more close knit communities with more social contact 7–11 . This 
increased social contact leads to easier transmission of meningitis causing pathogens and 
thus a higher carriage and infection rate, as will be discussed in more detail later. 
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Figure 2. A breakdown of the number of cases on meningitis by age group. The graph shows 
a clear two peak incidence trend at the ages of 0-1 and 15-39 5 . 
 
Bacterial meningitis in the UK and other developed countries is most commonly caused by 
infection of meningococcal bacteria such as Neisseria meningitidis, Haemophilus influenza, 
Myobacterium tuberculosis and Streptococcus pnuemoniae (Figure 3.) 5 .  
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Figure 3. A breakdown of the causes of bacterial meningitis cases. The main causes of 
meningitis in the UK and the developed world are pneumococcal, Neisserial and 
streptococcal pathogens 5 .  
 
Although over the last few decades the infection and associated mortality rate of 
meningococcal disease has been falling there are still some major challenges to be overcome, 
particularly with regards to meningitis caused by Neisseria meningitidis. 
1.3 Neisseria meningitidis  
N. meningitidis is the second or third leading cause of meningococcal disease in the UK 5  and 
has been associated worldwide with both meningitis epidemics 12,13  and some of the most 
invasive strains of menigococci. N. meningitidis is a Gram negative pathogenic bacteria which 
is part of the Neisseriae genus 1,14 , this genus also includes N. lactamica and N. gonorrhoeae 
which both exclusively colonise humans. N. meningitidis has been shown to exclusively 
colonise the nasopharynx of humans 15–17  in a similar way to N. lactamica. In order for 
infectious disease to occur N. meningitidis must be able to spread from the hosts 
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nasopharynx into the circulatory system allowing for systemic infection to occur, the 
virulence factors associated with this switch from commensal to invasive will be discussed in 
detail later. The systemic infection of the pathogen leads to the onset of septicaemia and the 
inflammation of the meninges classically associated with meningococcal disease 9,14 . Despite 
N. meningitidis’ association with infectious disease it is most commonly found as a 
commensal bacteria which is carried asymptomatically by between 10-25% of the population 
at a time 1,7,14 .  Carriage rates have been show to exceed this figure in groups living in close 
communities such as students, military recruits and young children, in these groups carriage 
can rise as high as 50% 8,9,11 . As a result of these increased carriage rates in young adults and 
the weak immune systems of young children, meningococcal disease shows two clear 
incidence peaks in children under 1 and people between the ages of 15-24 (Fig 4) 5 . 
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Figure 4. Meningococcal meningitis has two clear incidence between the ages of 0-4 and 15-
24 and a lesser peak at 70-79 5 . This is thought to be due to the weakened immune systems 
of infants and the elderly and increased social contact at ages 15-24. 
 
N. meningitidis is not one homogenous species and is instead further subdivided into 12 
separate serogroups 14,18 . These are distinguished from one another by differences in the 
capsular polysaccharide structure, with mortality rate of the infection often varying by 
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serogroup. Serogroups A, B, C, Y and W-135 have been shown to account for most of the life 
threatening outbreaks of neisserial meningitis worldwide 14,18 . Generally serogroup B and C 
are the most common cause of life threatening neisserial meningitis in the UK (Fig 5.) and 
other developed countries, whilst serogroup A is accountable for the epidemic 
meningococcal disease found in the African meningitis belt (Fig 6.) 12,13 . 
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Figure 5. Neisserial meningitis is most often caused by serogroup B Neisseria meningitidis 
strains in the UK and the developed world 5 . This incidence changes drastically globally, for 
instance serogroup A is the most prevalent disease causing serogroup in sub-Saharan Africa 
12 .  
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Figure 6. The global epidemiology of invasive meningococcal disease, this figure shows how 
the major disease causing serogroup of Neisseria meningitidis varied globally. Generally 
more developed countries have more prevalent invasive disease outbreaks from serogroup 
B isolates, whilst less developed countries have more outbreaks caused by serogroup A 
isolates. (Figure taken from  13 ) 
 
N. meningitidis is becoming a growing target for vaccine development due to its high 
incidence in young children coupled with its high mortality rate and associated long term 
after effects.  
1.4 Vaccines 
Invasive meningococcal disease is now routinely treated with β lactam antibiotics such as 
third generation cephalosporin 1 , however there is now a growing arsenal of meningococcal 
vaccines aimed at providing protection against most major serogroups 11,13,19–22 . The aim of 
these vaccines is to prevent invasive disease from ever occurring and therefore lowering 
invasive disease rates and the morbidity rates associated with invasive meningococcal 
disease. 
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Vaccines were first famously invented by Edward Jenner in 1798 as a method of preventing 
the spread of smallpox using the related cow pox virus. Since then vaccine development has 
rapidly expanded and given rise to three major subclasses of vaccine. These are vaccines 
containing live attenuated bacteria, such as in the BCG vaccine, vaccines containing purified 
bacterial matter or vaccines containing carrier proteins conjugated to polysaccharides126. 
Lately this search for vaccine targets has been aided by the use of reverse vaccinology. 
Reverse vaccinology was coined in 2000 by Rappuoli127 after whole genome sequence 
allowed the mining of sequences for surface displayed antigens which could be potential 
targets for vaccine development. Reverse vaccinology allows a user to mine a data sequence 
for proteins of interest using computer algorithms, this identifies DNA fragments which 
encode proteins (ORFs) and excludes those which have homology to known cytoplasmic 
proteins. These ORFs are then screened for features typical of surface displayed proteins126. 
Another version of this reverse vaccinology approach highlights any potential proteins which 
show homology to known or putative virulence factors128. These selected regions are then 
cloned and subjected to high-throughput expression before being tested for immunogenicity 
in a mouse model. In order to test the immunogenicity, the serum from the mice is used in a 
western blot against the whole bacterium and the protein of interest, this confirms the 
specificity and immunogenicity of the protein. This is then further tested in a series of ELISAs 
and flow cytometry experiments using whole live bacteria126. More recently the first 
commercially available vaccine developed through reverse vaccinology was meningitis B 
vaccine129. 
Most modern vaccines against meningitis serogroup B have made use of outer membrane 
vesicle (OMV) technology. Initially these vaccines were used in strain specific cases using wild 
type non-recombinant OMVs giving monovalent coverage, for example in the Cuban 
meningitis B vaccine125. Modern vaccine development has made use of two different 
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methods of OMV generation and purification. Spontaneous OMVs (S-OMVs) can be purified 
from culture supernatant, this gives rise to natural OMVs containing most lipoproteins 
associated with the membrane but high levels of LPS inclusion. Detergent extracted OMVs 
(D-OMVs) are formed by treating cells with detergent, this reduces the LPS load of the OMVs 
and therefore lowers unwanted immunogenic responses but can also lower the level of other 
important lipoproteins which are less tightly associated with the OM130.  
As mentioned above most modern vaccines targeting Neisseria meningitidis are based on 
outer membrane proteins, these can then be conjugated to a carrier protein such a tetanus 
toxoid 2 . The carrier protein is a non-toxic protein which increases the immune response 
elicited by the vaccine by providing T cell helper epitopes 2,23 . These T cell helper epitopes 
are recognised by specific T cells causing proliferation and differentiation of B cells 24,25 . T cell 
helper epitopes are short amino acid sequences consisting of 7-10 amino acids which are 
able to bind to histocompatibility complex proteins found on the surface of T cells 24,25 . The 
binding of these carrier proteins cause a change in the immune response to the capsular 
proteins in the vaccine from a B cell dependent response to a T cell dependent response. 
This is achieved by activating CD4+ T helper cells which are required for memory B cell 
formation, therefore this T helper cell activation allows a long lasting immune system 
memory to be formed against the vaccine 24,25 . This increases the overall effectiveness of the 
vaccine in both children and adults whilst simultaneously increasing the length of the time 
for which the vaccine provides protection from meningococcal disease. 
Vaccines currently on the market tend to be multi-valent polysaccharide vaccines which are 
either specific, bivalent or tetravalent in order to confer immunity to multiple serogroups 
26,27 . The vaccines provide meningococcal protection in two main ways; by directly protecting 
the vaccinated individual and also by providing a “herd” immunity protection 2,21,26 , 28 . The 
“herd” immunity effect is due to the fact that in populations with some vaccinated 
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individuals the overall carriage rate of the pathogen are lower, this therefore lowers the risk 
of colonisation and disease in non-vaccinated individuals 28 . As seen previously in Figure 5, 
N. meningitidis serogroup B is currently the leading cause of meningococcal disease in the 
UK and the western world, however there is currently only 1 vaccine (Bexsero, 
GlaxoSmithKline) that has a protective effect against serogroup B meningococcal disease 
19,20,26,29,30 . This vaccine is a very recent development and so its protective effects are as yet 
unknown, however it has been estimated that it will be protective against around 78-88% of 
serogroup B N. meningitidis strains found in Europe and the UK 31,32 . The main problem with 
developing a protective serogroup B vaccine has been that the capsular proteins in serogroup 
B strains mimic NCAM (neural cell adhesion molecule) 14 . This prevents the vaccine from 
eliciting a strong immune response, therefore rendering the vaccine useless or at best very 
weakly protective. As a result, the Bexsero (4CMenB) vaccine contains 3 proteins which have 
been found to be crucial for N. meningitidis serogroup Bs survival and invasive pathogenesis. 
The 3  remaining proteins are factor H binding protein (fHbp), neisserial adhesin A (NadA) 
and Neisseria heparin binding antigen (NHBA) these 3 proteins are also combined with outer 
membrane vesicles derived from the NZ98/254 strain of MenB which contain porin A (PorA) 
20,33 . Porin A has been shown to exhibit high sequence variability therefore, In order to 
account for this vaccines must include a large variety of PorA subtypes in order to gain 
sufficient strain coverage125. As a result in Bexsero many types of outer membrane vesicles 
have been included, such as OMVs derived from NZ98/254 are included as they were 
previously used in a local vaccine which was shown to have a strong protective effect against 
certain MenB strains involved in a meningitis outbreak in New Zealand 33 . 
Despite the release of Bexsero there is still room for  further Men B vaccine development 
and improvement due to the ability of Neisseria meningitidis to undergo capsule switching 
via horizontal gene transfer 18 . This phenomenon allows bacteria within the same genotype 
to express different capsules therefore rendering vaccines based upon capsular proteins less 
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effective. This has led to the frequent use of tetravalent vaccines which target the 4 
serogroups most commonly associated with invasive meningococcal disease, therefore 
limiting the effect of capsule switching.  However it has been observed that invasive 
serogroup Y and C bacteria were able to acquire a serogroup B capsule via horizontal 
transfer, thus making them more difficult to target with a vaccine 18 . This raises the possibility 
of hyperinvasive strains developing a resistance to vaccines by switching to capsule types 
that are not covered by currently available vaccines. As such a new target for global 
meningitis vaccine development is required, the new targets will likely be ubiquitous 
virulence factors expressed by the pathogen rather than capsular proteins. 
1.5 Virulence factors 
The virulence of N. meningitidis has been attributed to a broad range of factors such as: 
capsule type, adhesins, pili, iron acquisition proteins and IgA1P production however, none of 
these factors alone have proven to be sufficient for invasive disease 1,34–36 . It therefore seems 
reasonable that a variety of these factors must interplay in order to allow the bacteria to 
switch from commensal to an invasive disease causing strain, although interplay between 
these factors has not been well studied and is not well understood.  
As previously mentioned N. meningitidis is split into 12 serogroups based upon the capsular 
structure 18,37 . These capsules are distinguished from one another by differences in the 
polysaccharide structure, with serogroup B, C, Y and W-135 all having a capsule formed from 
sialic acid linked to neuraminic acid 37 . In comparison Serogroup A has a capsule formed from 
N-acetyl mannosamine-1-phosphate 37. The use of sialic acid in the capsules of serogroup B, 
C, Y and W-135 mediates the hosts immune response to the bacteria as sialic acid is 
commonly found on human cell surfaces. The most notable mimicry is that of the serogroup 
B capsule which contains the same sialic acid-neuraminic acid polymer as is found in the 
human neural cell adhesion molecule18,37. As mentioned earlier this lowers its 
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immunogenicity greatly, therefore allowing it to evade clearance by the immune system to 
a much greater degree than other serogroups. As previously mentioned N. meningitidis is 
also capable of capsule witching via horizontal gene transfer, further aiding the pathogens 
ability to evade the immune system.  
The neisserial capsules not only help to lower the immunogenicity of the bacteria they also 
help to prevent the desiccation of the bacteria and thus increase the survival rate of the 
bacteria when compared with acapsular strains 38 . Capsules achieve this protection by 
protecting the encapsulated bacteria from environmental factors, allowing it to survive for 
several days ex vivo 38 . The protection from desiccation can most clearly be highlighted by 
comparing the transmission of encapsulated N. meningitidis to the acapsular N. 
gonorrhoeae. Both of these pathogens are obligate human pathogens in the same family 
however, N. meningitidis can be transferred from person to person relatively easily via close 
contact with respiratory secretions (eg. Sneezing) or saliva whereas, N. gonorrhoeae requires 
intimate contact for transmission 14 . These differences in the ease of transmission are 
primarily due to the lack of a capsule in N. gonorrhoeae and therefore its susceptibility to 
drying out and becoming non-viable. The protection from environmental factors provided by 
the capsule also increases the invasive capacity and survival rates of the N. meningitidis 
strains, with acapsular strains tending to be less invasive and having poor survival rates. One 
of the main causes for increased invasive capacity in invasive strains is that the capsule often 
contains other virulence factors such as pili or adhesins 39 .  
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Figure 7. The major surface antigens of N. meningitidis. N. meningitidis has a number of 
major surface antigens which contribute towards its ability to colonise the human 
nasopharynx and cause invasive disease. Factors such as the pili and adhesins allow the 
bacteria to adhere to the epithelial cells of the nasopharynx, whilst factors such as the iron 
uptake proteins and the capsule increase its survivability within a hostile environment. 
The adhesion of N. meningitidis to host epithelial cells in the nasopharynx has been shown 
to be a vital part of colonisation and as a result is sternly linked to virulence and invasive 
disease progression. The adhesion of N. meningitidis to epithelial cells is mediated by a 
number of factors such as pili, NadA, Opa and Opc Fig 7., as such most of these can be classed 
as essential for bacterial survival and in some cases as potential virulence factors. 
Opa and Opc are a pair of related membrane proteins both expressed by Neisseria 
meningitidis which are composed of 8 and 10 transmembrane domains respectively which 
form a β barrel with 4 surface exposed loops 40,41 . 
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Figure 8. The crystal structure of OPCa from Neisseria meningitidis 42 . This structure 
highlights the classic β barrel shape formed from 8 transmembrane anti-parallel β sheets. 
(Structure downloaded from EMBL-EBI PDB entry no. 1K24 and modified in PyMOL) 
 
The Opa proteins expressed by Neisseriae are around 28 kDa and are crucial to the adherence 
of bacteria to epithelial cells, as well as the invasion of host cells40,41. As a result of their 
function they are thought to play a vital role in determining the virulence of the pathogen 
due to their ability to promote colonisation of the mucosal membranes of the nasopharynx 
as well as facilitating invasion of host cells in order to gain access to required nutrients such 
as iron 41 . This invasion of host cells may also allow the bacteria to traverse the mucosal 
membrane and invade the circulatory system giving rise to systemic disease 43 . Opa proteins 
are also capable of very rapid genetic mutation due to a conserved repeat which allows 
recombination between related Opa proteins from other neisserial strains via horizontal 
gene transfer 44 . This genetic and protein mutation leads to surface antigenic variation which 
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helps to protect the pathogen from host immune responses, as well as allowing neisserial 
species to acquire Opa genes which may increase the pathogens virulence 45 . 
Opa and Opc both recognise and bind to cell surface receptor proteins found on host 
epithelial cells. Opa recognises members of the CEACAM protein family 44  which are found 
on epithelial cells as well as some immune system cells, such as neutrophils and T and B 
lymphocytes, whilst Opc recognises HSPGs 43 . The ability to bind either of these families of 
proteins therefore mediates adherence to host epithelial cells, allowing bacterial 
colonisation and the adherence that is crucial for invasive disease progression. The binding 
of CEACAMs by Opa and causes the Neisseria to be engulfed and allows access to the sub-
epithelial spaces through polarised epithelia whereas, the binding of HSPGs allows uptake of 
the bacteria into non-polarised epithelia 46,47 . This reaction helps to prevent clearing of the 
pathogen from the mucosal membranes via agglutination by IgA or any sweeping 
mechanisms by causing it to adhere strongly to cell surfaces or allowing it to colonise sub-
epithelial layers that are not prone to these sorts of clearing methods. 
Binding to CEACAMs is also notable as CEACAMs are upregulated by inflammatory cytokines 
such as interferon ɣ which is released during bacterial colonisation and infection 48 . This 
response can increase the density of CEACAMs on the mucosal cell surface by between two 
and six fold, therefore facilitating adherence and invasion of Opa expressing meningococcal 
strains 48 .  
The binding of Opa to CEACAMs has also been shown to inhibit the activation and 
proliferation of CD4+ T lymphocytes 49 . During infection N. meningitidis have been shown to 
produce outer membrane vesicles (OMVs) or “blebs”, these OMVs often contain Opa 
proteins which retain their binding capacity for the CEACAMs found on immune cells or 
epithelial cells 49 . It has therefore been speculated that Opa in OMVs could bind CEACAM1 
proteins found on CD4+ T lymphocytes and inhibit their action by activating the tyrosine 
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phosphatases SHP-1 and SHP-2 which prevent kinase dependent activation signals from 
being triggered 49 . This inhibition of T lymphocytes could then create an immunosuppressed 
zone around the site of infection allowing immune system evasion and further colonisation 
of the epithelial cells to take place 49 . Interestingly in contrast to this neutrophils have been 
shown to express cell surface CEACAM 1, 3 and 6 to which Opa positive Neisseria have been 
shown to bind. This allows the neutrophils to use the CEACAMs as a method of binding and 
phogocytosing the bacteria, preventing further colonisation 50,51 . In particular binding of 
CEACAM 3 on neutrophils by Opa causes phagocytosis and stimulation of the oxidative burst 
response used to kill invading pathogens 44 , 50 . One interesting thing to note is that Opa 
containing OMVs may activate the neutrophils and subvert their effects from the bacteria, 
therefore mitigating this effect 44 . Finally the binding of CEACAM 1 on B lymphocytes by Opa 
has been shown to initiate the cell death pathway in B cells, leading to the reduction in 
antibody production by B cells 52 . This allows for sustained colonisation by the pathogen and 
allows repeat infections of the host. 
A further adhesion mediating factor are the pili, these hair like structures are made from 
multiple subunits of pilins which assemble into long filaments 36 . Type IV pili have been found 
on the bacterial surface of a wide range of bacterial species including E. coli, Vibrio cholera 
and N. meningitidis and carry out a broad range of functions including allowing adhesion of 
bacteria to host epithelial cells 53 . Type IV pili have a core role in adhesion of the bacteria to 
host cells and as such they have been identified as key virulence factors as they allow 
colonisation and host cell invasion 54 . Not only do pili mediate adherence of the bacteria to 
epithelial cells, they also promote auto aggregation of the bacteria into microcolonies or 
bacterial aggregates 54 . Within these microcolonies it has been shown that N. meningitidis 
proliferates readily and is capable of surviving not only within the hosts nasopharynx but also 
resisting the pressure exerted by blood flow 55,56 . Further to their role as adhesins pili also 
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confer a number of other advantages to the pathogen such as motility and the ability to 
uptake DNA readily from its environment 36 .  
The motility given to N. meningitidis by pili is known as twitching motility, this achieved by 
the rapid withdrawal and extension of the pili using energy from ATP synthase 57 . This 
motility allows the bacteria to migrate across the hosts’ cells, which is key to the spread of 
infection and the colonisation of the mucosal membranes 57  36 3636.   
Furthermore type IV pili are also involved in genomic variation of N. meningitidis by 
permitting the bacteria to uptake DNA from extracellular space 53 . This DNA can then be 
integrated into the genome of N. meningitidis due to its natural competency.  This natural 
competency along with a method of obtaining and importing DNA allows for a large degree 
of both genomic and antigenic variation within a colony of N. meningitidis 53 . This variation 
can lead to increased virulence of the pathogen or better survivability of the bacteria due to 
better host immune evasion.  
Another prominent virulence factor being used in vaccine development is neisserial adhesin 
A (NadA) 58 . NadA has been shown to be present in a higher proportion of invasive strains, 
around 30%, compared to commensal strains, around 16%, and crucially has been detected 
in nearly all hyperinvasive strains detected clinically 59,60 . NadA is a trimeric autotransporter 
protein involved in adhesion of host epithelial cells as well as interactions with host immune 
cells during colonisation and infection 59 . NadA has been shown to be transported to the 
outer membrane of N. meningtidis where it forms large, highly stable oligomers 59 , 61 . These 
large oligomers have been shown to mediate adherence to epithelial cells in vitro, therefore 
it is theorised that they perform a similar role to other bacterial adhesins in vivo 61 . In a similar 
set of experiments it has also been found that, in a similar way to Opc, NadA is ably to 
promote invasion of epithelial cells 61 . This invasion promotes survival of the bacteria and 
protection from killing by host immune responses by allowing the bacteria to colonise sub-
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epithelial layers. What is important to note is that it appears that Opc and NadA operate 
independently of one another as strains containing only one of the proteins still retains 
invasive properties, whereas strains lacking both proteins exhibit a 10 fold reduction in 
invasive capacity compared with strains expressing both 61 . 
Bacteria, like many other forms of life, require iron in order to survive and proliferate and as 
such iron acquisition is a key regulator of bacterial pathogenicity 62,63 . Due to irons ability to 
undergo redox reactions it plays an essential role in many catalytic reactions performed 
within cells and is also required for electron transport and therefore respiration. However 
due to irons ability to create reactive oxygen species that would cause damage to nearby 
cells around 95% of iron in mammalian hosts is sequestered by heme, cytochromes or other 
enzymes therefore rendering it non-bioavailable for pathogens 64 . As a direct result many 
bacteria have evolved ways of obtaining iron from the hosts cells in order to survive, it has 
also been shown that the ability of a pathogen to obtain iron from its host directly relates to 
its pathogenicity. This is because iron allows a pathogen to survive the oxidative burst of 
phagocytosis used to kill invading bacteria whilst also allowing it to survive and replicate 
more efficiently63.  
In Gram negative bacteria such as Neisseriae 3 types of iron acquisition systems have been 
identified; direct uptake, bipartite haem receptors and hemophore mediated uptake systems 
65 . Whilst these all vary in their methods of iron acquisition, they all allow bacteria to acquire 
and uptake iron before transporting it across the cell membranes and into the cell.   
The bipartite haem receptor system was first described in Neisseria 63  and uses a two part 
ton B dependent outer membrane receptor and lipoprotein, known as HpuAB to acquire 
haem 66 , 67 . More recently homologs for HpuA have been discovered in other bacterial 
species, suggesting that this system is not just confined to Neisseriae.  The two parts of the 
bipartite system are HpuA, a surface exposed lipoprotein, and HpuB which is a 
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transmembrane protein 66 . Together they are capable of binding haemoglobin, releasing the 
haem group and then transporting the haem into the cell, utilising the TonB pathway 66 , 67 . 
In order to move haem across the cell membranes TonB harnesses the proton motive force 
in an energy dependent manner, this allows the bacteria to intake the haem allowing cellular 
enzymes to degrade the haem and release the iron 66 . 
More recently two proteins, Gly1-ORF1 and Gly1-ORF2, have been identified as possible 
conserved iron scavenging and acquiring proteins. It has been shown that neisserial strains 
expressing Gly1-ORF1 show haemolytic activity in vitro and that Gly1-ORF2 shows homology 
to HemD which is involved in the haem biosynthesis pathway in converting linear tetrapyrole 
molecules into uroporphyrinogen III synthase therefore strengthening the case for the 2 Gly1 
genes being involved in iron acquisition and release. 
 
Figure 9. Crystal structure of HemD from Pseudomonas aeruginosa 68. The HemD protein has 
been shown to have homology to Gly1-ORF2, this may indicate that they fulfil similar roles 
within the bactera. Structure downloaded from EMBL-EBI PDB entry no. 4ES6 and modified 
in PyMOL. 
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The neisserial heparin binding protein (nHBP) is a surface exposed protein first detected 
during a reverse vaccinology screen to identify potential N. meningitidis serogroup B vaccine 
targets 69 . During this study it was shown that immunisation of mice with this protein created 
antibodies capable of eliciting complement mediated killing of the bacteria, as a result it is 
now one of the key components in Bexsero (4CMenB) 20 , 69 . Due to its discovery route initially 
very little was known about the structure or function of the protein, despite the fact it was 
thought to be a possible vaccine candidate 69 . Further study by Serruto et al. showed that 
nHBP was capable of binding both heparin and heparin sulphate 69 , this is particularly 
interesting as the binding of heparin is associated with an increase in resistance to 
complement mediated killing 70,71 . What is unclear is how the binding of heparin by nHBP 
elicits this response, although it has been theorised that the bound heparin could be 
interacting with complement regulatory proteins found in serum and preventing 
complement mediated killing 70,71 . Furthermore the binding of heparin by nHBP could 
facilitate attachment of the pathogen to host epithelial cells in a similar way to other 
adhesins by binding surface exposed heparin sulphate on the hosts epithelial cells 69 . 
Another potential key virulence factor, and the focus of this study, is IgA1 protease (IgA1P). 
IgA1P, as the name suggests, was initially discovered in 1793 due to its ability to cleave IgA1 
which is secreted at the mucosal membrane 72 . As a result, it was thought that IgA1P may 
have a role in host immune evasion, which would allow the bacteria to protect itself from 
host immune response and effectively colonise and infect the host. What makes IgA1P look 
particularly promising as a virulence factor is the fact that clinical studies of meningitis have 
shown that invasive strains of both N. meningitidis and H. influenzae have up to a fivefold 
elevation in IgA1P production when compared to carriage isolates of the same bacteria 34,35,73 
. This therefore seems to indicate a strong link between the virulence of a strain and the level 
of IgA1P production 34,35,74,75 . It has also been reported that ~98% of invasive isolates produce 
IgA1P compared with around 76% of carriage isolates 34 . This suggests that although IgA1P 
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expression may not be required for invasive disease and may not initiate invasive disease, it 
could be a strong factor in bacterial survival on the mucosal membrane allowing further 
colonisation and infection to take place. 
1.6 IgA1P 
1.6.1 Background 
As previously mentioned IgA1P was discovered by Mehta et al. and was named due to its 
apparent specificity for human IgA1 molecules and its inability to cleave other 
immunoglobulins 72, 73 . Since its initial discovery in 1973 IgA1P has been found to be 
conserved in many of the major infectious disease causing Gram negative bacteria such as 
N. meningitidis, H. influenzae and S. pneumoniae 34,35,75,76 . Interestingly it appears to be 
particularly highly conserved in those bacteria that colonise host mucosal surfaces 73 . It was 
later isolated from Neisseria gonorrhoeae and used to discover the type V autotransporter 
system, of which it became the archetypal and founding member 77 . 
IgA1P is formed of 4 domains (Fig 9) which are common to all type Va autotransporters these 
are; the leader, the passenger, the linker and the β core 78,79 . The β core has been found to 
have a fairly diverse N terminus region between organisms however, it has a key conserved 
region of 300 amino acids in the C terminus which plays a vital role in the protein export 
process 74 . 
 
Figure 10. A simplified view (not to scale) of the IgA1P pre-protein. IgA1P is translated as a 
large pre-protein prior to translocation and self export with several domains which allow for 
efficient IgA1P extracellular transport. The leader sequence is coloured orange, the protease 
passenger domain in pink, the γ peptide in purple, the α protein in blue and the β core 
domain in green. Together the γ peptide in purple, the α protein in blue form the linker 
region of the protein 
 
Mature IgA1P secreted by Gram negative bacteria is divided into 3 classes based upon the 
active site of the protease, these 3 types are; Serine protease, as found in N. meningitidis, N. 
gonorrhoeae and H. influenza, Metalloproteases as found in S. pneumoniae and Cysteine 
proteases as found in Prevotella melaninogenica 74,79 . The three types of IgA1P all have 
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similar structures as well as very similar functions and have been found to cut the hinge 
region of the heavy chain of IgA1 but not IgA279. This is inability to cleave IgA2 is due to a 
deletion mutation in IgA2 which causes loss of the protease recognition site 79,80 . 
 
Figure 11. The crystal structure of IgA1P from H. influenzae 75 . The red ribbon show the 
protease domain (residues 26-337) with loop D (205-243) of this domain highlighted in 
yellow, the light blue ribbon shows domain 2 (residues 564-657), the green ribbon shows 
domain 3 (residues 710-743), the magenta ribbon shows domain 4 (residues 786-819), the 
dark blue ribbon shows the rest of structure, including the long β spine (residues 338-369, 
388-563, 658-709, 744-785 and 820-989). The catalytic triad (residues H100, D164 and S288) 
are rendered as light blue ball and stick models and circled in green (Structure downloaded 
from EMBL-EBI PDB entry no. 3H09 and modified in PyMOL) 
 
The mature and exported IgA1P itself consists of five domains (Fig 11) with the most 
important of these being the large protease domain which contains the active site 75 . There 
is also a large β-helix “spine”, which may facilitate substrate binding and orientation, as well 
as 3 smaller domains known as domain 2,3 and 4 75 . The overall sequence and structure of 
IgA1P has been shown to be highly similar to haemoglobin protease (Hbp) from E. coli, which 
is the only other serine protease autotransporter with a solved crystal structure 75 . 
Interestingly IgA1P also has high structural homology to both the trypsin and chymotrypsin 
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serine proteases, although the solved Haemophilus influenzae IgA1P has unique insertion in 
a region known as loop D of the protease domain(Fig 12) 75 .  
 
Figure 12. A close up of the protease domain of IgA1P from H. influenzae shows how the 
unique loop D insertion (yellow) forms a lid over the active site of the protease (light grey). 
This lid prevents the protease from cleaving non-specifically by covering the active site unless 
certain specific interactions between itself and the substrate are made (Structure 
downloaded from EMBL-EBI PDB entry no. 3H09 75  and modified in PyMOL) 
 
This unique loop insertion is thought to act like a lid, covering the active site of the protease 
and preventing non-specific cleavage from occurring 75 . The theory is that the loop D 
insertion is able to interact with the β barrel section of the Fc fragment of intact IgA1, which 
stabilises loop D in an open conformation therefore uncovering the active site and allowing 
cleavage to occur 73 . What is particularly interesting is that modelling of the Neisseria 
meningitidis IgA1P using the Phyre2 protein fold recognition server 81  suggests that the 
unique loop D insertion is absent in this protein (Fig 13). This may account for the propensity 
of IgA1P from N. meningitidis to cleave molecules other than IgA1, as will be discussed in 
detail later in this chapter. 
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Figure 13. A comparison of the IgA1P loop D insertions. The predicted structure of the N. 
meningitidis IgA1P is shown on the left and in the centre (The left hand structure was 
predicted using the Phyre2 protein fold recognition server 81  whilst the centre structure is 
based on a threading model using the N. meningitidis sequence and the solved H. influenzae 
crystal structure), the structure on the right shows the solved H. influenzae structure (PDB 
entry 3H09 75 ). The red surface shows the protease domain (residues 26-337) with loop D 
(205-243) of this domain highlighted in yellow, the light blue surface shows domain 2 
(residues 564-657), the green surface shows domain 3 (residues 710-743), the magenta 
surface shows domain 4 (residues 786-819), the dark blue ribbon shows the rest of structure, 
including the long β spine (residues 338-369, 388-563, 658-709, 744-785 and 820-989). The 
catalytic triad (residues H100, D164 and S288) are rendered in light grey. These images show 
that the unique loop D insertion found in the H. influenzae structure is likely absent in the 
neisserial structure, this might explain its ability to cleave multiple substrates, as will be 
explained later. 
 
The largest domain within IgA1P is the β helical spine which is a 100 Å long domain formed 
from β helices, with a hydrophobic core made of stacked leucine and isoleucine residues and 
a hydrophilic external face 75 . The β spine forms the backbone of the molecule to which the 
other domains extend and are attached 75 . The spine also forms stabilising disulphide binds 
with the cysteine residues present in domain 4 75 . These bonds have been useful in 
determining the size and shape of the protease as it is exported, allowing the pore diameter 
and export mechanism to be calculated 75 . 
As well as the β spine and the protease domains there are 3 smaller domains known as 
domains 2, 3 and 4 75 . Despite the fact that these domains are relatively small it is thought 
that they play a crucial role in substrate orientation and specificity (Fig 14). Domain 2 is a 
small domain formed off the stalk of the β helix which has been shown in crystal packing 
studies to have independent movement from the β helical spine 75 . This allows it to interact 
with the unique loop D of another IgA1P molecule placing itself over the active site of the 
other molecule, therefore acting as a lid and preventing random cleavage 73 . As previously 
mentioned this unique loop D insertion is most likely absent in neisserial IgA1P and as such 
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domain 2 alone may be acting as a lid, it is also possible that this is just an artefact that has 
arisen due to crystal packing effects. Domains 3 and 4 are smaller domains than domain 2 
and also are β strand insertions which extend away from the β helical spine and lie between 
the β helical spine and the protease domain at the base of domain 2. These smaller domains 
create a unique topography which is most likely involved in substrate recognition and 
specificity 75 . 
 
Figure 14. The crystal structure of H. influenzae as viewed from above, this shows how 
domain 2 (light blue) extends away from the β spine (dark blue) as well as the other domains 
(domain 3-green, domain 4-magenta). Domain 2 can be seen to extend away from the rest 
of the protein on a thin stalk which allows it independent movement, whilst domain 3 and 4 
create a uniquely structured cleft for substrate binding. (Structure downloaded from EMBL-
EBI PDB entry no. 3H09 75  and modified in PyMOL) 
 
The final domain is the protease domain, as the name suggests this domain contains the 
active site of the protein and is required for its enzymatic function(Fig 15) 75 . It has been 
shown that N. meningitidis, N. gonorrhoeae and H. influenzae all contain a consensus 
sequence around the serine active site of GDSGSPLF 82 , with the serine involved in the 
enzymatic reaction highlighted in red. This consensus sequence is also found in other related 
serine proteases such as trypsin and chymotrypsin 82  which also have been shown to have 
similar structures to IgA1P 75 . 
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Figure 15. Close up of the catalytic triad which makes up the active site of IgA1P. The residues 
H100, D164 and S288 which form the catalytic triad have been rendered as ball and stick 
models and circled in green (Structure downloaded from EMBL-EBI PDB entry no. 3H09 82  
and modified in PyMOL). 
 
1.6.2 Link to virulence 
Although IgA1P is predicted to be a virulence factor due to its up-regulation in invasive strains 
and also its role in the cleavage of IgA as of yet researchers have only been able to predict 
IgA1Ps role in virulence. This is due to the fact that any attempt at animal modelling has 
failed due to the specificity of IgA1P for the human IgA 74 . Further reasoning behind IgA1P 
being a virulence factor is that it has been found to be constitutively expressed during the 
bacterial growth phase 83 , although its exact role in virulence is unclear at the present time. 
Most research seems to conclude that IgA1P is most likely involved in host immune response 
evasion prior to the secretion of specific antibodies as well as protecting the bacteria from 
TNFα mediated apoptosis 84,85 . 
Since its initial discovery it has been postulated that IgA1P would play a vital role in immune 
evasion and host colonisation in pathogenic organisms which colonise the mucosal 
membranes. This theory stems from the proteins ability to cut IgA1 and also from studies 
which show up to a fivefold up-regulation of IgA1P expression in invasive isolates 34,35 . It has 
been shown that this fivefold upregulation in expression of IgA1P is not due to co-expression 
with another virulence factor, therefore showing that elevated IgA1P levels play an active 
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part in virulence determination and are not just a by-product of the expression of a linked 
factor. This was confirmed by monitoring IgA1P expression levels in different isolates of the 
pathogen when allowed to undergo random mating 86 . This random mating led to a random 
assortment of alleles being present within the different pathogens, however despite the 
random alleles present IgA1P levels were nearly consistently detectable in all of the invasive 
isolates that were tested. 
1.6.2.1 The structure and function of IgA 
Immunoglobulin A is the most abundantly secreted immunoglobulin at the mucosal surfaces 
within the body and these mucosal surfaces are estimated to have a combined area of up to 
400m2, 87,88 . As a result IgA is the most secreted immunoglobulin in the body and any bacteria 
hoping to colonise the nasopharynx (such as Neisseria meningitidis), gut or urogenital tract 
must be able to evade its effects in order to colonise and survive within a host. The role of 
IgA at the mucosal membrane is not generally to kill the bacteria directly but rather to aid 
expulsion of the bacteria or signal phagocytic ingestion 87,89 . This is generally achieved via the 
ability of secretory IgA to cause opsonisisation/agglutination of pathogens on the mucosal 
membranes; this then targets them for clearance by the cilia. This agglutination prevents 
colonisation of bacteria upon the mucosal membranes and also limits the exposure of the 
epithelial cells to the pathogenic effects of the bacteria 87,89 .  
The IgA protein itself is formed from 2 light and 2 heavy chains, similar to the other 
immunoglobulins. What differentiates IgA from other immunoglobulins is its ability to 
function as a monomer, dimer or trimer although secretory IgA at mucosal surfaces is most 
commonly found as a dimer86.  These dimers are comprised of two IgA molecules with a small 
J chain that links them together, along with an associated glycoprotein call the secretory 
component,88.  
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Figure 16. IgA is most commonly found in 3 forms at the mucosal surface a) IgA monomer b) 
Iga dimer with J chain rendered in orange and the secretory component rendered in blue c) 
IgA trimer. Of these forms the Iga dimer is most commonly secreted at the mucosal surface 
and is capable of agglutinating bacteria for removal by ciliated cells. It has also been found 
to be weakly capable of activating the complement system for direct pathogen killing, 
however this appears to be a minor role as other immunoglobulins are much more effective 
at activating this system86. 
 
1.6.2.2 Cleavage of IgA and other targets by IgA1P 
In humans there are 2 subclasses of IgA known as IgA1 and IgA2, these have subtle structural 
differences with a key difference being that IgA2 has a deletion mutation within the hinge 
region of the heavy chain 87,89 . This deletion mutation removes the IgA1P recognition site, 
making IgA2 resistant to cleavage by the protease 79,80 . This deletion mutation is found within 
a duplicated octapeptide repeat in the heavy chain which contains both the recognition and 
the cleavage sites for the IgA1P enzyme. Although IgA1P is unable to cleave IgA2 it can cleave 
IgA1, which makes up around 50% of all secreted IgA at the mucosal surface86. Cleavage of 
IgA1 by IgA1P is possible at two different consensus sequences, this gives rise to two 
subclasses of IgA1P enzymes. Type 1 IgA1P has been shown to cleave between Pro-Ser 
residues, whilst type 2 IgA1P is known to cleave between Pro-Thr residues 73,87,90 . 
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Figure 17. Diagram to show the duplicated octapeptide within the heavy chain hinge region 
of IgA1 along with the cleavage sites of N. meningitidis. Arrow 1 shows the site for type 1 
cleavage of IgA1 by IgA1P and arrow 2 shows the type 2 cleavage site of IgA1 by IgA1P. As 
can be seen, cleavage products produced by IgA1P subtypes vary in length therefore allowing 
classification of the enzyme type 91 . 
 
Interestingly study of Haemophilus influenzae has shown that it is possible for a single strain 
to encode and express both type 1 and type 2 IgA1P proteins 92,93 . It has been speculated 
that having both subclasses of IgA1P may make the bacteria more invasive and by providing 
the bacteria with more host immune evasion. The N terminal region of IgA1P has been shown 
to alter the specificity of the enzyme and is instrumental in determining whether the enzyme 
exhibits type 1 or type 2 cleavage, this N terminal region is known as the cleavage specificity 
determinant (CSD) region 94 . Both types of cleavage result in production of an intact Fab and 
an Fc fragment, which vary in length depending on the subtype of IgA1P that carried out the 
cleavage 94 . This cleavage of the IgA1 molecule therefore renders it unable to carry out its 
function within the host as the IgA molecule can no longer crosslink with other Fc regions in 
order to agglutinate and neutralise the pathogen 87,90,91 . This therefore confers an increased 
survival chance to the pathogen allowing for prolonged survival and colonisation of the 
mucosal membrane. 
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Figure 18. IgA binds to pathogenic antigens causing agglutination, however IgA1P can lessen 
this effect and by causing fabulation. a) shows the normal binding of IgA to bacterial antigens, 
during this process the Fab region of the IgA molecule binds the antigen leaving the free Fc 
tail capable of making interactions with other Fc regions for agglutination to occur or white 
blood cells in order to elicit a direct immune response, b) shows the process of agglutination 
and how interaction between Fc regions allows the cross-linking of bacteria into a large group 
capable of being expelled by the cilia, c) shows how, after exposure to IgA1P, the hinge region 
of IgA has been cleaved. This leaves an intact Fab region which is still capable of binding and 
masking the bacterial antigen in a process called fabulation while removing the Fc region 
therefore preventing an immune response and agglutination of the pathogen 91,95 . 
 
Although IgA1P was initially thought to only cleave IgA1 it has more recently been shown to 
be able to cleave a wide range of substrates. This observation is linked to the more recent 
discovery that IgA1P is able to tolerate changes in its consensus cleavage sequence, allowing 
it to interact with and cleave proteins other than IgA1 85,96 . In addition to the hinge region of 
IgA1 IgA1P has also been found to cleave the type II tumour necrosis factor receptor (TNFRII), 
synaptobrevin and lysosomal associated membrane protein (LAMP) 1 and 2 85,97 , 98 , 99 . 
Cleavage of all of these targets may be linked to an increase in virulence and invasiveness of 
the pathogen 85,100 .  
The cleavage of LAMP1 is a perfect example of how IgA1Ps off target effects can increase the 
pathogens virulence by prolonging colonisation and preventing clearance of the bacteria. 
LAMP1 is a key glycoprotein in lysosomes which is involved in the stabilisation of lysosomal 
membranes which contains a region with a high degree of similarity to the IgA1 hinge region 
85,97 , 98 . It has been shown in vitro that it is possible for IgA1P to cleave this region causing a 
drop in active LAMP1 levels by between 20-50% 85,97 , 98 . It is hypothesised that in vivo this 
would lead to destabilisation of the lysosomal membranes therefore promoting survival of 
the bacteria within the epithelial cells 85,97 , 98 . 
Cleavage of LAMP2 is further evidence of how the cleavage of other targets by IgA1P can 
increase the virulence of the pathogen.  LAMP2 is another lysosomal membrane protein that 
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has been hypothesised to be involved in intracellular signalling effects within phagocytic 
cells. Therefore the cleavage of LAMP2 would affect lysosomal structure and function within 
phagocytes, preventing pathogen neutralisation from being carried out 85 . This increases the 
pathogens ability to survive within a host and allows it to evade clearance by the immune 
system.  
The cleavage of TNFRII is also interesting as TNFRII normally controls apoptotic events in 
monocytes by binding tumour necrosis factor α (TNFα) and hence acts as a key regulator of 
host immune response. Therefore interference by IgA1P with the effects of TNFRII would 
allow pathogenic bacteria such as N. meningitidis to prevent apoptosis of the niche required 
by the pathogen induced by TNFα and therefore survive for a longer period of time 84,100 . This 
cleavage of TNFRII is particularly interesting as it has been shown that secretion of IgA1P is 
linked to increased release of pro-inflammatory cytokines such as IL-6, IL-8 and TNFα from 
monocytes 84 . These pro-inflammatory cytokines have been shown to be key to the ability of 
N. meningitidis to cause disease and are elevated in the cerebrospinal fluid of patients 
suffering with meningitis, therefore the release of IgA1P is simultaneously contributing to 
virulence whilst protecting the organism from the effects of the inflammatory cytokines 84 . 
There is also growing evidence that IgA1P produces a very immunogenic response in vivo and 
that people vaccinated against IgA1P have gained a long lasting immune response which in 
some cases has actually proven to become stronger overtime due to asymptomatic carriage 
25,101 . 
The strong immune response to IgA1P is thought to be due to the stimulation of T cells by 
both invasive and carriage strains, this then leads to high circulating levels of anti-IgA1P 
antibodies 102 . However due to the heterogeneity of the IgA1P sequence any antibodies that 
are produced by the host due to a prior infection will not necessarily prevent the IgA1P 
secreted in a subsequent infection from being effective. Despite this fact antibodies against 
IgA1P have been shown to be long lasting in vivo and therefore possibly capable of helping 
to prevent meningococcal invasion. It should also be noted that antibodies against type 1 
IgA1P are not effective against type 2 IgA1P and vice versa. 
The strong immunogenic response provided by both IgA1P and the co-secreted α protein, as 
will be described later, however may prove useful for vaccine production, although the 
heterogeneity of IgA1P itself will serve as a challenge if a universal vaccine is to be made in 
the future. There is however the possibility of fusing the α protein to IgA1P or other secreted 
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Neisserial proteins in an attempt to create a vaccine that is highly immunogenic and also 
effective against two separate secreted factors involved in colonisation and invasion. 
 
1.6.3 Export pathway 
In Gram negative bacteria there are 6 major families of secreted proteins; I,II,III,IV,V and VI 
all of which are highly conserved and are functionally independent in protein export 79 . The 
type V autotransporter family to which IgA1P belongs to can be divided into 3 subtypes; Va- 
autotransporter proteins. Vb- two partner secretion system and Vc 78,79 . Since its discovery 
in 1973 IgA1P has become the archetypal type Va autotransporter protein and all other type 
Va proteins have been shown to have homologous structures to IgA1P 79 . The type Va 
autotransporter proteins encode many of the necessary domains required for the protein to 
be export competent however, despite the family name, it is has been found that proteins 
such as Skp, Sec and Omp85 are all essential for export and processing of the proteins once 
translated 103,104 . All of the type Va autotransporters studied to date have been found to have 
similar structures and biogenesis pathways but have shown slight variation in the methods 
of cellular export 79 . As mentioned in section 1.6.1 type Va autotransporters are comprised 
of 4 domains which are all crucial for export; the leader sequence, the passenger domain, 
the linker domain and the beta core. Together these domains all carry out specific roles 
during export from the cell, the leader targets the protein through the inner membrane, the 
passenger domain is the enzyme for export, the linker is a helical flexible region and the beta 
core forms a pore in the outer membrane allowing export of the passenger domain 105 . 
The leader domain of IgA1P has been described as an unusually long sec dependent signal 
sequence, for which Sec B seems to act as the designated chaperone 75,76 . During transit 
through the IM Sec B binds to the IgA1P pre-protein and targets it to Sec A for transport 
through the inner membrane 79 . The leader sequence itself consists of a positively charged 
N-domain, an H-domain containing hydrophobic amino acids and a C-domain with a signal 
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peptidase recognition site as well as a C-terminal cleavage region 78 .  All of these regions are 
key to allowing the leader sequence to target the protein for transport across the inner 
membrane 79 . A further role of the leader sequence is to slow the cleavage of the protein in 
the periplasm. This slow cleavage of sec prevents the protein from folding fully in the 
periplasm by keeping the protein tethered to the inner membrane, therefore keeping it in a 
translocation competent state 78 .  
After the pre-protein has undergone inner membrane translocation the passenger and linker 
domains remain in an unfolded or partially folded state within the periplasm. During this 
time the β-core interacts with the outer membrane and forms a β barrel structure which 
inserts into the outer membrane and acts as a pore for the passenger and linker domains 79 . 
It was recently shown that the β domain alone is not capable of folding and inserting itself 
into the outer membrane properly and that in Neisseria a protein called Omp85 is absolutely 
essential for IgA1P export and processing. Omp85 is thought to act as a chaperone for the β 
core by facilitating protein assembly within the outer membrane 103,106,107 . As mentioned 
previously the IgA1P protein is kept in an unfolded state in the periplasm, this is due to the 
fact that a fully folded IgA1P protein would not be able to fit through the pore made by the 
β core. Although it has been shown that the leader sequence helps to keep the protein in 
this unfolded state it is unclear how the protein is protected from proteolytic degradation in 
the periplasm. This is because partially folded or unfolded proteins are routinely degraded 
by periplasmic proteases in order to clear the periplasm of unwanted or unneeded proteins. 
The β barrel structure which is formed by the β core is made up of 15 β sheets aligned in an 
anti-parallel fashion, as is typical for a classic β barrel 76,108 . Within the family of type Va 
autotransporters the β domain structures are all homologous but have extremely diverse 
sequences, as a result the conserved structure of the β domain is believed to be key in its 
ability to form an outer membrane pore capable of translocating the protease domain 78 . 
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Figure 19. Comparison of the β barrel structures formed by various type Va autotransporters 
proteins. E. coli EspP translocation domain (green), Neisseria meningitidis NalP translocation 
domain (blue) and the predicted structure of the Neisseria meningitidis IgA1P βcore (pink, 
predicted using Phyre 2 protein fold recognition server 81 ). Although the proteins have very 
different sequences the proteins all form highly similar β barrel structures with a short 
internal α helix. (Structures downloaded from EMBL-EBI PDB entry no. 2QOM 109  and 1UYN 
107 and modified in PyMOL) 
 
The β domains also contain a consensus amino acid sequence at the very end of the C 
terminus which has alternating hydrophilic and hydrophobic residues with a terminal F or W 
residue 79 . This sequence is also found in other Gram negative outer membrane proteins and 
is believed to have a role in stabilisation, localisation and folding of the protein 79 . Recently 
it has been shown that in order to efficiently insert into the outer membrane the β barrel 
requires a molecular chaperone, such as Skp. This chaperone has been shown to bind to the 
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unfolded β core allowing it to interact with a number of LPS molecules, this makes the β core 
folding competent and allows efficient outer membrane insertion 104 . There is also recent 
experimental evidence of an auto chaperone domain within the protease domain of IgAP. 
This region was found by carrying out a position specific iterated-BLAST search (NCBI) of a 
region found in the passenger domain of BrkA from Bordetella Pertussis, which was shown 
to have a chaperone role in exporting the domains through the β pore 110 . This domain tends 
to be β helical in shape in order to contribute to the energy independent translocation that 
takes place through the outer membrane and has been found to lie in the C terminus of the 
beta spine in IgA1P 110 . 
 
 
Figure 20. A diaGram showing the type Va autotransporter pathway. The leader sequence is 
coloured orange, the protease domain pink, the γ peptide purple, the α protein in light blue 
and the β domain in green. This diaGram show how the leader sequence first inserts into the 
inner membrane in a sec dependent manner, this rotates allowing the rest of the pre-protein 
to be cleaved into periplasmic space. This cleavage happens very slowly therefore preventing 
any degradation of the protein within the periplasmic space. During this slow cleavage the β 
domain forms a β barrel structure in the outer membrane where the interior acts as a pore 
so that the protein can translocate to extracellular space. After this translocation has 
occurred an auto processing event occurs whereby the IgA1P folds and cleaves itself from 
the pre protein and also cleaves the linker domain in order to release a γ peptide and the α 
protein. (Adapted from  74 ) 
 
In the case of IgA1P after translocation across the outer membrane an autoprocessing event 
occurs where the integral serine protease cuts a cleavage site in the passenger domain 
releasing itself into the extracellular space 105 . This autoprocessing event can occur as the β 
helix of the protease that requires cleaving for mature protein release mimics the IgA1 hinge 
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region allowing proteolysis and self-cleavage to occur. The fully folded IgA1P can also then 
cut the linker region in 2 distinct places, this cleavage event release 2 discreet proteins known 
as α and ɣ 25,76 . 
 
1.7 Alpha 
As its name suggests the α protein is a long α helical peptide which can vary in length from 
400 aa in its long form to around 200 aa in its shorter form. The long and short forms also 
differ slightly in composition with the longer form, which is expressed by more invasive 
strains such as MC58, containing 4 nuclear localisation signals (NLS) and the short form, 
which is expressed by carriage strains such as NMB, only containing 1 NLS which appears to 
be inactive 111 . These NLS are short positively charged runs of 5-6 aa which help to target the 
protein to the nuclei of surrounding eukaryotic cells 111 . 
 
Figure 21. The crystal structure of the α monomer. The α protein is composed of one long, 
slightly curved alpha helix. (Unpublished crystal structure provided by Prof PJ Artymiuk of 
the University of Sheffield UK). 
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Figure 22. Unpublished crystal structure of the α protein derived from Neisseria meningitidis 
IgA1P showing how under crystal packing conditions large multimers of up to 24 proteins are 
formed (structure supplied by Prof PJ Artymiuk of the University of Sheffield UK). 
 
These NLS have recently been shown to allow α protein bound to IgA1P to invade host cells 
and deposit IgA1P inside 111 . This then allows the IgA1P to cleave many host specific targets 
such as LAMP or TNRFRII, which would otherwise be inaccessible, in order to prevent 
apoptosis mediated destruction of the N. meningitidis niche or to prolong the survival of the 
pathogen by creating lysosomal instability 85,97 , 98 , 99 . 
Structural data on the α peptide shows a long continuous alpha helical protein with 
amphipathic helices capable of dimerising to form multimers 111 . This is a structure that is 
typical of DNA binding proteins, with a recent paper showing that α may be involved in 
binding extracellular DNA (eDNA) facilitating biofilm formation within the host 112 . The α 
protein also has a pI of around 10 which results in a strong positive charge at neutral pHs, as 
found within the host, which may facilitate its eDNA binding ability 112 . The α proteins high 
pI is due to the fact that 80% of the protein is comprised of arginine, glutamic acid, alanine, 
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glutamine and lysine residues which are highly charged. Also it does not contain any cysteine, 
tryptophan or phenylalanine residues, therefore making protein quantification difficult. 
As was mentioned previously the α protein is released along with the γ peptide via an 
autoproteolytic event where IgA1P cleaves the linker region in order to release itself and the 
α and ɣ peptides from the β barrel 25 . This is autoproteolytic cleavages is possible due to the 
fact that α is flanked by 2 autoproteolytic cleavage site sites, PPSP and PPEL in NMB, which 
are used to release alpha from the β barrel and also potentially IgA1P. These are recognised 
in the same way that the cleavage sites are recognised in intact IgA1 allowing cleavage after 
the proline residue.  
Despite the α protein being conserved in Neisseria meningitidis, Neisseria gonorrhoea, 
Haemophilus influenzae and possibly Streptococcus pneumoniae the α protein has only been 
shown to be secreted during IgA1P export from neisserial species and not in other 
meningococcal bacteria such as H. influenzae. As yet there is no clear evidence for why this 
is, but it is possible that α stays attached to the outer membrane of these bacteria via the β 
domain and performing some other function. 
A series of studies have shown that IgA1P is capable of giving rise to long lasting immune 
responses with antibodies to IgA1P being detectable up to 5 years after meningococcal 
carriage. It is possible that this long lasting protection may be partially due to the α protein 
which is often linked to IgA1P during export. The alpha protein is a highly repetitive protein 
which has been show to contain a number of T cell helper epitopes 25 , which are short runs 
of 7-10 amino acids. These epitopes activate CD4+ helper T cells which then stimulate 
maturation of B cells into memory B cells which provide long lasting immunity 24 , 25 . 
It is hypothesised that the ability of alpha to create memory B cells could be exploited and 
used in vaccine development, with alpha acting as a carrier protein in vaccine formulations. 
As such it could increase the immunogenic response to other proteins in the vaccine and give 
rise to long lasting vaccine coverage.  Furthermore, alphas propensity to form large 
multimers could also be utilised. By fusing a target protein to α, it may be possible to create 
a large multimer of both target and α. This would effectively increase the size of the target 
protein, therefore lowering the rate of renal clearing whilst also increasing the 
immunogenicity of the protein.  
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Figure 23. A predicted structure of an α-Gly1-ORF1 fusion, showing how theoretically the α 
protein could retain its ability to form multimers. This would increase the complex’s size, 
therefore increasing its immunogenicity and renal clearing time. (image created in PyMOL 
using structures provided by Prof JR Sayers and Prof PJ Artymiuk of the University of 
Sheffield, UK) 
 
This could possibly increase the effectiveness of the vaccine by keeping the protein in the 
circulation system for a longer period of time whilst simultaneously increasing the 
production of memory B cells against it. 
 
1.8 Gamma 
The gamma (γ) peptide makes up a small section of the linker region in IgA1P secreted by 
Neisseria along with the much longer α protein. It is released during the same autoproteolytic 
event that releases α and IgA1P from the β barrel. As previously stated it is a very short 
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peptide consisting of just 25 aa residues: PATNTASQAQTDSAQIAKPQNIVVA, with a predicted 
weight of just 2.5 kDa. 
Structure prediction shows that it may form an alpha helix although an unstructured loop 
may be more likely. 
Despite very little being known about the ɣ peptide it appears to be conserved in Neisseria 
meningitidis, Neisseria gonorrhoea and Haemophilus influenzae. As such it is likely to have 
some function in these bacteria and was therefore investigated over the course of this 
project. 
 
1.9 Hypothesis 
The hypothesis of this study was fourfold;  
Firstly, that the Neisseria meningitidis IgA1P would show a high structural homology to the 
solved Haemophilus influenzae IgAP protein. This would be tested using mutant IgA1P 
proteins derived from a plasmid containing E. coli M72 cell line.  
Secondly that the α protein derived from neisserial IgA1P would show binding of serum or 
blood based factors which would account for its high level of immunogenicity. 
Thirdly that the α protein may exhibit potential as a carrier protein due to its multiple T cell 
helper epitopes. 
Finally that the γ peptide will have a functional role within the bacteria due to its conserved 
nature. 
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Chapter 2- Materials and methods 
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2. Materials and Methods 
All chemicals were analytical grade and supplied by Fisher Scientific unless otherwise 
stated. 
2.1 Bacterial Culturing 
2.1.1 Culture media 
Lysogeny broth (LB) was used to culture small volumes of E. coli cells, this contained 1% (w/v) 
tryptone, 0.5% (w/v) yeast extract and 0.5% (w/v) sodium chloride. For larger cultures of E. 
coli 5YT growth medium was used as this provides a higher concentration of nutrients which 
can sustain bacterial growth for longer. The 5YT medium used contained 4% (w/v) tryptone, 
2.5% (w/v) yeast extract and 0.5% (w/v) sodium chloride. For isolating single colonies of E. 
coli LB agar plates were used, these contained 1% tryptone, 0.5% (w/v) yeast extract, 0.5% 
(w/v) sodium chloride and 15 g/L bacto agar. All of these media were also used with a plasmid 
appropriate antibiotic for positive selection. The two antibiotics used were ampicillin and 
carbenicillin at 100 µg/ml, which are both degraded by β lactamases.  Ampicillin was used in 
small scale cultures and carbenicillin was used for larger cultures such as the fermenter as 
the breakdown products are less toxic than that of ampicillin. 
2.1.2 Bacteria 
For all work carried out E. coli M72 cells were used either alone or transformed with one of 
the plasmids listed in section 2.1.3. E. coli M72 cells encode a heat sensitive version of the cI 
protein known as cI857, this specifies that M72 cells use a λPL repressor system on the 
plasmid vector 113 . 
2.1.3 Plasmids 
All of the genes of interest had previously been cloned into the pJONEX4 plasmid which is 
based upon pBR322 with a pUC19 multiple cloning site and a λPL promoter 114 .The λPL is a 
heat inducible promoter composed of 3 operator regions, one of these regions is the CI857 
heat sensitive repressor protein which is supplied on the M72 cells. The variants of this 
plasmid used were; pJONEX4_NMB_alpha containing the region encoding the alpha protein 
of IgA1P from the NMB strain of N. meningitidis, pJONEX4_NMB_cys_γ_α containing the 
region encoding the γ and α proteins of IgA1P from the NMB strain of N. meningitidis which 
has been modified with a C terminal cysteine residue, pJONEX4_neisserial_Gly1_ORF1his 
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containing the gene for Gly1-ORF1 from N. meningitidis and pJONEX4_ IgA1P containing the 
IgA1P gene isolated from  N. meningitides (for plasmid sequences See Appendix II). 
 
Figure 24. Map of the pJONEX4 expression plasmid. All inserted genes were cloned in using 
the multiple cloning site of pUC19 so as to be under the control of the λPL promoter with the 
lac promoter as an antisense promoter. Image generated using Plasmapper 115 . 
 
2.1.4 SDS PAGE reagents 
 The reagents used for SDS PAGE were; loading dye consisting of 2 ml 10% SDS, 4 ml glycerol, 
3 ml 250 mM Tris.HCl pH8, 1 ml 0.5% (w/v) bromophenol blue and 100 µl 500 mM 
ethylenediaminetetraacetic acid (EDTA) pH 7, SDS-PAGE running buffer comprised of 121.4 
g Tris, 163.2 g Bicine, 100 ml 10% SDS, 7900 ml dH20 and 4 ml 500 mM EDTA.  
The reagents used to stain and de-stain the acyrlamide gel were; Coomassie stain which 
consisted of 400 ml methanol, 100 ml acetic acid, 2 mg/ml Coomassie blue, 500 ml dH20 
water and Coomassie de-stain which was composed of 200 ml methanol, 100 ml acetic acid 
and 700 ml dH20. 
2.1.5 Culturing 
An LB agar plate containing 100 µg/ml of ampicillin was streaked with bacteria from a 
glycerol stock of bacteria stored at -80oC, this was then incubated at 30oC overnight. After 
incubation a single colony was picked and used to inoculate 6 ml of LB containing 100 µg/ml 
of ampicillin and incubated whilst shaking at RT until mid-log phase was reached. The 6 ml 
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culture was then either used in order to elucidate optimal protein expression conditions or 
1 ml was then used to inoculate 100 ml of LB containing 100 µg/ml of ampicillin which was 
then incubated with shaking at RT O/N. 
2.1.6 Monitoring protein expression  
Cells were cultured in 6ml of LB media as described in section 2.1.5 using E. coli M72 cells 
containing  either the pJONEX4_NMB_cys_γ_α or the pJONEX4_NMB_α plasmid. A 1ml 
sample was taken from the culture and centrifuged at 14000 x g in order to separate the cells 
from the supernatant, these were then stored at -20oC, the remaining culture was then 
induced at 42oC and sampled at 2hrs, 4hrs, 8hrs and 24 hrs post induction as before. 
2.1.7 Fermentation  
A 5 L fermenter was filled with 5 L of 5YT then autoclaved and carbenicillin added to give a 
final concentration of 100 µg/ml. The temperature of the media was then maintained at a 
30oC and aerated with sterile air at 5 L/min. Next 400 ml of overnight culture (cultured as in 
section 2.1.6) was used to inoculate the fermenter prior to sealing it. After sealing the 
fermenter a stirrer was set to 300 rpm in order to ensure mixing of the culture allowing even 
growth. The culture was then incubated at 30oC until mid-log phase was reached; the 
bacteria were then induced overnight by increasing the fermenter temperature to 42oC. 
After induction the cells were centrifuged in an ultracentrifuge at 3500 x g at 4oC for 20 min.  
The supernatant was then removed and the pellet resuspended by shaking in 200 ml of 25 
mM Tris pH8, 2 mM EDTA and 100 mM NaCl. Resuspended cells were then transferred to a 
single bottle and centrifuged again as before.  The supernatant was again removed and the 
cells made into ~10 g aliquots wrapped in cling film then foil and stored at -80oC. 
2.1.8 SDS PAGE gel  
An SDS PAGE resolving gel was made using; 3.3 ml of 30% acrylamide (National Diagnostics), 
4.4 ml of dH20, 2 ml of 500 mM pH 8.3 Tris-bicine, 100 µl 10% SDS, 200 µl 25 mg/ml APS and 
15 µl tetramethylethylenediamine (TEMED) this was allowed to set in a gel tank ,made in 
house. Once set the ethanol was then removed before a 3ml stacking gel was made as 
follows; 0.5 ml 30% acrylamide, 1 ml dH20, 1.5 ml pH 6.9 Tris, 30 µl of 10% SDS, 60 µl 25 
mg/ml APS and 7 µl TEMED this was then poured on top of the resolving gel and allowed to 
set with a 20 µl well comb inserted. 
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2.1.9 SDS PAGE  
Culture samples of interest had 1ml removed and were centrifuged at 13000 x g for 1 min, 
the pellet was then resuspended in 200 µl of 25 mM Tris pH 6.9, 12.5 mM EDTA and vortexed 
thoroughly before 10 µl of 10% SDS was added. Samples were heated at 95oC for 3 min, 15 
µl of the sample was then mixed with 10 µl of loading dye containing fresh dithiothreitol 
(DTT) before being heated again at 95oC for 3 min. Supernatant samples were only mixed 
with loading dye as above and boiled once at 95oC.  
A gel rig was then filled with 1x SDS PAGE running buffer. The samples were then loaded into 
separate wells as was an appropriate ladder. A constant current of 20 mA was applied until 
the samples reached the bottom of the stacking gel, the current was then increased to 30 
mA until the dye front reached the bottom of the gel. The gel was then removed from the 
rig and stained using Coomassie stain whilst the container was gently heated in a hot water 
bath. This was done for 5 min then the gel was then gently shaken with Coomassie stain for 
5 min. The stain was then removed and the staining process was then repeated with 
Coomassie de-stain and an image was taken on a camera capable of capturing Coomassie 
blue stained images. 
2.1.10 Preparation of competent cells 
A 100 ml overnight culture of E. coli M72 cells were cultured as section 2.1.5 without the 
addition of antibiotics. This was then chilled on ice for 10 min then centrifuged at 250 x g for 
10 min at 4oC, the supernatant was then removed and the cells resuspended in 10 ml of 100 
mM CaCl2 and incubated on ice for 20 min. This was then centrifuged as before, the 
supernatant removed and then resuspended in 85 mM CaCl2 with 15% glycerol and stored 
at -80oC in 250 µl aliquots. 
2.2 Protein purification 
2.2.1 Buffers 
 For protein purification 3 buffers were used. Cell lysis buffer consisting of 50 mM Tris pH8, 
5 mM EDTA, 150 mM NaCl and 5% glycerol (v/v) and was used for the initial cell lysis. 
Potassium phosphate buffer (KPB) was used for ion exchange chromatography when using a 
Hi-trap Heparin HP column (GE Healthcare) and was comprised of 20 mM potassium 
phosphate which was made from a mixture of K2HPO4 and KH2PO4 salts dependent on final 
pH, 1 mM EDTA, 1 mM DTT and 5% glycerol (v/v). For ion exchange on the Hi-trap Q HP 
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column (GE Healthcare) Q buffer was used and was made of 20 mM Tris pH8, 1 mM EDTA, 1 
mM DTT and 5% glycerol (v/v). 
2.2.2 Purification of cys-gamma-alpha and alpha 
A 10 g frozen cell pellet (prepared as in section 2.1.6) was resuspended in cell lysis buffer 
using 5ml per Gram, then treated with lysozyme to give a final concentration of 200 µg/ml 
and stirred on ice until viscous. The solution was then treated with sodium deoxycholate and 
DTT to give final concentrations of 500 µg/ml and 1 mM respectively. Phenylmethylsulfonyl 
fluoride (PMSF) was then added to give a final concentration of 2.3 µg/ml, the solution was 
then mixed for 5 min. 
The resulting solution was then sonicated at 20% amplitude using a microtip for 4 x 30 s, with 
a 1 min rest on ice between sonications. The sonication allowed full lysis of the cells and the 
release of cell bound protein into solution. This mix was then centrifuged at 40000 x g for 30 
min at 4oC and the resulting supernatant diluted with an equal volume of sterile deionised 
water.  
Polyethylenimine (PEI) was then added to this diluted supernatant in order to precipitate out 
the DNA released from the lysed cells, the amount of PEI needed was first calculated by 
slowly adding PEI to a 1ml Sample of the lysate. This volume of PEI was then scaled up inline 
with the volume of lysate present. This step insures a clean protein preparation allowing 
easier purification. It was then centrifuged at 48000 x g for 20 min and ammonium sulphate 
added to create a 4 M solution, this was mixed and then left for 1 hour at 4oC. This allows 
the precipitation of protein from solution allowing easy separation of the proteins from any 
unwanted cellular material still in solution. The resulting slurry was centrifuged at 15000 x g 
for 20 min and the pellet resuspended in pH 5.5 KPB this was then dialysed at 4oC against 
300 ml of pH 5.5 KPB 3 times for 5 hours or longer between buffer changes, in order to 
remove ammonium sulphate. 
Ion exchange chromatography was then carried out on the sample. For the purification of 
both NMB alpha protein and the cys-γ-α protein a 5 ml Hi-trap Heparin HP column (GE 
Healthcare) was used according to the manufacturer’s instructions with pH 5.5 KPB as the 
column running buffer. This was then followed by further ion exchange chromatography 
using a 1 ml Hi-trap Q HP column (GE Healthcare), used according to the manufacturer’s 
instructions with Q buffer as the column running buffer, followed by another 5 ml Hi-trap 
Heparin HP column which was run identically to the first. For all of the columns the dead 
volume of the system was collected along with the flowthrough, wash fraction and the eluted 
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fractions. In all cases 20 fractions were eluted from the column using a 0.1 M-1 M sodium 
chloride gradient based upon the column running buffer. Between each column the column 
dead volume, flowthrough, wash and collected fractions were analysed by SDS-PAGE (section 
2.1.9) in order to locate the protein of interest. The fractions containing the protein of 
interest then underwent buffer exchange dialysis prior to application to the subsequent 
column. 
Pure protein was then quantified by the far UV protein assay (section 2.2.3) and then 
concentrated and stored in 50% glycerol at -20oC. 
2.2.3 Purification of IgA1P 
IgA1P protein was purified either using size exclusion chromatography, section 2.7.4 or nickel 
affinity resin. Fresh nickel beads were loaded into a column and washed with 2 column 
volumes of dH2O, cells were then lysed as detailed in section 2.2.2 without PEI precipitation. 
Ammonium sulphate precipitated protein was resuspended in Ni load buffer (25 mM Tris.hcl, 
0.5 M NaCl, 20 mM imidazole and 5% glycerol pH8) and dialysed against 400 ml of the same 
buffer. The nickel column was prepared for sample loading as per the manufacturer’s 
instructions before the cell lysate was loaded on to the beads, the flowthrough was collected 
as the lysate was loaded on to the column. The column was then washed with Ni load buffer 
and a series of stepwise elutions were performed using 100, 200 and then 500 mM imidazole, 
these elutions were collected and stored separately prior to SDS PAGE analysis. 
2.2.4 Far UV protein assay 
Samples of protein underwent buffer exchange dialysis against pH7 20 mM KPB, buffer 
exchanged samples were then diluted fourfold with distilled water to pH7 5 mM KPB, this 
was also done with buffer outside the dialysis bag as a blank. 
Absorbance of the samples at 220 nm was measured using a NanoDrop ND-1000 
spectrophotometer (Thermoscientific) with a 10 µl load. The sample was then diluted until 
an absorbance reading at 220 nm (A220) of between 0.2-0.5 A220 was reached. At 220 nm a 
mg of protein gives an absorbance reading of 11, therefore the concentration of the sample 
was calculated by using the following equation:  
((A220x dilution factor ) x( 1000/loadsize)) / (1/L) = A220/mL 
 (A220/mL) / 11 = Sample concentration in mg/mL 
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Where L = light pathlength (cm) and load size = load on to NanoDrop ND-1000 
spectrophotometer (µl) 
2.2.5 BCA assay  
Protein concentrations were measured using the BCA protein assay kit (Thermoscientific) by 
following the small volume protocol for low concentration solutions.  BSA standards were 
made at 250, 125, 50, 25, 5 and 0 μg/mL by diluting 2mg/mL BSA in the same buffer as the 
protein. BCA working reagent was made by mixing 50 parts of BCA reagent A with 1 part of 
BCA reagent B in order to give sufficient volume to add 200 μL to every sample or standard.  
The standards or sample (25 μL) were pipetted in to a microplate well, samples and standards 
were all measured in triplicate, and 200 μL or working reagent was then added to every well 
and mixed using a shaker. The plate was then covered and incubated at 37oC for 30 minutes. 
The absorbance of the wells was then measured using a plate reader at 562nm. 
2.3 Protein structural studies 
2.3.1 Crystallography buffers 
All crystallography screens were set up using protein in pH7 20 mM potassium phosphate, 
made from a mix of K2HPO4 and KH2PO4, 1 mM EDTA and 1 mM DTT.  
2.3.2 X-ray crystallography screens  
The following 96 well crystallography screens were used in order to assess the crystallisation 
conditions required for both the α protein and the c-γ-α protein;  PACT suite, JCSG+, HR2-
137, MPD, pH clear, ammonium sulphate suite, classic suite and PEG suite (All supplied by 
Qiagen except HR2-137 which was supplied by Hampton Research)  . The use of multiple 
screens per protein allowed many different crystallisation conditions to be tested, therefore 
allowing more efficient crystallisation condition optimisation. 
2.3.3 X-ray crystallography  
Crystallography screens were set up using c-γ-α and α stocks buffer exchanged via dialysis 
into pH7 20 mM potassium phosphate, 1 mM DTT and 1 mM EDTA. Screens were set up using 
a Matrix Hydra II (Thermoscientific) set to take up 100 µl of buffer and precipitant mix and 
0.2 µl of protein sample.  Both α and c-γ-α were screened against all of the screens listed in 
section 2.3.2 prior to optimisation of crystal growth conditions. 
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2.3.4 Circular dichroism 
Protein stocks were buffer exchanged in to 1xPBS using a Vivaspin 6 MWCO 5000 column 
(Sartorius) and diluted to around 0.1mg/mL, 100 μL of the sample was then placed in a quartz 
cuvette and loaded in to a Jasco J-10 Spectropolarimeter with the following settings;  
Parameter Value 
Sensitivity 100 mdeg 
Start 300 nM 
End 190 nM 
Data pitch 1 nM 
Scanning mode Continuous 
Scanning speed 20 nM/min 
Response 8 Sec 
Band width 1 nM 
Slit width 1 nM 
Accumulations 5 
Raw data was then exported into GraphPad Prism for analysis.  
2.4 Protein interactions with blood 
2.4.1 Buffers 
In order to measure protein interactions with blood the proteins first had to be resuspended 
in carbonate buffer consisting of 25 mM sodium hydrogen carbonate, 1 mM DTT and 5% 
glycerol buffer adjusted to pH 8.5 which allowed FITC labelling. In order to purify leukocytes, 
erythrocyte lysis buffer was used to preferentially lyse the erythrocytes in human whole 
blood samples obtained via the Clinical Research Facility (The Royal Hallamshire Hospital, 
Sheffield). This lysis buffer was composed of 168 mM ammonium chloride, 10 mM potassium 
hydrogen carbonate and 126 µM EDTA adjusted to pH 7.3. For washing blood cells prior to 
incubation with labelled proteins PBS was used and contained 137 mM sodium chloride, 2.5 
mM potassium chloride, 1 mM sodium hydrogen phosphate and 2 mM monopotassium 
phosphate adjusted to pH 7.4. Prior to analysis on the FACScalibur cells were resuspended in 
FACS buffer made of PBS with 1% BSA (w/v). Western blotting was also performed on SDS 
PAGE gels, for transferring the protein on to Amersham Hybond-ECL blotting membrane (GE 
Healthcare) transfer buffer consisting of 20% methanol, 48 mM Tris and 27 mM glycine all in 
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dH2O. For the washing of the membrane washing buffer was used which consisted of 1 x PBS 
with 0.05% (v/v) tween was used and for the blocking of non-specific antibody binding on 
the membrane blocking buffer was used which consisted of 1 x PBS with 0.05% (v/v) tween 
and 1% (w/v)  milk powder.  
2.4.2 FITC Labelling 
FITC labelling was carried out in order to allow the measurement of protein interactions with 
blood cells via flow cytommetry as discussed in section 2.4.4. α, c-γ-α and BSA at 0.4 mg/ml 
in carbonate buffer were incubated with a 5 fold molar excess of FITC dissolved in DMF, this 
was increased to a 10 fold molar excess in the case of BSA, in the dark for 1 hour at RT. Excess 
FITC was removed by dialysing at 4oC overnight against 400 ml of 250 mM pH 8.5 sodium 
carbonate buffer.  
2.4.3 Flow cytometry analysis of protein interactions with blood 
 2.4.3.1 Interactions with whole blood 
A 100 µl aliquot of whole blood was mixed with the 100 µl of the 3 FITC labelled proteins 
from section 2.4.2 diluted to varying  concentrations in order to give a final concentration of 
the proteins of 100 µg/ml, 40 µg/ml, 200 µg/ml, 5 µg/ml and 0 µg/ml whilst keeping the 
buffer concentrations equal. The resulting mix was incubated at RT for 20 min and then 
centrifuged at 300 x g and the pellet washed twice with cold PBS, the washed pellet was then 
resuspended in 0.5 ml of FACS buffer before protein-cell interactions were measured and 
analysed using a FACScalibur (BD Biosciences) and Cellquest software (BD Biosciences). The 
obtained measurements for forward scatter (FSC) and side scatter (SSC) allowed the cells to 
be sorted by size and granularity. White blood cells were then excluded from analysis by size 
and granularity measurements in order to focus on interactions between the labelled 
proteins and erythrocytes in the presence of serum based factors. This was followed by 
taking SSC and fluorescence measurements in order to quantify protein-cell interactions.  
2.4.3.2 Interactions with white blood cells 
A 100 µl aliquot of whole blood was mixed with 100 µl of the 3 FITC labelled proteins from 
section 2.4.2 in order to give final concentrations of 100 µg/ml, 40 µg/ml, 20 µg/ml, 5 µg/ml 
and 0 µg/ml whilst keeping the buffer concentrations equal. This mixture was incubated at 
RT for 20 min then incubated for 5 min after the addition of 1.3 ml of erythrocyte lysing 
solution. The solution was then centrifuged at 300 x g and the pellet washed twice with cold 
PBS, the washed pellet was then resuspended in 0.5 ml of FACS buffer before protein-cell 
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interactions were measured and analysed using a FACScalibur (BD Biosciences) and Cellquest 
software (BD Biosciences). Any remaining erythrocytes were excluded from analysis by size 
using the measured SSC and FSC readings this also allowed white blood cell gating according 
to size and granularity, prior to quantifying protein-cell interactions by measuring SSC and 
fluorescence.  
2.4.4 Electrophoretic mobility shift analysis of interactions with blood 
An electrophoretic mobility shift assay was used to analyse interactions between α and c-γ-
α and whole blood and serum. This assay uses a band shift analysis technique that monitors 
the change in migration between a control sample of the protein and a sample of the protein 
incubated with a prospective interaction partner. If a positive interaction is detected the 
protein will migrate slower through the SDS PAGE gel due to the increase in molecular weight 
caused by the interaction of the two proteins. In this assay α and c-γ-α were incubated with 
either; whole human, ovine or equine blood or human serum as well as a cross linking agent. 
These samples were then analysed by western blotting in order to measure any shift in 
protein position on the acrylamide gel caused by the binding of blood or serum proteins by 
α or c-γ-α and its resultant larger size and therefore slower migration. 
2.4.4.1 Western blotting 
Western blotting was carried out using a 13% (w/v) acrylamide SDS PAGE gel made up of 4.3 
ml 30% acrylamide, 3.5 ml dH2O, 2 ml 500 mM Tris-Bicine pH 8.3, 100 µl 10% (w/v) SDS, 50 
µl 25 mg/ml APS and 16 µl TEMED with a stacking gel made as in section 2.1.7 which was 
allowed to set with a 15 µl well comb inserted. The SDS PAGE gel was then loaded and run 
at a constant current of 40 mA until the dye front reaches the bottom of the gel as in section 
2.1.9. This gel was then soaked in transfer buffer along with the membrane and 2 blotting 
paper pads for 10 minutes. The protein was then transferred from the gel to Amersham 
Hybond-ECL blotting membrane (GE Healthsciences) using a Biorad semi-dry transfer cell at 
10 V for 1 hour. This membrane was then blocked overnight using 10 ml of blocking buffer 
at 4oC whilst the tube was rolled, it was subsequently washed in 5 ml of washing buffer at RT 
for 30 min whilst rolling. Primary antibody was diluted to a 1:2500 dilution in 10 ml of 
blocking buffer, the membrane was then incubated in 5 ml of this for 1 hour at RT whilst 
rolling, after an hour the membrane was again washed with 5ml of washing buffer for 30 
minutes at RT whilst rolling. The membrane was then incubated with 5 ml of 1:10000 diluted 
secondary horse radish peroxidase conjugated antibody for 2 hours at RT whilst rolling then 
washed with 5 ml of washing buffer for 20 minutes at RT whilst rolling. The membrane was 
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then imaged by incubating it for 2 minutes with Pierce ECL western blotting substrate (Pierce) 
before exposing Kodak BioMax chemiluminescense film (Kodak) to the membrane for 1 min 
in a developing cassette in the dark room before developing and fixing the film. 
2.4.4.2 Cross linking of protein to serum and whole blood 
De-fibrinated blood samples, in this case equine and sheep, were centrifuged at 500 x g for 
5 minutes before the cells were washed in PBS twice by resuspending the cells in 1 ml of PBS 
and centrifuging as before. These cells were then diluted to a 1:10 dilution using PBS, human 
serum was also used and diluted  1:10 with PBS, 35 µl of the diluted serum or cell samples 
was the mixed with 25 µl of 100 µg/ml α or c-γ-α protein then made up to 100 µl using PBS. 
This mixture was then incubated on ice for 1 hour. After 1 hour 5 µl of 2.5% (w/v) 
glutaraldehyde was added to each reaction and the resulting mix incubated on ice for 2 
hours, the reaction was subsequently stopped by the addition of 10 µl of 1 M Tris pH 8.3 with 
a 15 minute incubation on ice. The reaction was then analysed by western blotting as 
described in 2.4.4.1 in order to identify any band shift caused by protein interaction.  
2.5 Analysis of protein interactions with blood 
2.5.1 Biotinylation of alpha 
Alpha protein was biotinylated using EZ-link NHS-biotin (Thermoscientific). Alpha was 
dialysed into 1x PBS buffer and then labelled with 10 mM NHS-biotin dissolved in DMF at 
either a 5 times molar excess or a 1:1 ratio of Alpha to NHS-biotin. The reaction was 
incubated at RT for 30 mins and then excess biotin was removed by dialysis against 1x PBS.  
2.5.2 IαI purification  
A 450 mL sample of pig blood was collected directly into a sterile container containing 63 mL 
of sterile filtered 15 mM citric acid, 100 mM sodium citrate, 16 mM sodium phosphate buffer 
at pH 5.6, 160 mM glucose and 2 mM adenine hydrochloride. Serum was isolated from the 
blood by centrifugation at 1500 x g for 20 minutes and then stored in 100 mL aliquots at -
20oC. 
A 100mL aliquot of serum was thawed at RT before being mixed with a buffer containing 20 
mM Tris.HCl, 4 mM EDTA and 0.3 M NaCl (Buffer A) to give a final volume of 1 L. Diluted 
serum was then gravity fed through a Q column containing 20 mL of Q HP resin (GE 
lifesciences) at 4oC. The loaded column was then washed with 300 mL of buffer A, this wash 
was then stored at 4oC. IαI was then eluted using 150 mL of buffer A with 0.6 M NaCl followed 
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by 150 mL of buffer A with 1 M NaCl, both elutions were stored separately at 4oC for analysis 
by SDS PAGE. 
2.5.3 Protein-Protein Interaction Analysis by Biolayer Interferometry 
Protein-protein interactions were analysed using a BLItz system (FortéBio) fitted with 
streptavidin coated Dip and Read biosensors (FortéBio). Interactions were analysed using a 
multistep kinetics protocol. A baseline was established using PBS, afterwards 4 μL of 
biotinylated alpha was added to the probe and incubated for 120 seconds. The probe was 
then washed for 30 seconds with fresh PBS, following this 4 μL of a potential binding partner 
was added to the probe, either IαI or whole serum, and incubated for a further 120 seconds. 
This step was followed by another 30 second wash in PBS and then a 120 second dissociation 
step to analyse the dissociation rate. 
2.5.3.1 Conditions used for Biolayer interferometry analysis of alpha and IαI 
interactions 
Biolayer interferometry analysis of the interaction between α and purified IαI was carried 
out as described in section 2.5.3. In order to test possible protein-protein interactions the 
following experimental conditions were used; 
Run 1- 1xPBS baseline (30 sec), 4 μl of Biotinylated α (20 μg/ml) bound to a streptavidin 
probe (120 sec), 1xPBS wash (30 sec), 4 μl of undiluted pig serum incubated with the probe 
(120 sec), dissociation step in 1xPBS (120 sec). 
Run 2- 1xPBS baseline (30 sec), 4 μl of Biotinylated α (2 0μg/ml) bound to a streptavidin 
probe (120 sec), 1xPBS wash (30 sec), 4 μl of 1.33 fold diluted pig serum incubated with the 
probe (120 sec), dissociation step in 1xPBS (120 sec). 
Run 3- 1xPBS baseline (30 sec), 4 μl of Biotinylated α (20 μg/ml) bound to a streptavidin 
probe (120 sec), 1xPBS wash (30 sec), 4 μl of 2 fold diluted pig serum incubated with the 
probe (120 sec), dissociation step in 1xPBS (120 sec). 
Run 4- 1xPBS baseline (30 sec), 4 μl of Biotinylated α (20 μg/ml) bound to a streptavidin 
probe (120 sec), 1xPBS wash (30 sec), 4 μl of 4 fold diluted pig serum incubated with the 
probe (120 sec), dissociation step in 1xPBS (120 sec). 
Run 5- 1xPBS baseline (30 sec), 4 μl of Biotinylated α (20 μg/ml) bound to a streptavidin 
probe (120 sec), 1xPBS wash (30 sec), 4 μl of 10 fold diluted pig serum incubated with the 
probe (120 sec), dissociation step in 1xPBS (120 sec). 
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Run 6- 1xPBS baseline (150 sec), 4 μl of 2 fold diluted pig serum incubated with the probe 
(120 sec), dissociation step in 1xPBS (120 sec). 
2.5.3.2 Conditions used for biolayer interferometry analysis of pre-incubated alpha 
and IαI interactions 
Further to section 3.2.2 several reactions were set up to measure protein-protein 
interactions using pre-incubated protein mixtures. It was hoped that by mixing the α and IαI 
proteins together and incubating them for 1 hour at RT it would eliminate any possible 
effects of steric hindrance caused by α annealing to the probe. In order to test this the 
following conditions were used; 
Run 1- 1xPBS baseline (30 sec), 4 μl of 0.2x biotinylated α protein (120 sec) 
Run 2- 1xPBS baseline (30 sec), 4 μl of 1x biotinylated α protein (120 sec) 
Run 3- 1xPBS baseline (30 sec), 4 μl of 0.2x biotinylated α protein which had been incubated 
with 100 μl of purified IαI at RT for 1 hour (120 sec) 
Run 4- 1xPBS baseline (30 sec), 4 μl of 1x biotinylated α protein which had been incubated 
with 100 μl of purified IαI at RT for 1 hour (120 sec) 
Run 5- 1xPBS baseline (30 sec), 4 μl of 0.2x biotinylated α protein which had been incubated 
with 100 μl of purified 1.5 fold diluted IαI at RT for 1 hour (120 sec) 
Run 6- 1xPBS baseline (30 sec), 4 μl of 1x biotinylated α protein which had been incubated 
with 100 μl of purified 1.5 fold diluted IαI at RT for 1 hour (120 sec) 
Run 7- 1xPBS baseline (30 sec), 4 μl of purified IαI (120 sec) 
2.5.4 Alpha-WBC and serum pulldowns 
White blood cells were isolated from whole blood using erythrocyte lysis buffer as in section 
2.4.3.2. Serum was isolated by centrifuging citrated whole blood at 20000 x g in a benchtop 
centrifuge for 2 minutes. Pulldown reactions were set up in triplicate in 0.5 mL eppendorfs 
containing 100μl of avadin agarose slurry (ThermoScientific Pierce) as follows; 
W- 50 μL Purified white blood cells, avidin beads, 100 μL 1xPBS, 50 μL 1x biotinylated NMB 
α, 20 μL of dimethyl 3,3'-dithiobispropionimidate  (DTBP) 
S-  50 μL Serum, avidin beads, 100 μL 1xPBS, 50 μL 1x biotinylated NMB α, 20 μL of DTBP 
WS—50 μL Purified white blood cells , 50 μL Serum, avidin beads, 50 μL 1xPBS, 50 μL 1x 
biotinylated NMB α, 20 μL of DTBP 
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The reactions were then incubated at RT for 1 hour, afterwards pH8 Tris was added to a final 
concentration of 50 mM to stop the crosslinking reaction. The reaction was left to quench at 
RT for 30 minutes, before being centrifuged at 20000 x g to separate the supernatant from 
the beads. The supernatant was then removed and the beads were washed in 0.5 mL of 
1xPBS. The beads and the supernatant were then analysed by SDS PAGE as outlined in section 
2.1.9 using a 7.5% acrylamide gel. 
2.5.5 Alpha-IαI pulldowns 
For the pulldown reaction 0.2mg of Biotinylated alpha (section 2.5.1) was added to 100 μL 
of streptavidin beads (ThermoScientific Pierce) along with 0.1 mg of DTBP that was 
previously resuspended at a concentration of 5 mg/mL in 1xPBS. The reaction was incubated 
at RT for 1hr before being stopped with pH8 Tris at a final concentration of 50 mM. Once 
stopped 20 μL of avidin agarose beads (ThermoScientific Pierce) were added and the mixture 
was incubated for a further 1 hour at RT and then centrifuged at 20000 x g using a benchtop 
centrifuge in order to separate the beads from the supernatant. The beads were then 
washed with either 0.1 M NaCl NaHCO3 buffer or 0.5 M NaCl NaHCO3 buffer and centrifuged 
again at 20000 x g. 15μL of either beads or supernatant were mixed with 10 μL of loading 
dye before being boiled at 95oC for 3 minutes and loaded onto 7% (w/v) SDS gel. 
2.5.5.1 Conditions used for the alpha and IαI pulldown assay  
A pulldown assay was carried out as detailed in section 2.5.5. In order to characterise any 
possible interactions between the two proteins the following experiments were set up; 
 Volume of α covered 
bead slurry 
Volume of purified 
IαI in 1xPBS 
Volume of 
1xPBS 
Volume of 0.1 
mg/mL BSA 
Tube 1 100 μl 200 μl 112.5 μl 0 
Tube 2 200 μl 200 μl 12.5 μl 0 
Tube 3 100 μl 200 μl 100 μl 12.5 μl 
Tube 4 200 μl 200 μl 0 12.5 μl 
2.6 PCR amplification and fusion of neisserial Gly1-ORF1 and 
Alpha protein 
2.6.1 Buffers 
A Tris base, acetic acid and EDTA buffer (TAE) was used as the running buffer for agarose 
gels; the TAE contained 40 mM Tris Base, 19 mM acetic acid and 1 mM EDTA. For eluting 
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DNA from columns during miniprep and also for resuspending and diluting primers DNA 
elution buffer was used and contained 20 mM Tris pH8 with 1 mM EDTA. 
2.6.2 Primers 
All primers were supplied by Eurofins and resuspended in DNA elution buffer and kept as a 
100 pmol/μL  stock which was diluted to 10 pmol/μL  working stock. Once diluted in DNA 
elution buffer the primers were stored at -20oC. For primer list see Appendix I. 
2.6.3 Miniprep of plasmid DNA 
Plasmid purification was carried out using the QIAprep spin miniprep kit (Qiagen) following 
the centrifuge protocol as supplied with the kit.  The protocol was carried out on 5ml of 
overnight cell culture made in LB containing 100 µg/ml of ampicillin as in section 2.1.4. The 
resulting purified plasmid was eluted from the miniprep column using DNA elution buffer 
and then stored at -20oC. 
2.6.4 Sequencing 
Sequencing was carried out by the Core Genomics facility located in the University of 
Sheffield Medical School (http://genetics.group.shef.ac.uk). A 20 µl sample of plasmid 
purified by miniprep (section 2.6.3) was provided to the facility and the sequencing M13 
primers were used to sequence the plasmid insert. Data was retrieved and analysed by a 
combination of FinchTV (Geospiza) and Multalin software. 
2.6.5 PCR amplification and mutagenesis 
PCR amplification and mutation was carried out on both the NMB α protein, located in the 
pJONEX4_NMB_alpha plasmid, the neisserial IgA1P gene, located on the pJONEX4_IgAP_WT 
plasmid, and the N. meningitidis Gly1-ORF1 gene, located in the 
pJONEX4_neisserial_gly1_ORF1-his. Using a Phusion high-fidelity PCR kit (New England 
Biolabs) separate 50 µl reactions without DMSO were set up according to the manufacturer’s 
instructions supplied with the kit. For these reactions 15-50 pg of the appropriate purified 
plasmid was used as a template, the template plasmids were isolated prior by miniprep 
carried out as described in section 2.5.3. In this study two different methods of PCR 
mutagenesis were used, 1 method used 4 primers (two internal and two external to achieve 
the mutation whilst the other used one pair which amplified the whole plasmid124. The 
former method was used initially however later in the study the latter method proved to be 
more reliable.  
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The PCR cycles used were generally: 95oC- 5 min, (95oC - 30s, 55oC - 1 min, 72oC - 1 min 30s) 
20 cycles, 72oC - 5 min. Although the 55oC annealing step was often tweaked in order to 
achieve a purer end product. Products were analysed using a 2% agarose gel as described in 
section 2.5.6 and the bands of the correct size were extracted from the gel using a QIAEX II 
gel extraction kit (Qiagen) as per the manufacturer’s instructions in order to remove 
contaminating templates, products and primers. The resulting pure plasmid was then 
transformed into chemically competent E. coli M72 cells as described in section 2.5.8. 
2.6.6 Agarose gel 
Agarose gels for DNA analysis were made using 2% (w/v) electrophoresis grade agarose 
(Sigma Aldrich) dissolved in TAE buffer heated in a microwave. Once cool 1 µl of 10 mg/ml 
ethidium bromide was added per 30 ml of gel solution and thoroughly mixed. This was then 
poured into a gel rig with a suitable comb in place to form 15 µl wells. 
2.6.7 PCR fusion 
Using a Phusion high-fidelity PCR kit (New England Biolabs) a 50 µl reaction without dimethyl 
sulfoxide (DMSO) was set up according to the manufacturer’s instructions supplied with the 
kit in order to fuse the purified PCR products. For this 15-50 pg of purified α PCR amplification 
product and 15-50 pg of amplified Gly1-ORF1 PCR amplification product were used as a 
template in conjunction with the M13 uni and M13 rev primers. PCR cycle: 95oC- 5 min, (95oC 
- 30s, 50oC - 1 min, 72oC - 1 min 30s) 20 cycles, 72oC - 5 min. Products were analysed using a 
2% agarose gel as described in section 2.5.6 and the bands of the correct size were extracted 
from the gel using a QIAEX II gel extraction kit (Qiagen) as per the manufacturer’s instructions 
in order to remove contaminating templates, products and primers. The resulting pure 
plasmid was then transformed into chemically competent E. coli M72 cells as described in 
section 2.5.8. 
2.6.8 Transformations 
A 100 μL aliquot of chemically competent cells were mixed with 10-50 ng of DNA and 
incubated on ice for an hour, heat shocked at 42oC for 1 min and then rested on ice for 10 
min. Cells were then plated on to LB amp plates. 
2.7 Analysis of the alpha proteins potential as a carrier protein 
2.7.1 Mouse antibody titre model 
Six week old female BALB/C mice were immunised with a 10 μg dose of alpha, gamma, c-ɣ-α 
or 50:50 mixture of alpha and gamma. All solutions were at 50 μg/mL diluted in PBS. A 0.2 
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mL dose of PBS was also given to the negative control mice to rule out any immune response 
to the procedure. 4 mice were used in all of the experimental groups and 2 mice were used 
as a negative control. The mice were immunised by IP injection at days 0 and 13 and tail vein 
bleeds were carried out on days 14 and 28. Whole blood was centrifuged at 1000 x g for 10 
minutes in order to obtain plasma, this was then frozen at -20oC. ELISAs were later carried 
out on this plasma in order to quantify the antibody titres as explained in section 2.7.2 
2.7.2 Antibody titre ELISA 
Plasma was serially diluted to dilutions of 1:500, 1000, 2000, 5000 and 10000 in PBS. 96 well 
ELISA plates were coated with 100 μl of 10 μg/mL of alpha, gamma or PBS and incubated 
O/N at 4oC to coat plates.  Plates were then aspirated and washed with PBS tween 0.05% 
(w/v), then blocked with 100 μL of PBS with 5% (w/v) milk powder at RT for 1 hour. Plates 
were aspirated and washed with PBS-T, serial dilutions were then added to individual wells 
and the plates covered with parafilm (Bemis) and incubated with shaking at RT for 2 hours. 
Plates were then aspirated and washed with PBS-T. Next 100 μL of anti-mouse IgG linked to 
HRP (Abcam) at a 1:2000 dilution in PBS was added to wells and incubated for 1 hour at RT 
with shaking. Plates were then aspirated and washed with PBS-T before 100 μL of 2,2’-Azino-
bis(3-ethylbenzthiazoline-6-sulfonic acid) (Sigma Aldrich), which quantifies HRP activity, was 
added to each well. This reaction was stopped with 1% (w/v) SDS solution after 2-5 min. The 
absorbance of each well was read at 405 nm using a plate reader. 
2.7.3 Crosslinking alpha with Gly1 homologues and tbFEND183K 
Alpha was crosslinked with a variety of Gly1 homologues, as well as the Trypanosoma brucei 
FEN D183K mutant. These crosslinked proteins would then be injected into female New 
Zealand white rabbits in order to quantify the potential of alpha as a carrier protein as 
explained in section 2.7.6. Both proteins to be cross-linked were dissolved in 1xPBS. Alpha 
was labelled using sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate 
(sulfo-SMCC) (Thermo Scientific) at a 5 times molar excess. The sulfo-SMCC was dissolved in 
water and then added to Alpha in 1xPBS and incubated at RT for 30 min, afterwards the 
excess sulfo-SMCC was removed by buffer exchange using a Vivaspin column (Sartorius) with 
a MWCO of 5000. Gly1 MH0579/1205/para, neisserial gly1 and tbFEND183K were all labelled 
with N-succinimidyl-S-acetylthiopropionate (SATP) at a 5 times molar excess. SATP was first 
dissolved in 50-100 μL of DMSO and then added to the protein in 1xPBS and incubated at RT 
30 mins, afterwards the excess SATP was removed by buffer exchange using a Vivaspin 
column (Sartorius) with a MWCO of 5000. The SATP was then deacetylated ready for 
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crosslinking by incubating it with 100-200 μL of deacetylation solution (0.5 M hydroxylamine, 
25 mM EDTA in 1xPBS at pH 7.2-7.5) at RT for 2 hours. The deacetlyated SATP labelled protein 
was then mixed with the sulfo-SMCC labelled alpha protein and incubated at RT for 30 min 
or 4oC O/N. Protein conjugates were purified using a size exclusion chromatography column 
attached to an ACTA rig as covered in section 2.7.4. 
2.7.4 Size exclusion chromatography 
A column packed with Sephacryl S-200 HR (GE Healthcare) was used in order to separate 
proteins based on molecular weight. Prior to loading on the column the protein sample was 
filtered through a 0.2 μm filter and the column was equilibrated with 10 column volumes of 
1xPBS. The sample, with a maximum volume of 10% of the columns volume, was then 
loaded. Sterile 1xPBS was then used to wash the column and up to 60 fractions were 
collected. These were then analysed by SDS PAGE as described in section 2.1.9.  
2.7.5 LPS assay 
Prior to being injected the crosslinked proteins were checked for LPS contamination, this 
ruled out elevated immune responses as a result of contamination. LPS content in samples 
was measured using Limulus Amebocyte Lysate (LAL) QCL-1000 kit (Lonza). Samples were 
then analysed using the supplied test tube protocol and glass test tubes which were washed 
with distilled water and sterilised in an autoclave for 20 min at 120oC.  
Standards were made at 1, 0.5, 0.25, 0.1 and 0 EU/mL (endotoxin diluted in LAL reagent 
water). 50 μL of sample or standard was placed in a glass test tube at 37oC then 50 μL of LAL 
was added and the reaction incubated at 37oC for 10 min. 100 μL of chromogenic substrate 
was then added and incubated at 37oC for 6 min. Finally 100 μL of 10% (w/v) SDS was added 
to stop the reaction. The absorbance of the samples and standards were measured at 405 
nm using a NanoDrop ND-1000 spectrophotometer (Thermoscientific). 
2.7.6 Generon New Zealand white rabbit Antibody model 
Four female New Zealand white rabbits were immunised with the following mixtures of 
proteins; 
Protein A- α crosslinked to the Mannheimia haemolytica Gly1 paralogue plus free 
Mannheimia haemolytica Gly1 homologue MH0579. 
Protein B- α crosslinked to the Mannheimia haemolytica Gly1 homologue MH0579 plus free 
Mannheimia haemolytica Gly1 paralogue. 
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Protein C- α crosslinked to Trypanosoma brucei FEN D183K mutant plus free Mannheimia 
haemolytica Gly1 homologue MH1205. 
Protein D- α crosslinked to the Mannheimia haemolytica Gly1 homologue MH1205 plus free 
Trypanosoma brucei FEN D183K mutant. 
These immunisations would give data as to whether proteins crosslinked to the α protein 
elicited a larger immune response to those that were injected without conjugation to α. 
Rabbits were immunised on day 1 and 14 with 200 μg of the respective protein mixture plus 
complete Freuds adjuvant. On day 28 the rabbits were then immunised with 100 μg of the 
respective protein mixture in the presence of incomplete Freuds adjuvant. Rabbits then had 
small test bleeds carried out on days 38 and 41 in order to check antibody titres prior to 
injection with 100 μg of the respective protein mixture in the presence of incomplete Freuds 
adjuvant on day 42. Rabbits then had small test bleeds carried out on days 52 and 55 in order 
to check antibody titres prior to a repeat injection of 100 μg of the respective protein mixture 
in the presence of incomplete Freuds adjuvant on day 56. Rabbits then had a final test bleed 
carried out on day 66 prior to a terminal bleed of around 46ml on day 67. Serum was then 
shipped to the University of Sheffield for analysis. 
2.7.7 Antibody purification 
In order to purify antibodies around 10 mg of the protein to which the antibody bound was 
immobilised on a 2 mL AminoLink Plus column (ThermoFisher) at pH7.2 in 1xPBS as directed 
by the supplied protocol. This involved first equilibrating the column at pH 7.2 using 1xPBS 
then adding the protein of interest along with 40µL of cyanoborohydride, resulting in a 
50mM final concentration of cyanoborohydride. The column was then incubated at RT for 6 
hours whilst being rolled. Post incubation the column was washed in 1xPBS prior to use. The 
rabbit serum containing the antibody was diluted two fold in 1xPBS and loaded on to the 
column, after the column had first been equilibrated with 6 mL of 1xPBS. The column was 
then incubated with the serum for 1 hour at RT whilst rolling before being centrifuged at 800 
x g for 1 minute at 10oC, this flow through was then set aside. The pure antibody was the 
eluted from the column using 6 mL of elution buffer (0.1 M glycine.HCl at pH2.5), to the pure 
antibody 300 μL of neutralisation buffer was then added (1 M Tris HCl at pH 8.5). Purified 
antibody was then stored at -20oC. 
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3. Investigation of alpha-host interactions 
3.1 Introduction 
As was discussed in chapter 1 the α protein has been the subject of some structural and 
functional characterisation over the last decade 25,95,102,111,112,116 . However, many questions 
still remain to be answered. Chief among these questions is why the α peptide so highly 
conserved in neisserial species and does it play a functional role in any step of the invasion 
and virulence of the pathogen. 
The function of the α protein has not been well characterised in vivo with previous studies 
hinting that α, through its possession of multiple nuclear localisation signals, could be able 
to target IgA1P into host cells in order for IgA1P to have maximum effect 116 . It has also been 
speculated that α could be involved in binding eDNA, a signal that could trigger neisserial 
biofilm formation in both blood vessels and at the mucosal layer 112 . This would mean that α 
could be involved in neisserial colonisation and survival within the host. Previous studies in 
the Sayers lab (Helena Parsons, MSc thesis, University of Sheffield, UK) have also shown that 
α may be involved in binding bikunin or the bikunin domain containing proteins such as Inter-
α-inhibitor, a serine protease inhibitor known to inhibit the function of trypsin and 
chymotrypsin 117 . This could be relevant in preventing these proteins from inhibiting the 
cleavage of IgA1P therefore allowing it to carry out its function in vivo. This could also explain 
the co-expression of alpha and IgA1P in as much as when IgA1P production is upregulated it 
is obviously required by the pathogen and as such inhibition of the protease must be 
prevented, this could therefore be carried out by a co-secreted factor such as α. 
The hypothesis of this work was that the alpha protein would interact with one or more 
serum based factors that could indicate a role in virulence determination, due to its co-
expression with another virulence factor IgA1P. This may then lead to further study of the 
proteins role in vivo and a better understanding of why the protein is highly conserved. 
In order to test this hypothesis the α protein was first expressed and purified and then a 
number of experiments were carried out using blood cells and serum derived proteins, from 
both human and animal samples as described below.  
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3.2 Results and discussion 
 
3.2.1 Alpha protein expression 
Cells were cultured in 6 ml of LB media as described in section 2.1.5 using E. coli M72 cells 
containing  either the pJONEX4_NMB_cys_γ_α or the pJONEX4_NMB_α plasmid. A protein 
expression check was then carried out as described in section 2.1.6. This highlighted the 
optimal time for bacterial harvest in order to gain the maximum yield of the protein of 
interest. 
In all cases multiple expression checks were carried out in order to confirm that the bacteria 
grew consistently and as such that the yield of protein and cells would be reproducible. 
It was found from multiple trials that a plateau in yield was reached after between 12 and 
24 hours of induction at 42oC, this is most likely due to the cells dying after this point. As a 
result, an overnight induction of the E. coli cells was routinely used (Fig 25).  
 
Figure 25. 10% (w/v) acrylamide SDS PAGE of a cys-ɣ-α expression time course. Lane 1 
protein weight marker (New England Biolabs), lane 2 uninduced cys-ɣ-α  cell pellet, lane 3  
cys-ɣ-α  cell pellet after a 1hr induction,  lane 4  cys-ɣ-α  cell pellet after a overnight induction. 
The expression of a protein at 35 kDa can clearly be seen post induction, this band 
corresponds to the 22 kDa cys-ɣ-α protein (Helena Parsons, MSc thesis, University of 
Sheffield, UK). The O/N induction was routinely used due to a plateau in expression being 
reached after 12 hours. 
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3.2.2 Alpha protein purification 
Cells were cultured in a 5 L fermenter containing 5YT as described in section 2.1.7 using E. 
coli M72 cells containing either the pJONEX4_NMB_cys_γ_α or the pJONEX4_NMB_α 
plasmid. This allowed a large volume of cells to be obtained from which the protein could be 
purified. Bacterial cell pellets containing α or cys-ɣ-α  were then treated as in section 2.2.2 
in order to purify the protein of interest.  Both α and cys-ɣ-α could be purified using the same 
protocol as the 26 peptide addition in the cys-ɣ-α did not significantly alter the attributes of 
the protein from those of the normal α protein.  The initial steps of this protocol were carried 
out in order to obtain a pure cell lysate containing no whole bacterial cells as well as 
removing any contaminating DNA which may interfere with ion exchange chromatography. 
The α and cys-ɣ-α proteins were both calculated to have a pI of around 9.3 and as such a 
pH5.5 buffer was used during ion exchange chromatography utilising a heparin matrix 
column. This is due to the fact that heparin has a negatively charged matrix which is often 
used for purifying DNA binding proteins and so the protein needed to be positively charged 
in order to adhere to the column. When proteins were applied to the Heparin HP column 
they bound to the matrix, although some may have been found in the flowthrough due to 
column overloading. The proteins eluted in fractions 6-12 of the salt gradient, as seen in 
Figure 26, and corresponds to a salt concentration of between 145-415 mM.  
 
Figure 26. A 10% (w/v) acrylamide SDS PAGE gel showing purification of c-γ-α  using a  
Heparin HP column at pH 5.5. In each case 10 μL of each sample was loaded onto the gel. 
Lane 1 protein weight marker (New England Biolabs), lane 2 crude protein extract, lane 3 
tubing dead volume, lane 4 column flowthrough, lane 5 column wash, lane 6-12 fractions 
from a sodium chloride gradient ranging from 145 mM NaCl to 415 mM NaCl. Lanes 6-12 
each correspond to a 1 column volume fraction. 
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After elution the fractions containing the protein of interest, in this case lanes 6-12, were 
pooled together. This pooled material contained the majority of the proteins of interest and 
so was dialysed and into Q column buffer and loaded on to an anion exchange column (Q-HP 
sepharose column GEhealthcare) at pH 8, in order to further purify the protein.  As the Q 
column is contains anionic exchange resin the protein eluted from the column in the 
flowthrough fraction as seen in Figure 27 whilst other cellular proteins bound to the resin, 
therefore purifying c-γ-α or α further.  
 
Figure 27. A 10% acrylamide SDS PAGE gel showing further purification of c-γ-α  using an 
anion exchange column at pH 8. Lane  1 protein weight marker (New England Biolabs), lane 
2 pooled protein fractions from first heparin column, lane 3 column flowthrough, lane 4 
column wash, lane 5-12 fractions from a sodium chloride gradient ranging from 100 mM NaCl 
to 415 mM NaCl. Lanes 5-12 correspond to a 1 column volume fraction. 
 
The flowthrough from the Q column was then dialysed into pH 5.5 potassium sulphate buffer 
and loaded onto another Heparin HP column .This repeat heparin column separated the pure 
c-γ-α or α from any remaining contaminants as seen in Figure 28. 
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Figure 28. A 10% acrylamide SDS PAGE gel showing the final purification of c-γ-α  using a  
Heparin HP column at pH 5.5.  Lane  1 protein weight marker (New England Biolabs), lane 2 
tubing dead volume, lane 3 column flowthrough, lane 4 column wash, lane 5-12 fractions 
from a sodium chloride gradient ranging from 145 mM NaCl to 460 mM NaCl. Lanes 5-12 
correspond to a 1 column volume fraction.  
 
The resulting purified protein was treated with 4 M ammonium sulphate in order to 
precipitate the protein and then centrifuged at 48000 x g for 20 min in order to pellet the 
protein. This pellet was then resuspended in 1-2 ml of pH 7 KPB in order to concentrate it. It 
was then quantified as described using either method from section 2.2.4 or 2.2.5. The 
quantified proteins were then tested for purity by western blot using a multiclonal anti-α 
rabbit antibody raised against purified α protein. This α protein used for antibody generation 
had previously been verified via mass spectrometry and the anti-α antibodies checked for 
specificity. 
3.2.3 Measurement of Interactions between alpha and human blood cells 
using flow cytometry 
FACS analysis of blood-protein interactions were carried out as described in section 2.4, the 
purpose of these experiments was to identify any potential cellular binding partners in the 
bloodstream for α or c-γ-α. These experiments both used FITC labelled proteins which could 
easily be detected using flow cytometry as well as a FITC labelled negative control. This 
allowed the identification and quantification of labelled proteins binding to either red blood 
cells or white blood cell populations. 
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3.2.3.1 Interaction between alpha and whole human blood 
In this experiment FITC labelled α, c-γ-α and BSA, all at 0.4 mg/ml, were incubated with whole 
blood at RT for 20 min before being centrifuged and re-suspended in FACS buffer as outlined 
in section 2.4.3.1. This process of centrifugation and resuspension effectively washed the 
cells therefore ensuring a sample free of debris. The resulting mix was then analysed using a 
FACScalibur machine (BD Biosciences) and Cellquest software (BD Biosciences). For this 
experiment interactions with erythrocytes were measured and therefore all other cells were 
gated out using SSC and FSC readings, the SSC and FSC readings measure the size and 
granularity of the cells in the sample. Erythrocytes are easily gated due to their small size and 
low granularity. Interactions between erythrocytes and fluorescent proteins were then 
quantified using SSC and fluorescence values in order to work out percentage of cells labelled 
fluorescently, when compared with a blank, and also the mean fluorescence intensity of the 
sample. 
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Figure 29. Analysis of the FACs data in Cellquest (BD Biosciences). The top graph shows that 
FITC labelled α and c-γ-α did not give a percentage labelling of erythrocytes higher than the 
negative control. However, the bottom graph shows that the average labelling intensity, as 
measured by geometric mean was higher for FITC labelled α and c-γ-α than for the negative 
control BSA. 
 
The result of this experiment, Figure 29 ,showed that the negative control, FITC labelled BSA 
protein, bound to erythrocytes at a much higher rate than expected which may hint at a non-
specific interaction between FITC and erythrocytes. Despite this, labelled proteins of interest 
were shown to bind to erythocytes with a similar percentage of labelling but a much higher 
geomtric mean than the negative control. This indicates that, potentially, the labelling is 
more specific. This is due to the fact that the geometric mean effectively quantifies the 
number of labels per erythrocyte and so although the same quantity of erythrocytes are 
labelled they are labelled at a much higher intensity. This hints that the α and c-γ-α proteins 
have a higher affinity for whole blood than BSA as they more efficiently bind to whole blood 
than the FITC-BSA, despite labelling the same percentage of cells in the sample. 
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3.2.3.2 Interactions between alpha and human white blood cells 
For this part of the experiment FACS interactions between FITC labelled α, BSA and c-γ-α, all 
at 0.4 mg/ml and white blood cells was measured. This was carried out as previous 
experiments in the Sayers group (University of Sheffield, UK) indicated that α protein may 
preferentially bind to neutrophils in the presence of serum based factors. To determine this 
the FITC labelled proteins were incubated at RT for 20 min with whole blood. At the end of 
this incubation erythrocytes were lysed using erythrocyte lysis buffer as described in section 
2.4.3.2 and the mixture centrifuged and resuspended in FACS buffer in order to wash the 
cells and ensure a sample free of debris. This was then analysed using a FACScalibur machine 
(BD Biosciences) and Cellquest (BD Biosciences) software. As only protein interactions with 
white blood cells were being investigated cellular debris and any remaining erythrocytes 
were gated out using FSC and SSC readings, effectively gating the sample by size and 
granularity. The interactions were then quantified using SSC and fluorescence in order to 
work out the percentage labelling, above the blank, of the white blood cells by the protein 
as well as the mean fluorescence intensity.  
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Figure 30. Analysis of the FACs data in Cellquest (BD Biosciences). The top graph shows that 
FITC labelled α and c-γ-α did not give a percentage labelling of leukocytes higher than the 
negative control. The bottom graph shows that the average labelling intensity, as measured 
by geometric mean was also lower for FITC labelled α and c-γ-α than for the negative control 
BSA. 
 
The results shown in Figure 30 showed that the negative control BSA had a higher percentage 
labelling of white blood cells than the proteins of interest. Also unlike in section 3.4.1 the 
geometric mean, which equates to labelling intensity, was lower in the reactions involving 
the test proteins compared to those reactions involving BSA. This indicates that the α and c-
γ-α proteins exhibit no specific interactions with any white blood cell populations. 
3.2.4 Measurement of interactions between alpha and human blood 
components using the electrophoretic mobility shift assay 
The mobility shift assay described in this section was carried out in order to identify the size 
of any serum based binding partner for α or c-γ-α, which would not only validate previous 
experiments within the Sayers group that suggested a serum based binding partner but also 
help to identify such a protein. The mobility shift assay effectively measures the change in 
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molecular weight of a protein of interest in order to identify what size protein it has bound 
to. This gives an idea of what the potential binding partner could be and allows for further 
pulldown experiments to be done to isolate such a partner. 
3.2.4.1 Interactions between alpha and serum or whole blood detected using an 
electrophoretic shift assay 
An electrophoretic shift assay was carried out as described in sections 2.4.4, 2.4.4.1 and 
2.4.4.2 then analysed using a western blot with rabbit anti-α antibody as the primary 
antibody and anti-rabbit HRP conjugated antibody as the secondary antibody. The primary 
focus of this experiment was to validate previous findings by the Sayers group that the α 
protein appears to have a serum based binding partner. For this experiment α and c-γ-α were 
mixed with a variety of different serums including human, equine and sheep. This is due to 
the fact that although human serum was likely to provide the most reliable binding data it 
was significantly more difficult to obtain than either of the non-human blood samples. It was 
hoped that α and c-γ-α would exhibit similar binding patterns in all of the samples allowing 
the use of animal serum in further experiments. The resulting image, Figure 31, showed that 
α was binding to a serum based factor with a molecular weight of at least 20-30 kDa. This 
was determined as α was detected at a higher molecular weight, between 50-60 kDa when 
cross-linked with human serum, compared with the molecular weight of 30-35 kDa at which 
it is normally seen to run on an SDS PAGE gel. However as there is no crosslinked control on 
this gel it cannot be ruled out that this is instead some multimerisation of alpha, although 
this is highly unlikely given the detection pattern on the western blot. However due to the 
poor running of the ladder it was not possible to determine the weight of the complex with 
any precision but there appears to be an increase in size of at least 30 kDa. Unfortunately, 
the lanes containing whole equine or sheep blood cross-linked to α showed poor detection 
by the anti-α antibody, possibly due to the inclusion of an anti-biotin antibody in order to 
detect the western blot ladder. The results from the human serum lanes further validate the 
previous findings of the Sayers group that both α and c-γ-α bind to a serum based factor 
which may in turn determine its cellular or systemic effects.  
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Figure 31. Western blot of an electrophoretic mobility shift assay between α or c-γ-α and 
whole blood. The red arrow indicates a 60 kDa protein marker, whilst the blue arrow 
indicates a 50 kDa marker.  Gel a) shows the image of α cross-linking data, Gel b) shows c-γ-
α cross-linking data. In both gels lane 1 shows a biotinylated protein weight ladder, lane 2 
blank, lane 3 protein cross-linked to human serum sample 1, lane 4 protein cross-linked to 
human serum sample 2, lane 5 protein cross-inked to equine blood, lane 6 protein cross-
linked to sheep blood. 
 
To further evaluate potential serum based binding partners for the α protein a pulldown 
experiment was carried out as described in section 2.4.4 using citrated human whole blood 
obtained from the clinical research facility in the Royal Hallamshire hospital, Sheffield (ethics 
for this collection was granted by the local ethics committee under UoS No: SMBRER39 “How 
do microbes interact with human blood”). Some of the citrated blood was used to isolate 
serum whilst some was used to isolate white blood cells, these samples were isolated and 
used as described in section 2.5.4.  
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Figure 32. A 10% acrylamide SDS PAGE gel showing the interaction between the α protein 
and white blood cells and serum. Lane 1 precision plus protein all blue prestained ladder 
(Biorad), lanes 2-4 the α pulldown of white blood cells, lanes 5-7 the α pulldown of human 
serum and lanes 8-10 the α pulldown of white blood cells in the presence of human serum. 
The bands at around 30 kDa correspond to the α protein, whilst the bands at 50-75 kDa and 
100-150 kDa correspond to serum based potential binding partners. 
 
As can be seen in Figure 32 the alpha protein is unable to interact and pulldown whole white 
blood cell, although this could be an artefact of the analysis by SDS PAGE, but is able to 
interact with a number of serum based proteins in the presence of a crosslinking agent. This 
crosslinking agent will stabilise transient interactions and so as a result some of these 
interactions may be false positives caused by stabilisation of non-specific interactions. What 
is clear however is that the α protein does seem to interact readily with a protein of around 
60 kDa, most likely human serum albumin and a large protein at around 100-150 kDa. This 
large protein is particularly interesting as previous studies in the Sayer lab (Helena Parsons, 
MSc thesis, University of Sheffield, UK) have suggested a possible interaction between α and 
a large protein, around 120 kDa, known as inter-α-inhibitor (IαI). This result possibly backs 
up these findings and lead to the experiments carried out in section 3.6. 
3.2.5 Measurement of interactions between the alpha protein and IαI from 
pig serum 
As previously mentioned previous work in the Sayers lab has suggested that the binding 
partner for α may be inter-α-inhibitor (IαI) or a related molecule called bikunin, suggesting 
that α binds to the chondroitin-4-sulphated light chain (Helena Parsons, MSc thesis, 
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University of Sheffield, UK). These findings also appeared to be replicated in section 3.3.4.1. 
In order to confirm these observations a set of experiments were carried out with the hope 
of characterising the binding partner more fully. In all of these experiments human serum 
was substituted for pig (Sus scrofa) serum as it was much more readily available, this was 
deemed to be an acceptable substitution as the Sus scrofa IαI and bikunin proteins have a 
high similarity to those found in humans.  
3.2.5.1 Confirming the interactions between alpha and IαI purified from pig serum 
using a pulldown assay  
In order to help characterise this potential interaction IαI was purified from pig serum, 
section 2.5.2, and incubated with biotinylated α protein as described in section 2.5.5. This 
experiment would help to determine whether or not alpha interacts with IαI in vitro and as 
such whether this interaction was likely to occur in vivo. 
In order to fully test the interaction between α and IαI multiple experimental conditions were 
used, these experimental conditions would include non-specific interaction controls and a 
variety of concentrations of the α protein, described in section 2.5.5.1.  
 
Figure 33. A 13% acrylamide SDS PAGE gel of an α-IαI pull down experiment. Biotinylated α 
was first bound to streptavidin beads and then used to pulldown purified IαI from pig serum. 
Gel A Lane 1  BLUeye prestained protein ladder (Gene flow), lanes 2-4 tube 1 supernatant, 
5-7 tube 1 pulldown, 8-10 tube 2 supernatant, 11-13 tube 2 pulldown. Gel B Lane 1  BLUeye 
prestained protein ladder (Gene flow), lanes 2-4 tube 3 supernatant, 5-7 tube 3 pulldown, 8-
10 tube 4 supernatant, 11-13 tube 4 pulldown. Tube 1 contained α and IαI mixed in a 1:2 
ratio, tube 2 contained α and IαI mixed in a 1:1 ratio, tube 3 contained α and IαI mixed in a 
1:2 ratio with the addition of 1.25 µg of BSA, finally tube 4 contained α and IαI mixed in a 1:1 
ratio with the addition of 1.25 µg of BSA (Tube contents are detailed in section 3.2.1). 
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As shown in the gel above the α coated beads failed to bind to any IαI as it was all found to 
be in the supernatant fractions rather than the pulldown fractions, which were boiled off the 
beads post washing. The data from this experiment contradicts the data from the previous 
experiment, which showed that in free solution α and IαI interact with one another. The lack 
of interaction in this experiment may be a result of the way the α protein was annealed to 
the beads used to pulldown other proteins. It is possible that the α protein being bound to 
the beads created a steric hindrance effect which inhibited the interactions, it could also be 
that the interaction between the two proteins is transient and was stabilised in the previous 
experiment using a crosslinking agent. 
3.2.5.2 Biolayer interferometry analysis of alpha and IαI interactions 
In order to fully characterise the interaction between the α protein and the IαI protein 
biloayer interferometry was used (BLItz machine, Fortebio). This machine has 
interchangeable fibre optic probes with different binding surfaces at the tip, this allows a 
variety of proteins to be bound to the tip of the probe. The BlItz system works by sending 
white light down the probe, some of this light is then reflected by the protein molecules that 
form the binding surface on the tip of the probe and some is reflected by an internal control 
reflective surface. These reflections create an interference pattern which sets a baseline for 
the probe, when another protein or molecule interacts and binds to the tip this changes the 
interference pattern. The software then calculates the thickness of the layer of bound 
protein based upon the change in interference pattern. This allows for multiple step kinetic 
experiments to be carried out, in this case biotinylated α was bound to a streptavidin probe, 
this was then placed into a solution of free IαI, the software then calculated if there was any 
interaction between the two proteins by measuring the thickness of the protein layer bound 
to the probe. 
The BLItz experiments were all carried out as described in section 2.5.3 using conditions 
described in section 2.5.3.1. Reactions were initially carried out using unpurified pig serum 
in the presence of biotinylated α (section 2.5.1) and in all cases a streptavidin probe was 
used.  
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Figure 34. Graph of the interaction between α and IαI as determined by the BLItz system. 
Each run detailed above corresponds to a colour coded line, and corresponds to a single 
experiment. In all runs, except run 6 (purple), the α protein was incubated with the probe 
for 120 sec, then following a wash step IαI was incubated with the probe for 120 sec. In the 
case of the experiment using 2 fold diluted serum alone, the α binding step was replaced 
with a 120 sec 1xPBS wash step. 
 
This graph at first glance appears to show an interaction between α and IαI, which appears 
to be concentration dependent, however inspection of run 6, the negative control run, shows 
that the serum itself is interacting directly with the streptavidin probe. This invalidated any 
interaction seen between α and IαI in this experiment.  
It was believed that a variety of serum based factors could interact directly with the probe 
and so as a result IαI was purified directly from the pig serum, as described in section 2.5.2. 
This purified protein was then used to repeat the above experiment, it was hoped that this 
would remove the background non-specific interactions allowing for a more accurate study 
of the interaction between the two proteins. 
In this experiment purified IαI was incubated with the biotinylated α for 1 hour at room 
temperature before being applied to the streptavidin probe. It was hoped that this may 
negate any steric hindrance effect caused when biotinylated α was bound to the streptavidin 
probe, this would allow the data to more accurately reflect the interaction between the two 
proteins. The experimental conditions for this are described in section 2.5.3.2 and in all cases 
a streptavidin probe was used.  
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Figure 35. Interaction between the α protein and IαI as measured by the BLItz system. Each 
run detailed above corresponds to a colour coded line, and corresponds to a single 
experiment. a) Shows all the experiments 0.2x biotinylated α protein was used whilst b) 
shows all the experiments in which 1x biotinylated α protein was used.  
 
As can be seen in Figure 35, above, no combination of alpha and IαI resulted in a significantly 
thicker layer being deposited on the BLItz probe than when alpha alone was loaded. This 
leads to the conclusion that alpha and IαI were not interacting on the surface of the probe. 
3.2.6 Site directed mutagenesis of alpha 
In order to facilitate some of the characterisation of the α protein a number of mutations 
were made within the α gene, either in terms of single point mutations or large additions. 
These mutations were carried out as described in either section 2.6.5 or 2.6.7 depending on 
what the desired outcome was.  
The aim of these PCR mutagenesis experiments were threefold; 1. To create a protein which 
could be easily purified, 2. To create a protein which would stabilise multimer formation and 
3. To create a fusion protein which would test the potential of α as a carrier protein. 
The first of these goals was achieved by introducing a six residue histidine tag on the N 
terminus of the α protein. This histidine tag would therefore allow easier purification of the 
protein using a chromatography column packed with nickel resin, but would also allow for 
immobilisation of the protein. The immobilisation of the protein would therefore allow 
protein-protein interaction studies to be carried out using either a BLItz machine, as 
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previously described, or using nickel chelate resin. The insertion was carried out using the 
method outlined in section 2.6.5.  
The second of these goals was to create series of mutants that would stabilise multimer 
formation, this wold then aid structural studies whilst also creating a molecule that was 
larger in solution. This increased size would possibly increase renal clearance times for any 
molecule attached to it which would have implications in pharmaceuticals. Due to the unique 
crystal structure of the α protein (Figure 22) formed from interlocked trimers of the α protein 
it was hypothesised that point mutations of residues 55 and 91 to cysteine residues would 
help to stabilise the multimer structure via disulphide bridging. Cysteine residues are not 
normally found within the α protein and so it was also hoped that these would provide 
specific points which could be labelled or used to link α to other proteins. 
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Figure 36. The unpublished crystal structure of α with residues 55 and 91 highlighted in red. 
As can be seen these residues, once mutated to cysteine residues, would be close enough to 
form disulphide bridges in a large multimer structure. This should help to stabilise the 
structure, making it more likely to be found under physiological conditions. 
 
In order to create this construct pJONEX4 NMB α was mutated as described in section 2.6.5 
in order to create two separate constructs, one containing a single cysteine point mutation 
at residue 55 and one containing a single cysteine point mutation at residue 91. 
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Figure 37. A 2% agarose gel on the products from the PCR mutagenesis reaction aiming to 
create a single cysteine point mutation within the α protein. Lane 1, New England Biolabs 1 
kb ladder, lane 2 55C α positive PCR reaction, lane 3 55C α negative PCR reaction, lane 4 91C 
α positive PCR reaction, lane 5 91C α negative PCR reaction. The negative control reactions 
were set up as the positive reactions just without the addition of the template plasmid. The 
gel shows clear amplification at around 3.2 kb, this was the size of the product that was 
expected from this mutagenesis.  
 
As can be seen in Figure 37 the PCR reaction appeared to be successful and so the bands at 
around 3.2 kb were gel extracted, as described in section 2.6.5, and transformed into 
chemically competent M72 E. coli cells, as described in section 2.6.8. Following successful 
transformation bacteria were cultured in small scale and checked for expression, using the 
method outlined in section 2.1.6. A small culture of each mutant were also used to isolate 
the plasmid from the mutants, section 2.6.3, this was then sent for sequencing at the Core 
Genomics facility located in the University of Sheffield Medical School 
(http://genetics.group.shef.ac.uk) 
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Figure 38. A 10% acrylamide SDS PAGE gel showing expression of the residue 55 (55 C) and 
the residue 91 (91 C) single cysteine α mutants. In both cases lane 1 is the BLUeye prestained 
protein ladder (Generon), lane 2 is the cell pellet of the uninduced bacteria, lane 3 is the cell 
pellet from bacteria that have been induced for 3 hours and lane 4 is the cell pellet from 
bacteria induced for 5 hours. What can clearly be seen is that both strains are strongly 
expressing a protein at around 30-35 kDa, the expected weight of α on an SDS PAGE gel. 
 
As can be seen in Figure 38 both strains appeared to be strongly expressing a protein of the 
correct weight. However, sequencing later revealed that both the mutation at residue 55 and 
91 were unsuccessful (Appendix III). 
  
93 
 
3.2.7 Creation of an alpha-Gly1 fusion protein 
In order to test the potential of α as a carrier protein a fusion of the α protein and the 
neisserial GLy1ORF1 protein were to be created. This fusion would fuse the N terminus of 
the Gly1 protein to the N terminus of the NMB α protein via a short 3 glycine and 1 serine 
linker and then the C terminus of Gly1 would then be fused to the C terminus of the NMB α 
protein via another short linker sequence. The aim was to create a large protein formed from 
two potential neisserial virulence factors which could be tested for immunogenicity, it was 
also hoped that this new fusion protein would be capable of multimer formation, similar to 
the α protein. 
 
Figure 39. A monomer of the predicted structure of the α-Gly1 fusion protein (image created 
in PyMOL using structures provided by Prof JR Sayers and Prof PJ Artymiuk of the University 
of Sheffield, UK). The orange and red domains each correspond to half of a Gly-1 monomer 
attached to the ends of the α protein, shown in light blue. 
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Figure 40. A prediction of the possible multimer formation by the α-Gly1 fusion protein. As 
in figure 39 the long alpha helices each have one half of the Gly-1 monomer attached at 
either end.  This large structure should be readily formed due to αs propensity to form 
trimers, this would hopefully increase renal clearing time of the protein and its 
immunogenicity (image created in PyMOL using structures provided by Prof JR Sayers and 
Prof PJ Artymiuk of the University of Sheffield, UK). This formation of multimers should also 
bring the two halves of the Gly1 monomer, fused to the ends of the α protein, close together. 
It was hoped that the Gly1 domains could then interact and form a full Gly1 protein which 
would be more useful for antibody generation. 
 
The fusion of these two proteins was to be achieved by introducing a XhoI restriction site in 
the centre of the Gly1ORF1 gene and also at the C terminus of the α gene, this would be 
complimented by a BtgI restriction site at the N terminus of the α gene and in the centre of 
the Gly1ORF1 gene. This would enable the Gly1 gene to be cut in two and then annealed to 
the end of the α protein, therefore creating the desired fusion protein. 
Multiple rounds of PCR mutagenesis were carried out, as described in section 2.6.5, in the 
end the insertion of both restriction sites in the α gene were successful. This required 
creation of a mutant with the BtgI site inserted, this was then used as a template in the 
reaction to insert the XhoI site. 
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Figure 41. 2% agarose gels on the α BtgI and XhoI PCR products. Lane 1 Quick load broad 
range ladder (New England Biolabs), lane 2 α BtgI positive reaction, lane 3 α BtgI negative 
reaction, lane 4 α XhoI positive reaction and lane 5 α XhoI negative reaction. The negative 
reactions were set up as the positive reactions except the template plasmid was omitted.  
 
The bands highlighted in Figure 41 were gel extracted as described in section 2.6.5 and sent 
for sequencing at the Core Genomics facility located in the University of Sheffield Medical 
School (http://genetics.group.shef.ac.uk). This sequencing revealed that the α protein had 
the correct restriction sites inserted in the desired places. Unfortunately, multiple rounds of 
PCR were unable to insert either of the restriction sites into the Gly1ORF1 gene. This could 
possibly be rectified by redesigning the primers, however it was decided that chemical fusion 
of the α protein to a complete neisserial Gly1 would achieve the same result in a more time 
efficient manner. 
3.3 Conclusions 
The α protein has been widely acknowledged as a co-expressed protein conserved across a 
number of neisserial and other meningococcal bacteria with a role in targeting the IgA1P 
protein into host cells 111,116 . What has remained unclear until now is whether the alpha 
protein has any other functions within the pathogen and how it elicits any such responses. 
The work shown in this chapter has helped to expand the current state of the knowledge 
base regarding the α protein and its function whilst also raising more question requiring 
answers and further investigation. 
The vector and E. coli strain chosen for this project were shown to express strongly, leading 
to an easy to purify product. The pJONEX4 vector utilises a heat shock promoter which is 
activated above 42oC, this plasmid was shown to give significant protein yields from a 5 L 
fermenter culture allowing rapid purification and experimentation to be carried out.  
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Pulldown interaction shown in this chapter demonstrates that the α protein is capable of 
interacting with a number of human serum based factors between 50-75 kDa and 100-150 
kDa. The most likely candidates for these interactions are human serum albumin at around 
65 kDa, which has been shown to bind a wide variety of proteins and IαI at around 125 kDa, 
despite the fact IαI is often found at around 220 kDa the active trypsin inhibiting form has 
shown to be around 125 kDa 118 . These proteins would explain the result shown in the latter 
half of section 3.2.4.1 whilst in the first half of section 3.2.4.1 alpha interacted with a protein 
of around 30kDa, this is most likely to correspond to bikunin based upon previous work 
carried out on α. Bikunin proteins have been found to contain 2 Kunitz type inhibitor domains 
119 , one of which has been shown to be an inhibitor of other serine proteases such as trypsin 
and chymotrypsin. Free bikunin tends to be only found at low circulating levels under normal 
conditions due to its short half-life 120 , instead pre-alpha inhibitor is the dominant protein 
found in the bloodstream containing a bikunin domain. This pre-alpha inhibitor is a 220kDa 
protein which is cleaved into a functional 125 kDa protein known as IαI, which has been 
shown to be a serine protease inhibitor but which may also have other roles in the host 119 . 
It is therefore possible that the interaction between α and bikunin and IαI plays a role in 
preventing the proteins from inhibiting IgA1P and allowing IgA1P to cleave targets within the 
host. 
Flow cytometry analysis of alphas interaction with blood cells revealed an unexpected 
interaction between red blood cells and α. Although the cells were not labelled to a greater 
degree than when incubated with the negative control protein, they were labelled with 
greater intensity when incubated with the labelled α. This hints that the interaction between 
α and red blood cells could be more specific than the interaction between red blood cells 
and BSA, what remains unclear is whether this is just an artefact of the high concentration 
of αused. The interaction between α and the red blood cells is particularly unexpected as the 
α protein contains multiple NLS which target α into cells nuclei 116 , which are of course lacking 
in red blood cells and platelets. Previous work in the Sayers lab (Helena Parsons, MSc thesis, 
University of Sheffield, UK) showed a possible interaction between α and a group of cells 
thought to be neutrophils. This interaction was confirmed at concentrations of 20 μg/ml and 
above as was expected from the previous work. The potential interaction with neutrophils is 
particularly interesting as it has been shown that bikunin readily locates to the membrane of 
neutrophils 121 , this would provide the alpha protein with a point to attach to on the 
neutrophillic membranes, thereby explaining the interaction. This is because previous work 
carried out by Helena Parsons indicated that the α protein was capable of interacting with 
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bikunin and inter-alpha-inhibitor (IαI), via the incorporated bikunin domain most likely. This 
bikunin interaction may also allow the targeting of IgA1P to neutrophils whereby it can cleave 
target proteins such as TNFRII 100 . This may lead to an increase in cytokine production leading 
to the increase in pro-inflammatory cytokines such as IL-6, IL-8 and TNFα that is classically 
associated with meningococcal disease 84 . The IgA1P targeted to neutrophils would also have 
access to LAMP proteins found in neutrophils and cleavage of these proteins may help to 
protect the bacteria from phagocytic killing in both the bloodstream and at the mucosal layer 
97,98 . As a result, the role of the α protein may be that of a targeting protein, directing IgA1P 
with an α protein still attached to host cells where it can have an effect. 
In order to fully characterise and confirm the interaction between α and IαI/bikunin a 
number of methods were used, including pulldown and BLItz assays. Under both of these 
conditions α failed to interact with purified pig IαI. The reasons for this could be three fold, 
firstly the purified IαI was around 220 kDa, in humans the form with this size is the inactive 
pre-alpha inhibitor form and not the 125 kDa active form. This might explain why α was 
unable to target it, as in vivo targeting the inactive form of the inhibitor would serve no 
function whilst being a burden on the pathogen. Secondly, despite the pig IαI protein being 
suspected to be highly similar to the equivalent protein in humans it is possible that α is 
unable to target it. Neisseria meningitidis is an obligate human pathogen and as a result its 
inability to target homologous proteins from other species should not be discounted. This 
issue has been raised in the past and it has been shown multiple times that a neisserial animal 
model is very difficult to achieve due to its specificity for a human host. Finally, in both the 
BLItz and the pulldown assay the α protein was biotinylated and immobilised to a 
streptavidin matrix. This biotinylation and immobilisation could cause problems in a number 
of ways. Chiefly amongst those problems could be the biotin groups masking interaction sites 
between the two proteins, this cannot be ruled out and in the future another form of tagging 
and immobilisation could be used, possibly N terminal histidine tagging which would allow 
immobilisation in a very specific place. One of the major issues that arose with the 
Biotinylation of the α protein is the lack of fine control over how many biotin groups have 
labelled each protein. This may result in a protein with multiple labels which effectively binds 
flush to the surface of the probe, therefore preventing interaction between the two test 
proteins. Once more this could be rectified using specific N terminal or C terminal labelling 
or a labelling method which only reacts with a single point on the protein, such as a cysteine 
residue. A further problem with the immobilisation to the matrix is that being immobilised 
to a matrix may cause steric hindrance, this would prevent the two proteins from interacting 
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fully resulting in a failure to show an affinity between the two proteins. Most of these 
problems could be solved in the future with the use of the human IαI protein and a different 
method of immobilisation or capture of the proteins. 
The final part of this study was to mutate the α protein in two specific ways, firstly the 
introduction of a cysteine group and secondly the fusion of α to Gly1ORF1. The first of these 
two mutations would help to stabilise multimer formation, which could have large 
implications for the α proteins potential as a carrier whilst also facilitating structural study. 
The second of these mutations was purely to be used to test the potential of α as a carrier 
protein for neisserial vaccine development. Unfortunately, in both cases it appears that the 
PCR mutagenesis failed, this is most likely down to issues with primer design which could be 
rectified in future attempts or indeed fusion of the proteins could be achieved chemically 
rather than through PCR.  
Overall the work shown in this chapter has helped to build the knowledge base relating to 
the function of the α protein in vivo. Multiple possible roles have been suggested based upon 
this work and the work of others including; targeting IgA1P to host cells via the NLS 111,116 , 
inhibition of serum based serine protease inhibitors and a possible interaction with red blood 
cells. During this study a reliable expression and purification method has been demonstrated 
allowing further work to be carried out which can address some of the issue discussed above 
and identify the role of α in host invasion and survival. 
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4. Characterisation of the structure of the neisserial alpha 
protein and its potential as a carrier protein 
 
4.1 Introduction 
As was explained in section 1.7 the α protein has so far been studied very little and as a result 
there is little evidence for its function in vivo or its structure. The name alpha and secondary 
and tertiary structure prediction have shown that the α protein is comprised of 1 α helix of 
around 200-400 amino acids long. However, very little experimental characterisation has 
been carried out. At the University of Sheffield Prof Artymiuk’s group crystallised the α 
protein (unpublished) at around 100 mg/mL, this crystal structure (Figure 22) does indeed 
show that α is thin alpha helical and forms multimers of up to 24 monomers. However this 
crystal structure was formed at very high concentration under non-physiological conditions, 
as a result this chapter aims to investigate the structure of α at lower concentrations, as well 
as in solution. This should help to define the structure of the α protein under more 
physiological conditions.  
This chapter also set out to investigate the potential of α as a carrier protein for vaccine 
formulation. The little characterisation of α that has been carried out has shown that the α 
protein contains a number of T cell helper epitopes 25,102 . These regions are short 7-10 amino 
acids sequences which are capable of CD4+ helper T cells which causes maturation of B cells 
into memory B cells 25 . This activation results in a long lasting immune system memory of the 
protein, it is thought therefore this characteristic of alpha could be exploited in vaccine 
development in a similar way to other carrier proteins. Carrier proteins are normally highly 
immunogenic proteins such as tetanus toxoid which boost the immune systems response to 
proteins that they are conjugated to 2,23 . This has the effect of increasing the stimulation of 
the immune system, leading to longer lasting antibody production23. It is thought that α could 
function in a similar way when conjugated to another protein by boosting the 
immunogenicity of that protein and causing production of memory B cells, leading to a very 
long lasting immunity.    
In order to answer a number of these questions this chapter set out with a number of aims; 
1. To characterise the structure of α at lower concentrations and in solution using a 
variety of techniques. 
2. To assess the potential of α as a carrier protein for vaccine development using a 
number of in vitro models. 
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4.2 Results and discussion 
 
4.2.1 Characterisation of the neisserial Alpha proteins structure 
The structure of the α protein is not well characterised, with only 1 unpublished crystal 
structure being available (supplied by Prof PJ Artymiuk of the University of Sheffield UK). This 
structure shows a multimer formed from 24 α monomers which form a large 3 dimensional 
star made of interlocking trimers. In order to further study this structure a number of 
experiments were carried out. These were designed with the aim of testing the capability of 
α to form multimers in solution as well as confirming the structure of α both in solution and 
in crystallo. 
4.2.1.1 Alpha multimer formation 
Α multimer formation was checked using both FITC labelled alpha protein, section 2.4.2, 
which was then run on an SDS PAGE gel, 2.1.9 and also a western blot, section 2.4.4.1, with 
a rabbit anti-α primary antibody and an anti-rabbit secondary antibody. 
The first method involved running FITC labelled proteins on an SDS PAGE gel and then 
imaging it using both standard white light and a secondary imaging technique which imaged 
the fluorescence, by imaging the SDS PAGE gel with a long exposure time in the dark. 
 
Figure 42. Crosslinking of labelled α and cys-ɣ-α in solution. Analysis of proteins on 10% SDS 
PAGE gels: Left panel Coomassie stained, right panel fluorescence visualisation. Lane 1 Blue 
prestained broad range ladder (New England Biolabs), lanes 2-4 FITC labelled α in increasing 
concentrations, lanes 5-7 FITC labelled cys-ɣ-α in increasing concentrations.  
The right panel of Figure 42 shows that α and cys-ɣ-α are capable of forming multimers in 
solution. This is due to the fact that α and cys-ɣ-α proteins usually appear at between 30-35 
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kDa on a SDS-PAGE gel, therefore it can be assumed that the bands at 58-~65 kDa equate to 
α/cys-ɣ-α dimers whilst the bands at between 80-100 kDa equates to trimers of the proteins.  
The second trial utilised western blotting in order to confirm the multimer formation as this 
would rule out non-specific interactions between the FITC labels as the cause of multimer 
formation. This trial also served as a test in order to identify which in house rabbit anti-α 
antibodies, which had been raised previously in the Sayers lab against α that had been 
verified by mass spectrometry,  had the highest affinity for α and least non-specific labelling. 
For this experiment 10 µL of 10 mg/mL α protein was loaded onto a 10% SDS-PAGE gel and 
then treated as described in section 2.4.4.1.  
 
Figure 43. Western blot showing α multimer formation. Lanes 1,4 and 7 Blue prestained 
broad range ladder (New England Biolabs), lanes 2, 3, 5 and 6 all contained the α protein but 
were probed with different primary antibodies.  
 
The two in house rabbit anti-α antibodies were able to detect α monomer efficiently  and 
also provided  further evidence of dimer formation in solution. This confirms the previous 
observation that alpha is capable of forming multimers in solution, at concentrations of 
around 10 mg/ml. What is absent in this second assay, compared to Figure 43, is the 
presence of trimers. This could indicate that they do not form readily or, more likely, could 
indicate that the larger trimers have not efficiently transferred to the membrane. 
4.2.1.2 Circular dichroism analysis of the alpha secondary structure 
In order to confirm the crystal structure observation that the α protein was purely alpha 
helical, circular dichroism was performed as described in section 2.3.4. Alongside the circular 
dichroism of α, a sample of cys-ɣ-α was also analysed. This would not only give further insight 
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into the structure of α but may also determine what structure, if any the short ɣ peptide 
forms in solution. 
 
Figure 44. CD spectra of the α and cys-ɣ-α proteins at a variety of different concentrations. 
Both α and cys-ɣ-α at all concentrations produce a spectra which very closely resembles the 
reference spectrum given by purely alpha helical proteins. 
 
The figure above shows the spectrum produced by performing circular dichroism on both α 
and cys-ɣ-α, the spectra clearly shows a form very similar to that produced by a pure alpha 
reference protein123. Due to time constraints the precise percentage of the structure that 
was α helical was not calculated, although its similarity to the alpha reference spectrum 
hinted that it would be around 100%.  What should be noted however is it requires a much 
higher concentration of cys-ɣ-α in order to produce a spectrum with similar intensity to that 
of 0.1 mg/ml α. Also of note is the fact that the α and cys-ɣ-α do not overlap perfectly, this 
indicates that there may be some subtle structural difference caused by the addition of the 
ɣ peptide. 
4.2.1.3 Crystallography trials on the alpha protein 
Crystallisation studies were carried out on both c-γ-α and α in order to determine the 
structures of the proteins which could then be used to validate any binding partners or 
mechanisms determined at a later date. In order to do this the crystallography screens 
described in section 2.3.2 were set up using an automated system which placed 0.2 µl of 
either 5.48 mg/ml α or 9.24 mg/ml c-γ-α in to the wells. The crystallography screens were 
then left at 17oC for two weeks allowing crystal formation to occur. However, for both 
proteins crystals only appeared in wells containing calcium or potassium salts. This gave an 
indication that the crystals were most likely composed of calcium phosphate or potassium 
phosphate, this was later confirmed as the case using methylene blue dye. 
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4.2.2 Investigation into the potential of the neisserial alpha protein as a carrier 
protein 
Previous studies have shown that the α proteins contain a number of T cell helper epitopes 
which may allow it to acts as a carrier protein in vaccine development. The function of these 
carrier proteins is to boost the immunogenicity of vaccine antigens in the formulation whilst 
also giving rise to long lasting protective immunity. The α protein seems uniquely suited to 
this task, section 1.7, and so as a result a number of experiments were designed in order to 
test the carrier protein potential of α in vivo. 
4.2.2.1 Alpha carrier potential analysis in a female BALB/C mouse model 
In order to determine the potential of α as a carrier protein it was injected into female 6 
week old BALB/C mice as described in section 2.7.1 and then antibody tires were analysed 
by ELISA as described in section 2.7.2. The ELISA analysis used for this experiment quantified 
the specific anti-α or anti-ɣ IgG found in each serum sample collected from the mice. This 
highlighted whether the α protein could boost the immunogenicity of ɣ, a very weakly 
immunogenic peptide, when injected as either a fusion of ɣ and α or a mixture of ɣ and α. In 
order to decide if α was boosting the immunogenicity of ɣ the anti-ɣ antibody titres of mice 
injected with a mixture or fusion of α and ɣ were compared to the antibody tires of those 
injected with α or ɣ alone or mice injected with 1xPBS only. This showed any difference in 
immune response achieved by injecting α alongside ɣ and determined the potential of α as 
a carrier protein. The fusion of α and ɣ was particularly important as it mirrors how carrier 
proteins are used in vaccine formulation, as often poorly immunogenic antigens are directly 
conjugated to a carrier protein, allowing them to boost the immune response to the target 
antigen. 
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Figure 45. Antibody titres derived from ELISA data on mouse serum 2 and 4 weeks post 
injection. Graphs a) and b) are antibody titres against α (a) and ɣ (b) two weeks post 
inoculation with the proteins. Graphs c) and d) are antibody titres against α (c) and ɣ (d) four 
weeks post inoculation with the proteins. 
 
Figure 45 Shows an interesting trend in both antibody tire in the mice against the α protein 
as well as against the ɣ protein. At both two and four weeks post injection it can clearly be 
seen that both α and a mixture of α and ɣ produce a very high antibody titre against alpha. 
This increased antibody titre is detectable above the baseline control injection of PBS up to 
a 2500 fold dilution of serum. This proves that the α protein is highly immunogenic in vivo, 
as predicted by its multiple T cell helper epitopes. With regards to the ɣ protein it appears 
that at week 2 a mixture of α and ɣ are able to provide a noticeable increase in antibody titre 
above the baseline up to a 500 fold dilution of serum. Unfortunately, by week 4 post 
immunisation this trend appears to be less clear cut, the mixture of α and ɣ do give an 
antibody titre that on average is higher than the baseline up to a 500 fold dilution of serum.  
Post analysis of this data an LPS assay was carried out upon the samples used in order to rule 
out any immunogenic effects of LPS contamination, as described in section 2.7.5, this 
quantified any LPS if any was present in the samples. It was highly important to have as little 
LPS contamination as possible as LPS is known to be highly immunogenic and therefore could 
skew any data obtained from the study. The results of the LPS assay confirmed that there 
was no endotoxin present in the samples used, therefore ruling out the possibility that the 
immune response was as a result of endotoxin contamination. 
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4.2.2.2 Crosslinking of Alpha to the Gly1 homologues or FEN D183K 
In order to more fully test the potential of α as a carrier protein a new animal model was 
designed. This model would use female New Zealand white rabbits which would be injected 
with a conjugate protein made up of the α protein covalently attached to another potential 
virulence factor from Mannheimia haemolytica or Trypanosoma brucei, section 2.7.3-6. 
 
Figure 46. A 10% acrylamide SDS PAGE of the result of crosslinking α to MH0579 form 
Mannheimia haemolytica. Lane 1 Precision plus prestained all blue protein ladder (Biorad), 
lane 2 α-MH0579 crosslink, lane 3 SMCC labelled α. The red box indicates MH0579 that has 
not crosslinked to α and the blue box corresponds to free α, the green box highlights fusion 
products created in the reaction. 
 
It can  be seen in Figure 46 that the crosslinking reaction, carried out as described in section 
2.7.3, was partially successful. Although not all of the SMCC labelled α reacted with the SATP 
labelled MH0579 the reaction yielded sufficient product to purify and isolate for use in rabbit 
inoculation, as described in section 2.7.6. This reaction was replicated for each protein 
conjugate desired and was successful in all cases. Success was determined by measuring the 
shift in size of the conjugated protein compared to the original size of the two constituent 
parts. In order to purify the conjugated proteins size exclusion chromatography was used, 
section 2.7.4. This separates proteins based upon molecular weight, with larger proteins 
being eluted in earlier fractions. Due to the large size difference between the conjugated 
proteins and the constituent proteins this was the most efficient way to purify the desired 
conjugate. 
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Figure 47. A Coomassie stained 13% acrylamide SDS PAGE showing the elutions from a size 
exclusion chromatography column packed with Sephacryl S-200 HR. Lane1 Precision plus 
prestained all blue protein ladder (Biorad), Lanes 2-19 elutions from size exclusion column. 
The green box highlights the α-MH1205 conjugates, the blue box highlights the unconjugated 
α and the red box indicates unconjugated Gly1 MH1205. Each elution corresponds to a 0.5 
mL fraction eluted at 0.5 mL/min, as the fraction number increases the mass of the protein 
collected should decrease with each fraction containing proteins within a 40-50 kDa range. 
This range could be further decreased by eluting fractions from the column at a slower rate, 
however this broader range gave sufficient separation of high weight conjugates from lower 
molecular weight contaminants. 
 
Figure 47 shows that using size exclusion chromatography alone pure conjugate protein was 
obtained that could be used for inoculation. These proteins were then concentrated and 
mixed into the designated inoculation mixes as described in 2.7.6 and sent to Generon, a 
contract research organisation, for injection into female New Zealand white rabbits as 
detailed in section 2.7.6. 
4.2.2.3 Purification of antibodies from the rabbit serum 
In order to isolate each antibody produced from the conjugate proteins an antibody 
purification step was carried out, section 2.7.7. This needed to be done as each rabbit was 
inoculated with a mixture of 1 alpha conjugate protein and 1 free protein, as listed in section 
2.7.6. These free proteins (MH0579, MHPara, MH1205 and tbFEND183K) were various 
proteins used by the lab group, in the case of the MH protein they were all Homologues of 
the Gly1 protein found in Mannheimia haemolytica, whilst tbFEND183K was a mutated flap 
endonuclease from Trypanosoma brucei. The purification process separated the various 
antibodies form the individual sera received, therefore allowing their affinity to be tested. 
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Figure 48. Western blot using a variety of purified antibodies. Lane 1 BLUeye prestained 
protein ladder (Geneflow), lane 2 neisserial α protein, lane 3 Gly1 paralogue MHPara from 
Mannheimia haemolytica, lane 3 Gly1 homologue MH0579 from Mannheimia haemolytica. 
Each of the sections utilised a different primary antibody;  section A probed with anti-
MHPara, B probed with anti-MH0579, C probed with anti-α, D probed with anti-α-MHPara, 
E probed with anti-α-MH0579 and F was probed with unpurified serum. 
 
As can be seen in Figure 48 the western blot showed that the whole serum contained 
antibodies capable of labelling all of the expected proteins and that pure anti-MHPara anti-
MH0579 and anti-α were obtained. However, probes D and E revealed that there were no 
proteins present capable of labelling both the α and the Gly1 homologue or paralogue. This 
was an expected outcome as any antibody able to do that would have to react with both 
proteins and the short chemical linker, this control was carried out to prove that no such 
antibody would be formed. 
4.3 Conclusions 
The research contained within this chapter has helped to expand the knowledge of both the 
structural and functional role of the neisserial α protein, whilst also assessing its potential as 
a vaccine tool. This study takes what was previously known about α and expands it whilst 
providing proof that the α protein may have some use as a carrier protein in neisserial and 
possibly other vaccines. 
As has been discussed very little published work has studied the structure of α, other than 
to state that it is α helical, and the unpublished work used concentrations and conditions 
that in no way mirrored those found physiologically. As a result this work aimed to define 
the structure of α under more physiological conditions and in solution. The results of 
studying α in solution showed that as seen in the crystal structure (Figure 22) α is capable of 
forming multimers, most often dimers or trimers. This mirrors what can be seen in the crystal 
structure, which is made up of 8 interlocking trimers. This confirms the ability of α to 
multimerise, which may indicate that its role in vivo relies someway on multimerisation. It 
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also hints that an α-protein conjugate may be able to multimerise, this would make it a highly 
useful carrier protein as it would greatly increase the immunogenicity of the attached protein 
whilst simultaneously increasing renal clearing time.  
These two factors combined will be worth investigating further in order to assess its potential 
as a carrier protein. Further structural work using circular dichroism also confirmed 
previously published data that α was a purely α helical structure. However, this research built 
upon this knowledge by also carrying out circular dichroism on a α-ɣ conjugate. This work 
has helped to elucidate the structure, if any, of the short ɣ peptide that is also co-secreted 
with IgA1P and α. It appears that the ɣ peptide has a slight structure as it caused a shift in 
the spectrum away from a α helical baseline. However, it is most likely that this is a random 
coil or globular domain. Unfortunately, crystallisation of α at a lower concentration was 
unsuccessful due to salts being present in the buffer, in the future this could be repeated 
with α in a more crystallography friendly buffer. The aim of this would be to discern whether 
α would still form 24-mers or whether at a lower concentration its crystal structure might 
more closely mimic that seen in solution and on western blots.  
Previous studies carried out on α have highlighted a number of T cell helper epitopes within 
the proteins, these function by activating CD4+ T helper cells causing maturation of B cells 
into memory B cells 25,102 . In this research it was hypothesised that these epitopes could be 
utilised by using α as a carrier protein, similar to tetanus toxoid2,23. These carrier proteins 
increase the immunogenicity of a protein they are conjugated to and help to improve the 
immune response against proteins contained within the vaccine. It was also hypothesised 
that the ability of α to form multimers, which was confirmed earlier, would increase the 
immunogenicity of target proteins further by creating large complexes with long renal 
clearing times.  
The BALB/C mouse model used in this study has provided interesting data that appears to 
confirm this hypothesis, certainly at 2 weeks post inoculation but also possibly at 4 weeks 
post inoculation. What can be seen in Figure 45 is that at week 2 a mixture of the α and ɣ 
proteins leads to an increased antibody titre against ɣ than when either are injected into the 
mouse alone. This seems to suggest that the presence of  α is indeed boosting the immune 
response against ɣ leading to a higher detectable antibody titre. What should be noted 
however is that the conjugate of α and ɣ, cys-ɣ-α, did not have this effect, or at least the 
effect was less noticeable than with the mixture. This was an unexpected result as most 
carrier proteins must be directly conjugated to the protein in order to have an effect, what 
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should also be noted is that the conjugated protein failed to elicit a response to the α protein 
either, which is normally highly immunogenic. This would suggest that the conjugated 
protein was possibly not purified or injected properly, in order to confirm this theory the 
study would have to be repeated with more stringent purification and injection conditions. 
At 4 weeks post inoculation these trends were much less defined, still the conjugate failed 
to elicit a response to α, whilst both the mixture of α and ɣ and α alone did. What is unusual 
is that the anti-ɣ antibody titres seem to be highly variable and do not mirror that seen at 
two weeks post injection. Still there is some indication that the mixture of αand ɣ causes an 
increased immune response to α, but the variability in the data and the fact that the α alone 
causes antibody generation against ɣ means that this speculative trend should probably be 
disregarded. The reasons for the large variation in the samples at week 4 are still unclear and 
could be multi-factorial, for instance the mice might have stopped responding to the proteins 
or the injections may have been carried out improperly or samples could have been mixed 
up during blood sampling. As a result of this the data from week 4 should likely be discarded 
and the experiment repeated, however the data collected from week 2 seems to support the 
hypothesis that α could be used as a carrier protein in vaccine development. The antibodies 
gained from the New Zealand white rabbit model, may confirm these findings, however due 
to a lack of time the antibody titres were not calculated. This could be rectified quickly by 
carrying out ELISAs on the serum samples obtained and may help to support the case for α 
as a carrier protein. 
Overall the research contained in this chapter has gone some way to building upon the 
previous knowledge of the structure of α by confirming that α is capable of forming 
multimers in solution and that it is a highly α helical protein with very high immunogenicity 
that could be exploited in the future. This chapter also provides the first glimpse at a possible 
structure for the ɣ peptide, hinting that it is most likely globular or made up of a short random 
coil. 
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Chapter 5- neisserial IgA1P mutation 
and structural characterisation 
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5.  Neisserial IgA1P mutation and structural characterisation 
 
5.1 Introduction 
The IgA1 protease is a protease found in a number of meningococci which has been shown 
to be capable of cleaving a number of host proteins involved in the immune response against 
invasive pathogens 85,98,100 . Previous study of IgA1P has found that it is upregulated heavily 
in invasive isolates when compared to commensal strains and so it is thought to be a 
potential virulence factor 34,35 . Despite being a founding member of the type Va 
autotransporter protein family very little structural characterisation has been carried out on 
the neisserial IgA1P, with all of the structural data available to date having been derived from 
experimentation on the Haemophilus influenzae IgA1P 75 . As a result, the core aim of this 
section of research was to create a number of neisserial IgA1P mutants which were easy to 
purify and express and which stayed stable over a long period of time post purification.  
Throughout the course of this research a number of mutant IgA1P proteins were produced 
with a number of aims in mind. Firstly, less active or inactive mutants were created as under 
normal conditions the IgA1P protein has been found to readily cleave itself, making structural 
work difficult to carry out. Therefore, in order to gain useful structural data on the neisserial 
IgA1P it was necessary to slow or stop the activity of the protease, this was achieved by 
mutating the active site serine at residue 288 to either a cysteine or an alanine. The effect of 
the cysteine mutation was to slow cleavage down by around 100-1000 fold, whilst the 
alanine mutation would effectively create a dead mutant incapable of cleavage. Secondly 
more easily purifiable IgA1P was desired, this was achieved via two separate mutations. In 
some cases a 6 histidine tag was added to the end of the protease domain, before the ɣ 
peptide, this would allow easy purification using nickel coated affinity resin. In conjunction 
with this some mutants had the β core domain removed, the effect of this was to prevent 
the passage of the protease through the outer membrane allowing it to be purified from the 
periplasm. These periplasm preparations contain much fewer proteins than full cell lysis 
preparations, therefore making protein purification simpler. 
These mutant strains would then enable a variety of structural studies to be carried out on 
the protein in order to get an accurate neisserial IgA1P structure, rather than the predicted 
structures in use currently.  
The aims of this section were 3 fold; 
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1. To create a number of IgA1P mutants with increased stability which would be easier 
to purify. 
2. To express and purify these mutant proteases 
3. To begin structural characterisation of the mutant IgA1 proteases. 
The hypothesis of this chapter was that the cysteine and alanine mutant IgA1 protease would 
show decreased cleavage and increased stability, whilst the histidine tagged or Δβ core 
mutants would be easier to purify. Also that the neisserial IgA1P would have a high structural 
similarity to the IgA1P from Haemophilus influenza but would lack a unique loop D insertion. 
5.2 Results and discussion 
 
5.2.1 Expression of the neisserial IgA1P protein 
The wildtype neisserial IgA1P was previously cloned into a pJONEX4 plasmid with a heatshock 
promoter, this was then transformed into M72 E. coli cells, as described in section 2.6.8. Cells 
were cultured as in 2.1.6 and checked for protein expression.  
 
Figure 49. A 12% acrylamide SDS PAGE showing the expression of the wildtype neisserial 
IgA1P. Lane 1 Pierce unstained protein MW marker (ThermoFisher), lane 2 uninduced IgA1P 
WT pellet, lane 3 uninduced IgA1P WT supernatant, lane 4 induced IgA1P WT pellet, lane 5 
induced IgA1P WT supernatant. A band can be seen to appear in the post induction cell pellet 
at around 110 kDa, this is around the expected size of IgA1P and so the protein was 
determined to be expressing well. Both lane 3 and 5 are blank as the supernatant collected 
from the cell culture was very dilute and few proteins are expressed extracellularly in this 
strain of E. coli as a result any proteins in the supernatant were likely below the detection 
threshold for coomassie stain on an SDS-PAGE gel. 
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As can be seen in Figure 49 the wildtype neisserial IgA1P was found to express when induced 
for 16 hours at 42oC.  Although the expression was not particularly strong it was deemed 
sufficient for purification and mutation. However due to time constraints the band was never 
formally identified using mass spectrometry or western blotting. The protein was however 
verified to a reasonable degree using its molecular weight along with the fact that this band 
appears only post-induction in these M72 cells containing a heat inducible IgA1P containing 
plasmid.. 
5.2.2 Purification of the neisserial IgA1P protein 
The neisserial IgA1P was either purified using size exclusion chromatography or if the protein 
contained a histidine tag nickel coated resin was used, sections 2.2.3 and 2.7.4. This resulted 
in pure protein being obtained, however the yields were generally very low due to the low 
expression of IgA1P when compared to the α protein. 
5.2.3 PCR site directed mutagenesis of the neisserial IgA1P gene in the 
pJONEX4 plasmid 
PCR mutagenesis of IgA1P was carried out using the method outlined in section 2.6.5. This 
resulted in the production of a number of IgA1P mutants; 
Wildtype- full length and Δβ core 
Alanine mutant- full length, Δβ core and Δβ core with 6 histidine tag 
Cysteine mutant- Δβ core and with 6 histidine tag 
Both the alanine and the cysteine point mutations cause the active site serine to lose an 
oxygen molecule which is a key nucleophile in the catalysis of the cleavage reaction. In the 
alanine mutant this is replaced with an unreactive carbon, whilst in the cysteine mutant the 
oxygen is replaced with a thiol group which is a much weaker nucleophile. This gives a fully 
inactive mutant and a weakly active mutant, both of which could then be used for structural 
characterisation studies. 
The production of all of these mutants was confirmed by sequencing at the Core Genomics 
facility located in the University of Sheffield Medical School 
(http://genetics.group.shef.ac.uk). These were then all transformed into M72 E. coli cells 
ready for protein expression testing, as described in section 2.6.8 
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5.2.4 Expression of the IgA1P mutant strains 
Expression of the mutant strains was characterised using the method outlined in section 
2.1.6. In this case the IgA1P proteins were expressed overnight for around 16 hours at 42oC 
before being analysed using SDS PAGE. 
 
Figure 50. A 12% acrylamide SDS PAGE showing the expression of various IgA1P constructs. 
The lane on the left of the paired lanes indicates the pellet obtained after centrifugation 
whilst the right hand lane corresponds to the supernatant. Lane 1 Pierce unstained protein 
MW marker (ThermoFisher), lanes 2-3 Uninduced full length IgA1P alanine mutant, lanes 4-
5 induced full length IgA1P alanine mutant, lanes 6-7 uninduced wildtype IgA1P with a β core 
deletion, lanes 8-9 induced wildtype IgA1P with a β core deletion, lanes 10-11 uninduced 
IgA1P cysteine mutant with a β core deletion, lanes 12-13 induced IgA1P cysteine mutant 
with a β core deletion, lanes 14-15 uninduced IgA1P alanine mutant with a β core deletion 
and a 6 histidine tag, lanes 16-17 induced IgA1P alanine mutant with a β core deletion and a 
6 histidine tag. 
 
As can be seen above multiple different strains were tested for expression, after many trial 
runs a set of conditions were found under which most mutant proteases would express. 
What should be noted is that once more the expression level is not very high, but it was 
sufficient for structural analysis by circular dichroism to be carried out, as described in 
section 5.2.5. The wildtype IgA1P and the created IgA1P mutants were purified from induced 
lysed cell pellets. Cell pellets were lysed and treated as in section 2.2.3 and purified using a 
nickel affinity resin (section 2.2.3) or size exclusion chromatography as detailed in section 
2.7.4. Unfortunately, due to the low level of expression exhibited by both the wildtype and 
mutant IgA1P proteins any images of SDS PAGE gels containing the pure protein were very 
faint and thus unusable in this document. IgA1P was not verified by mass spectrometry, 
however the size of the protein along coupled with the fact that the band only appeared in 
induced bacteria containing an IgA1P plasmid indicated that the protein was most likely 
IgA1P. 
5.2.5 Analysis of the neisserial IgA1P protein using circular dichroism 
Purified IgA1P cysteine mutant at 0.18 mg/ml was used in a circular dichroism experiment as 
described in section 2.3.4.  
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Figure 51. The circular dichroism spectrum for IgA1P cysteine mutant. The spectrum 
unfortunately shows very little data as the blank (1xPBS) actually absorbed more greatly than 
the protein.  
Figure 51 shows that despite the relatively high concentration of IgA1P the circular dichroism 
spectrum shows very little absorbance, but the little spectra that can be seen gives a mostly 
α helical spectra. This contradicts what is predicted for the structure of IgA1P, but the very 
low intensity of the absorbance means that the result should likely be discarded. 
5.3 Conclusions 
Neisserial IgA1P is a widely studied protein in terms of function but as of yet there is very 
little known about its structure 34,35,85,96 . The information that is predicted for the neisserial 
structure comes from extrapolation of the Haemophilus influenzae IgA1P structure 75  and so 
is at best a guess. The work contained within this chapter goes someway to setting up a wide 
variety of structural analyses in the future, by creating more easily purifiable proteases as 
well as more stable protease which can be used for crystallography and spectroscopy trials. 
These mutants will allow a much greater understanding of the IgA1P structure, rather than 
the threading or prediction based models that are currently in use 81 .  
These mutants are predicted to be much more stable than the wildtype IgA1P and as a result 
are also more useful in vaccine and drug design. IgA1P is a predicted meningococcal virulence 
factor predicted to be involved in the switching of the pathogen from commensal to invasive 
34,35 , whilst simultaneously protecting the bacteria from the effects of the immune system 
through a number of cleavage interactions 35,84,100 . As a result, the IgA1P is thought to be a 
potential vaccine candidate for meningococcal disease and in particular disease caused by 
Neisseria meningitidis. The increased stability of these new mutant IgA1P proteins would 
allow them to be included in vaccine trials more easily as they will no longer be capable of 
degrading themselves, in theory this should increase the effectiveness of the vaccine. What 
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has also been shown about IgA1P is it is capable of creating a very large immunogenic 
response when expressed during meningococcal disease 25,101 , probably due to its large size, 
this again raises the question about whether it would be a good addition to a neisserial or 
meningococcal vaccine.  
Unfortunately attempts to study the IgA1P cysteine mutants using circular dichroism failed 
to provide and useful data. Normally proteins for analysis using circular dichroism are used 
at a concentration of 0.1 mg/ml, however in this study the IgA1P mutant was at nearly double 
that concentration but still failed to absorb properly. This could be due to the large size of 
IgA1P, this large size increases its molecular weight and decreases the number of protein 
molecules found at such a low concentration. For example, in 100 μl of α at 0.1 mg/ml there 
would be around 3.2x1017 molecules present whereas for IgA1P at the same concentration 
the would be around 5.0x1016 molecules, a 10 fold reduction in the number of molecules 
present, therefore in order to get a similar intensity spectrum the IgA1P would need to be at 
0.9-1 mg/ml. In the future this could be easily be achieved using one of the new IgA1P mutant 
strains that is much easier to purify. 
This chapter whilst not answering many of the research questions it set out to has instead 
laid the groundwork for future study of neisserial IgA1P by creating a number of IgA1P 
mutant strains that have a predicted decrease in activity and are easier to express an purify. 
In the future this will allow much greater study of the proteases structure and allow for more 
thorough investigations into its potential as a vaccine candidate.  
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Chapter 6- Conclusions and future 
work 
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6. Conclusions and future work 
As has been discussed in previous chapters the experimental results in this chapter have 
helped to add to the existing published work on neisserial α and IgA1P whilst building a 
platform for ongoing experimental work. 
The α protein currently has very little published structural and functional data. Previous 
studies have outlined its general secondary structure and that it may be involved in targeting 
IgA1P into host cells using NLS and that it may have a role in binding eDNA 111,112 . In this thesis 
this role has been expanded to also include host protein interactions, via bikunin or IαI and 
a high immunogenicity and ability to invoke a long lasting immune system memory 25 . These 
role shave helped to expand the understanding of the neisserial α protein and also hinted 
that it could be used in future vaccine development as a carrier protein or as a potential tool 
for biotechnology as a host cell targeting protein. These roles were previously thought of, 
but this study has helped to provide the data necessary to confirm these hypotheses.  
With regards to the structural characterisation of α previous studies have shown that it is a 
long α helical monomer containing multiple NLS and T cell helper epitopes 25,111 , whilst as yet 
unpublished data from the University of Sheffield has also shown that the protein is capable 
of forming large multimers in crystallo. The research carried out in this thesis has helped to 
confirm the observation that α can multimerise by showing multimerisation in solution using 
multiple different methods. The multimerisation shown in solution however is markedly 
different from the multimerisation in crystallo, in that in crystallo multimers comprised of up 
to 24 monomers are formed whilst in solution this drops to 2-3. In order to confirm this 
crystal structure the crystallography trials should be repeated as before but at a much lower 
concentration. The crystal structure shown in this thesis (Figure 22) was obtained at around 
100 mg/ml, in order to more closely mirror physiological conditions whilst still retaining the 
ability to form crystals these trials should be repeated a lower concentration, possibly around 
10-15 mg/ml. It is hypothesised that under these conditions the crystals will more likely show 
trimers of α that are similar to those found in solution. 
The development of multiple cysteine labelled α proteins has helped to lay the groundwork 
for further study both structurally and into this ability to act as a carrier protein. The cysteine 
residues will both provide single points for thiol modification allowing 1:1 cross linking of the 
α protein to target proteins, whilst also helping to stabilise multimer formation in solution. 
This multimer formation is thought to be key to its ability to induce a large immunogenic 
response and increased renal clearing times, as a result these cysteine modified proteins 
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should provide a great foundation for studying the in vivo effects of α as a carrier protein. 
This multimer stabilisation should aid crystallisation as well as multimer formation, this will 
allow research to be carried out to determine whether multimer formation is crucial to the 
function of the α protein. This could be studied by measuring the affinity of alpha binding to 
a substrate, such as bikunin, in both monomer and multimer form using technology such as 
the BLItz system. If any change in affinity for the substrate is detected in either form, this 
may indicate that α protein has a functional form in vivo. 
Further to these mutant strains the research contained in this thesis has shown that the 
protein itself coupled with its T cell helper epitopes seem to be able to elicit a large immune 
response in a mouse model. Until now the ability to use α as a tool for biotechnology or a 
carrier protein had been speculated, but this work provides the first proof that α could 
certainly be used as a carrier protein. In order to further prove this the as yet untested serum 
provided from the New Zealand white rabbit immunisations may provide further evidence 
for this carrier protein role, these will have to be tested via ELISA to produce antibody titre 
data. This antibody titre data can then help to confirm the observations made in the BALB/C 
mouse model by indicating that in the presence of α the immunogenicity of other proteins is 
increased. If the rabbit sera confirms the observations made in the mouse model the next 
step would be to compare the efficacy of α to commonly used carrier proteins such as 
tetanus toxoid or diphtheria toxoid, both in terms of ability to induce a large immune 
response upon inoculation and the ability to produce a long lasting immune system memory. 
This data would be invaluable in evaluating the potential of the neisserial α protein as a 
carrier protein in vaccine development. 
The relatively little functional data published on neisserial α has shown its ability to bind 
eDNA and its ability to target IgA1P to host cells 111,112 . These most likely cover the major 
roles of α in vivo but until now very little work has been done on elucidating a protein binding 
partner in the host. In this study the observation that α most likely interacts with IαI through 
a bikunin domain has been further investigated. The data contained in this thesis shows that 
whilst α in unable to bind IαI from pig serum it does interact with a number of proteins from 
human serum. In order to further characterise this interaction, proteins that interact with α 
should be isolated using a pull down experiment and subjected to mass spectroscopy. This 
would give a much clearer understanding of how the α protein elicits a response in vivo and 
what its major role is in infection and colonisation.  
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IgA1P is the founding member of the type Va autotransporter family, which since its 
discovery in 1973 has been well researched both functionally and structurally72. Research 
into the export pathway has shown that IgA1P, despite its family name, requires multiple 
other factors in order to export properly and carry out its function in vivo 103,104. This function 
has been well characterised thus far and seems to involve triggering invasive disease by 
protecting the bacteria from neutralisation by the host immune system whilst also causing 
the inflammatory response associated with invasive meningitis34,35,84,100. The only area with 
lacking research regarding neisserial IgA1P is structural studies, there is currently only one 
published structure for IgA1P and that is from Haemophilus influenzae75. Whilst these 
proteins share homology to one another in order to carry out proper drug design and 
characterisation study an accurate structure is required. The research contained within this 
thesis on neisserial IgA1P, whilst not adding greatly to the current published knowledge has 
created a number of mutant proteins and a reliable way of expressing and purifying protein 
which should enable rapid further study of IgA1P, both structurally and functionally.  
Currently the only available structures of neisserial IgA1P are derived from prediction based 
models utilising the published Haemophilus influenzae IgA1P structure 75 . While this are a 
useful starting point for protein characterisation they are often flawed and so reliable and 
accurate structural data is required if further research is to be carried out on the protein. The 
plasmid construct and purification methods contained in chapter 5 have shown that a pure 
IgA1P protein can be obtained relatively easily, although the yield of this purification is very 
low. In order to begin structural characterisation circular dichroism and crystallography trials 
should be carried out using the inactive or very weakly active mutant IgA1P proteins created 
in this research. These proteins would enable the protease to be more easily purified and 
crystallised, as the WT IgA1P has a tendency to undergo auto proteolytic cleavage and quickly 
degrade itself in solution. This means that under normal conditions the WT IgA1P cannot be 
used to produce accurate structural data, due to its incomplete nature. These structural trials 
should provide an accurate IgA1P structure that can then be used in further research. In 
conjunction with this dynamic light scattering trials should also be carried out in the presence 
of IgA. Dynamic light scattering is a fast but low resolution method of determining the 
orientation in which a substrate is bound to a protein. It uses the backwards scattering of 
incident laser light caused when the light strikes the particle to determine the dimension 
known as hydrodynamic diameter, this equates to the size of the molecule 122 . Due to the 
large size of the substrate the orientation of substrate binding will alter the reported 
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hydrophobic diameter, it is therefore possible to calculate the orientation of binding as well 
as any dimerisation of substrate or protein.  
 
Figure 52. A pictorial representation of the principle of dynamic light scattering. Depending 
upon the orientation of binding the reported hydrophobic size alters, therefore using the 
reported hydrophobic size along with the dimensions of the proteins in question it is possible 
to elucidate the orientation of binding and whether any dimerisation has occurred. 
 
 This would give an indication as to where the substrate binds the protease and whether the 
smaller domains in the protease are involved in orientating the substrate, at the time of 
writing there are many theories on substrate binding orientation but very little evidence for 
any of them. This experiment would provide the much needed evidence that would answer 
how the IgA1P protein binds its substrates. 
Further to this structural study more functional trials could be carried out on neisserial IgA1P 
with regards to its substrate specificity. It has been previously published that neisserial IgA1P 
exhibits a broad range of substrates in vitro, including IgA1, LAMP and TNFRII. However, the 
affinity of IgA1P for these substrates has never been demonstrated, as such the affinity for 
IgA1P for each substrate could be measured in vitro. This would provide a crucial indication 
as to whether or not these interactions are likely to occur at physiological concentrations or 
whether they are an artefact of in vitro methodology. 
Alongside this structural and functional work, the potential of IgA1P as a vaccine candidate 
could be evaluated using a serum bactericidal assay. In this assay anti- neisserial IgA1P 
antibodies could be incubated with a variety of commensal and invasive isolates grown in 
conditions similar to that found in the nasopharynx or bloodstream to test whether the 
inhibition of IgA1P is sufficient to slow bacterial growth or promote bacterial death. 
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Overall this work has helped to expand the current published knowledge on both the 
Neisseria meningitidis α and IgA1P proteins whilst creating several mutant proteins which 
will enable further rapid study of both proteins. 
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Appendix I- PCR primers 
Alpha N His insertion  
AlphaNHis_ndeR2 5’ AGCAGCCAACTCTGCAGCTATTTAAGCTGTATCACGGTGGTAT  3’ 
AlphaNHis_ndeF 5’AAATACATATGCATCATCACCACCATCATAGCCCGCAGGCAAATCAAGCCGAA 
3’ 
Short_alphaNH    5’ ATAAACATATGCATCATCACCACCATCACAGCCCGCAGGCAAATC 3’ 
Alpha_revstop     5’ GATGAAGCTTTATTACGGTGGTATAGCCCTGCG 3’ 
Alpha_RBH2         5’ gatgaagcggatccccggtggtatagccctgcg 3’ 
alphaNhis_F         5’ caccaccacAGCCCGCAGGCAAATCAA 3’ 
alphaNhis_R        5’ atgatgatgCATAATTAAATCCTCGATGAATTCTGATGTG 3’ 
 
Alpha-gly fusion 
Alpha_fus_rev2   5’ ACGACGTTTGGGTTGGCCTCCCCACGGACCGCCAGATTGTGCTGCTTG 
M13 uni (-21)       5’ TGTAAAACGACGGCCAGT 
Gly1_Fus_F2        5’ CAAACCGTGTGGGCGGGCGGTCCGTGGGGAGGCGATACGGTGTTTTCCT 
M13 rev (-49)      5’ GAGCGGATAACAATTTCACACAGG 
Gly1_fus_F1         5’ TGGAGGAGGTCGAACTGATACGGTGTTTTCCTGTAAAACGG 3’ 
Alpha_fus_Rev1   5’ ACTTCCACCACCTCCACATTGTGCTGCTTGGC 3’ 
NeisGly_Btg1F     5’ TTCCGACAGGccgcggGGTATGGGCAGCGG 3’ 
NeisGly_Btg1R     5’  CGCCCCAACAGGTCAGCT 3’ 
NeisGly_Xho1F    5’ AGGTATGGGCctcgagCGTTGGGCAACGATG 3’ 
NeisGly_Xho1R     5’ TGCCACCTGTCGGAACGC  3’ 
Alpha499Btg1F     5’ ggcggatcaAGCCCGCAGGCAAATCAA3’ 
Alpha499Btg1R     5’ tccccgcggAATTAAATCCTCGATGAATTCTGATGTG 3’ 
Alpha1024Xho1F   5’ tcactcgagCCAAAGCTTGGCGTAATC 3’ 
Alpha1024Xho1R    5’ tccgcctccCCTGCGGTTACGACGTTT 3’ 
 
Cysteine mutations within alpha 
55C_alpha_F           5’ AAAAGCAGAATGTGAACGCAGCAGCGCCGAACTTGC 3’ 
55C_alpha_R          5’ TGGCGGGGTCGCCAGCTCT 3’ 
91C_alpha_F          5’ TCAAGCATTGTGTGTACGCCGAAAAGCAGAAGCC 3’ 
91C_alpha_R          5’ GCCCTCACGTTCGGCTTCG 3’  
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IgAP beta spine truncation 
IgAP trunc 753 F     5’ caccactagtagGTTAATCAATCCGCATCATTCTC 3’ 
IgAP trunc 753 R     5’ gtgatgatgatgCGCAATTTCTGCGGCTTTG 3’ 
IgAP trunc 818 F     5’ caccactagtagGCGACACAGATTAACGGC 3’ 
IgAP trunc 818 R     5’ gtgatgatgatgTCCAAAGCTGTTTAAAGCC 3’ 
 
IgAP SA mutation 
Ex_forIgAP1             5’ CAACCAGTGCAGGCGGCGGCGTTGAAACCTATAAAGATAAAAACCGT 3’ 
SArev_1                    5’ CAAATAATGGTGAACCGGCATCGCCTAACACAG 3’ 
SAfor_1                     5’ TGCTGTGTTAGGCGATGCCGGTTCACCATTATTTG 3’ 
Ex_revIgAP1             5’ GCATCCAAACGACCGCCACGGAAACCGAAATATAGG 3’ 
 
Adding 6 his tag to IgA1P 
IgAPprism6H          5’ ATAAACATATGCATCATCACCACCATCACGGAGCGACACAGATTA 3’ 
IgAPγHis_F             5’ tcatcaccaccacCCTGCCACAAACACGGCT 3’ 
IgAPγHis_R             5’ tgatgggatccgccAGACGGGACCGGTTTGAC 3’ 
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Appendix II- Plasmid sequences and inserts 
pJONEX4 
TCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACA
GCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGG
CGGGTGTCGGGGCTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATA
TGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCGCATCAGGCGCCATTCGCCA
TTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCT
GGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCAC
GACGTTGTAAAACGACGGCCAGTGAATTAGATAACCATCTGCGGTGATAAATTATCTCTGGC
GGTGTTGACATAAATACCACTGGCGGTGATACTGAGCACATCAGAATTCGAGCTCGGTACCC
GGGGATCCTCTAGAGTCGACCTGCAGGCATGCAAGCTTGGCGTAATCATGGTCATAGCTGTT
TCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGT
GTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCC
GCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAG
AGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCG
TTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCA
GGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAA
GGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGAC
GCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGA
AGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCT
CCCTTCGGGAAGCGTGGCGCTTTCTCAATGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGG
TCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTA
TCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGC
CACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGT
GGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTT
ACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGG
TTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGA
TCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATG
AGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAAT
CTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTA
TCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACT
ACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTC
ACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTC
CTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGT
TCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTC
GTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCC
CCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTG
GCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATC
CGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGC
GGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACT
TTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCT
GTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTT
TCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGG
GCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCA
GGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGG
TTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATTATTATCATGACA
TTAACCTATAAAAATAGGCGTATCACGAGGCCCTTTCGTC                 
 
pJONEX4 with NMB α Insert 
TCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACA
GCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGG
CGGGTGTCGGGGCTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATA
TGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCGCATCAGGCGCCATTCGCCA
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TTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCT
GGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCAC
GACGTTGTAAAACGACGGCCAGTGAATTAGATAACCATCTGCGGTGATAAATTATCTCTGGC
GGTGTTGACATAAATACCACTGGCGGTGATACTGAGCACATCAGAATTCATCGAGGATTTAA
TTATGAGCCCGCAGGCAAATCAAGCCGAAGAAGCAAAACGCCAACAAGCAAAAGCGGAGCAA
GTGAAGCGTCAGCAAGCAGAAGCAGAGCGTAAATCGGCAGAGTTAGCAAAACAAAAAGCAGA
AGCCGAACGCGAAGCAAGAGAGCTGGCGACCCGCCAAAAAGCAGAACAAGAACGCAGCAGCG
CCGAACTTGCACGTCGACATGAAAAAGAACGCGAAGCGGCAGAGTTGTCGGCAAAACAAAAA
GTCGAAGCCGAACGTGAGGCTCAAGCATTGGCGGTACGCCGAAAAGCAGAAGCCGAAGAGGC
AAAACGCCAAGCTGCAGAGCTTGCACGCCAACAAGAAGAAGCACGAAAAGCTGCAGAGTTGG
CTGCTAAGCAAAAAGCGGAAACTGAACGCAAAGCAGCAGAAATTGCCGAGCAAAAAGCGGAA
GCCGAACGTGAAGCCGCCGAACTTGCCAAGCAAAAGGCGGAAGAAGAAGGTCGCCAAGCAGC
ACAATCTCAACCCAAACGTCGTAACCGCAGGTAGATACCAAAGCTTGGCGTAATCATGGTCA
TAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAG
CATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCT
CACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGC
GCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCG
CTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCA
CAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAAC
CGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAA
AAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTC
CCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCC
GCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCAATGCTCACGCTGTAGGTATCTCAGTTC
GGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCT
GCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTG
GCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTT
GAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGA
AGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGT
AGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGA
TCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTT
TGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTT
AAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGA
GGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGT
AGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGAC
CCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAG
AAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAG
TAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTG
TCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTAC
ATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAA
GTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTC
ATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATA
GTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATA
GCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATC
TTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATC
TTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGG
GAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGC
ATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACA
AATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATTATTA
TCATGACATTAACCTATAAAAATAGGCGTATCACGAGGCCCTTTCGTC 
pJONEX4 with Cys-γ-α insert 
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TCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACA
GCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGG
CGGGTGTCGGGGCTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATA
TGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCGCATCAGGCGCCATTCGCCA
TTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCT
GGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCAC
GACGTTGTAAAACGACGGCCAGTGAATTAGATAACCATCTGCGGTGATAAATTATCTCTGGC
GGTGTTGACATAAATACCACTGGCGGTGATACTGAGCACATCAGAATTCATCGAGGATTTAA
TTATGTGCCCGGTCCCGTCTCCTGCCACAAACACGGCTTCTCAAGCACAAACGGACAGTGCA
CAAATCGCCAAGCCTCAAAATATCGTCGTCGCACCGCCTAGCCCGCAGGCAAATCAAGCCGA
AGAAGCAAAACGCCAACAAGCAAAAGCGGAGCAAGTGAAGCGTCAGCAAGCAGAAGCAGAGC
GTAAATCGGCAGAGTTAGCAAAACAAAAAGCAGAAGCCGAACGCGAAGCAAGAGAGCTGGCG
ACCCGCCAAAAAGCAGAACAAGAACGCAGCAGCGCCGAACTTGCACGTCGACATGAAAAAGA
ACGCGAAGCGGCAGAGTTGTCGGCAAAACAAAAAGTCGAAGCCGAACGTGAGGCTCAAGCAT
TGGCGGTACGCCGAAAAGCAGAAGCCGAAGAGGCAAAACGCCAAGCTGCAGAGCTTGCACGC
CAACAAGAAGAAGCACGAAAAGCTGCAGAGTTGGCTGCTAAGCAAAAAGCGGAAACTGAACG
CAAAGCAGCAGAAATTGCCGAGCAAAAAGCGGAAGCCGAACGTGAAGCCGCCGAACTTGCCA
AGCAAAAGGCGGAAGAAGAAGGTCGCCAAGCAGCACAATCTCAACCCAAACGTCGTAACCGC
AGGTAGATACCAAAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATC
CGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAA
TGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCT
GTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGC
GCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTA
TCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAA
CATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTT
TCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGA
AACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCC
TGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGC
TTTCTCAATGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGC
TGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGA
GTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCA
GAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACT
AGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGG
TAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGC
AGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGAC
GCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTT
CACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAA
CTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTT
CGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACC
ATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAG
CAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCC
ATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCG
CAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCAT
TCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCG
GTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCAT
GGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGA
CTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGC
CCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGG
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AAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGT
AACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGA
GCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAAT
ACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCG
GATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGA
AAAGTGCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAATAGGCG
TATCACGAGGCCCTTTCGTC 
pJONEX with wildtype neisserial IgA1P insert (based on IgAp from accession number 
AF235032.1) 
TCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACA
GCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGG
CGGGTGTCGGGGCTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATA
TGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCGCATCAGGCGCCATTCGCCA
TTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCT
GGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCAC
GACGTTGTAAAACGACGGCCAGTGAATTAGATAACCATCTGCGGTGATAAATTATCTCTGGC
GGTGTTGACATAAATACCACTGGCGGTGATACTGAGCACATCAGAATTCAAACCTTATGAAA
ACCAAACGTTTTAAAATTAACGCCATATCCTTATCCATCTTTCTTGCCTATGCCCTTACGCC
ATACTCAGAAGCGGCATTGGTCAGAGACGATGTCGATTATCAAATATTCCGTGACTTTGCAG
AAAACAAAGGCAAATTTTTTGTCGGCGCAACCGATTTATCAGTGAAAAACAAACAAGGTCAA
AACATCGGCAACGCATTATCCAACGTACCGATGATTGATTTTAGCGTTGCAGATGTCAACAG
ACGTACATTAACCGTCATCGATCCCCAGTATGCCGTCAGCGTCAAACATGTAAAAGGAGACG
AAATCTCTTATTACGGGCATCACAATGGGCACTTAGATGTTAGCAATGATGAAAACGAATAT
CGTTCAGTTGCACAAAATGACTACGAACCAAATAAAAATTGGCATCACGGTAATCAAGGTCG
TCTTGAAGACTACAACATGGCACGCCTTAATAAATTCGTAACAGAAGTCGCACCTATTGCAC
CAACCAGTGCAGGCGGCGGCGTTGAAACCTATAAAGATAAAAACCGTTTTTCTGAGTTTGTG
CGAGTTGGAGCAGGTACGCAATTTGAATATAACAGCCGCTACAATATGACAGAGCTTTCACG
AGCTTATCGTTATGCCATTGCAGGTACGCCTTATCAAGACGTGAATGTCACATCGAATCTAA
ATCAAGAAGGCTTGATTGGCTTCGGTGATAATTCAAAACATCATTCCCCAGAAAAACTCAAA
GAAGTTTTATCTCAAAACGCATTGACTAACTATGCTGTGTTAGGCGATAGCGGTTCACCATT
ATTTGCTTATGATAAACAAGAAAAACGCTGGGTCTTTTTAGGTGCTTACGATTATTGGGCAG
GCTATCAAAAAAACTCTTGGCAAGAATGGAATATCTATAAAAAAGAATTTGCAGATAAAATC
AGACAACGCGATAACGCCGGCACCATCAAAGGTAATGGAGAACATCATTGGAACATTACTTT
TGGCACAAACAGCAAGATTGGTTCTACAGCGGTAAGGCTTGCCGGCAATGAAAAGGATGCAA
ACAACGGACAGAATGTTACCTTTGAAGACAACGGCACTTTGGTATTGGATCAAAACATCAAC
CAAGGCGCGGGCGGTCTGTTTTTCAAAGGCGATTACACAGTCAAAGGTATAAATAATGACAT
CACTTGGCTAGGTGCGGGGATTGATGTTACCGACGGCAAAAAAGTCGTTTGGCAAGTCAAAA
ATCCGAACGGCGACAGATTGGCAAAAATCGGCAAAGGCACATTAGAAATAAACGGCACAGGC
GTTAACCAAGGGCAATTAAAAGTCGGCGACGGTACGGTTATTCTGAATCAACAAGCCGATGC
CGACAAAAAAGTCCAGGCTTTCTCCCAAGTCGGCATTGTCAGCGGACGCGGTACATTGGTAT
TAAATAGTTCAAATCAGATTAATCCCGATAACCTATATTTCGGTTTCCGTGGCGGTCGTTTG
GATGCCAATGGCAATGACTTGACTTTTGAACACATCCGCAACGTGGATGAAGGCGCGCGCAT
TGTCAACCACAACACAAGCCACGCCTCCACGATCACGCTAACGGGTAAATCTTTAATTACCA
ATCCGAACAGCCTTTCGGTACATAGCATACAAAATGACTATGACGAAGATGATTATAGTTAT
TACTACCGACCAAGGCGCCCGATTCCGCAAGGCAAAGACCTTTATTACAAAAACTATCGTTA
TTACGCCCTAAAATCCGGCGGCAGCGTGAACGCACCGATGCCCGAGAACGGTGTAACAGAAA
ATAACGACTGGGTCTTTATGGGATATACGCAAGAAGAAGCCAAGAAAAACGCGATGAACCAC
AAAAACAATCAGCGTATTAGCGGTTTTAGCGGTTTCTTTGGCGAAGAAAACGGAAAAGGACA
TAACGGTGCATTAAACCTTAATTTCAACGGCAAAAGCGCGCAAAACCGTTTCTTGTTAACAG
GCGGCACTAATTTAAACGGAAAAATAAGCGTAACTCAAGGCAATGTCTTGTTATCAGGTCGT
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CCAACACCACACGCAAGAGATTTTGTGAACAAATCTTCAGCCCGAAAAGACGCACATTTCTC
CAAAAACAATGAAGTCGTATTTGAAGACGACTGGATAAACCGCACATTCAAAGCCGCAGAAA
TTGCGGTTAATCAATCCGCATCATTCTCTTCCGGTAGAAATGTATCCAACATTACCGCCAAC
ATCACCGCGACAGACAACGCCAAAGTAAATTTGGGTTACAAAAACGGCGATGAGGTTTGCGT
GCGCTCGGACTATACCGGTTATGTTACCTGCAACACAGGCAACTTATCCGATAAGGCTTTAA
ACAGCTTTGGAGCGACACAGATTAACGGCAATGTGAATCTGAACCAGAATGCGGCATTGGTC
TTGGGCAAGGCTGCATTATGGGGGCAAATTCAAGGGCAAGGAAACAGCCGTGTCAGCCTAAA
CCAACATAGCAAATGGCATTTGACTGGCGACAGCCAAGTACACAATCTGTCATTGGCGGATA
GCCATATTCATTTGAACAATGCCTCCGATGCGCAAAGTGCAAATCAATACCACACGCTCAAA
ATCAATCATTTATCCGGTAACGGGCATTTTCATTACCTGACGCACTTGGCGGAAAATCTTGG
AGATAAAGTGCTTGTGAAGGAATCCGCATCCGGTCATTATCAGCTCCATGTTCAAGATAAAA
CAGGCGAACCCAATCAGGAAGGGCTGAATCTCTTTGATGCATCATCCGTACAAGACCGCTCC
CGCCTTTCTGTTTCCTTGGCGAATAACCATGTAGATTTAGGCGCATTGCGTTATACAATCAA
AACAGAAAACGGTATTACCCGATTGTACAATCCTTATGCCGAGAACCGCCGCCGAGTCAAAC
CGGTCCCGTCTCCTGCCACAAACACGGCTTCTCAAGCACAAACGGACAGTGCACAAATCGCC
AAGCCTCAAAATATCGTCGTCGCACCGCCTAGCCCGCAGGCAAATCAAGCCGAAGAAGCAAA
ACGCCAACAAGCAAAAGCGGAGCAAGTGAAGCGTCAGCAAGCAGAAGCAGAGCGTAAATCGG
CAGAGTTAGCAAAACAAAAAGCAGAAGCCGAACGCGAAGCAAGAGAGCTGGCGACCCGCCAA
AAAGCAGAACAAGAACGCAGCAGCGCCGAACTTGCACGTCGACATGAAAAAGAACGCGAAGC
GGCAGAGTTGTCGGCAAAACAAAAAGTCGAAGCCGAACGTGAGGCTCAAGCATTGGCGGTAC
GCCGAAAAGCAGAAGCCGAAGAGGCAAAACGCCAAGCTGCAGAGCTTGCACGCCAACAAGAA
GAAGCACGAAAAGCTGCAGAGTTGGCTGCTAAGCAAAAAGCGGAAACTGAACGCAAAGCAGC
AGAAATTGCCGAGCAAAAAGCGGAAGCCGAACGTGAAGCCGCCGAACTTGCCAAGCAAAAGG
CGGAAGAAGAAGGTCGCCAAGCAGCACAATCTCAACCCAAACGTCGTAACCGCAGGGCTATA
CCACCGGAACTGTCATCTGATGCAACAACCCGAGCTTTGCCTAGGATAGCGAGAAATTCAAA
TCCTGATGCCAGCGATTATGAAAAAATCCCCTTGGATGCGTTGGAAGATGAAGATGTATCCG
AATCGGTTGACACATCAGACAAACAGCCTCAAGACAATACGGAACTTCATGAAAAAGTTGAG
ACAGTGAGTTTGCAACCAAGAGCCGCGCAGCCGCGAGCCCAAGCCGCCGCGCAAGCCGATGC
AGTCAGCACCAATACCAACTCGGCTTTATCTGACGCAATGGCAAGCACGCAATCTATCTTGT
TGGATACAGGTGCTTCATTAACACGGCACATTGCACAAAAATCACGTGCTGATGCCGAAAAG
AACAGCGTTTGGATGTCGAACATCGGTTATGGCCGTGATTATGCTTCCGCACAATATCGCCG
GTTTAGTTCGAAACGCACGCAAACACAAATCGGCATTGACCGCAGCTTGTCCGAAAATATGC
AGATAGGCGGCGTATTGACTTACTCTGACAGTCAGCATACTTTTGATCAGGCGAGCGGCAAA
AATACTTTTGTGCAAGCCAACCTTTATGGTAAGTATTATTTAAATGATGCTTGGTATGTGGC
CGGCGATATTGGTGCAGGCAGCTTGAGAAGCCGGTTACAAACGCAGCAAAAAGCAAACTTTA
ACCGAACAAGCATCCAAACCGGCCTTACTTTGGGCAATACGCTGAAAATCAATCAATTCGAG
ATTGTCCCCAGTGCGGGAATCCGTTACAGCCGCCTGTCATCTGCAGATTACAAGTTGGGTAA
CGACAGTGTTAAAGTAAGTTCTATGTCAGTGAAGACACTGACGGCCGGACTGGATTTTGCTT
ATCGGTTTAAAGTCGGCAACCTTACCGTAAAACCCTTGTTATCTGCAGCTTACTTTGCCAAT
TATGGCAAAGGCGGCGTGAATGTGGGCGGTAATTCCTTCGCCTATAAAGCAGATAATCAACA
GCAATATTCAGCAGGTGCCGCGTTACTGTACCGTAATGTTACATTAAACGTAAATGGCAGTA
TTACAAAAGGCAAACAATTGGAAAAACAAAAATCCGGACAAATTAAAATACAGATTCGTTTC
TAAAATACTAAATTCATAGCAAAATAAAATGCCGTCTGAACTCAGGCTCTAAGCTTGGCGTA
ATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATAC
GAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATT
GCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAAT
CGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTG
ACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATA
CGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAA
GGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACG
AGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATAC
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CAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGG
ATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCAATGCTCACGCTGTAGGT
ATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAG
CCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTT
ATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTA
CAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGC
GCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAAC
CACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGAT
CTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGT
TAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAA
ATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCT
TAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTC
CCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGAT
ACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGG
CCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGG
GAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGG
CATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAA
GGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATC
GTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTC
TCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCAT
TCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACC
GCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACT
CTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGAT
CTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCC
GCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATA
TTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGA
AAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCTAAGAA
ACCATTATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGCCCTTTCGTC 
pJONEX with the gene for Gly1-ORF1 from N. meningitidis inserted 
TCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACA
GCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGG
CGGGTGTCGGGGCTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATA
TGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCGCATCAGGCGCCATTCGCCA
TTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCT
GGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCAC
GACGTTGTAAAACGACGGCCAGTGAATTAGATAACCATCTGCGGTGATAAATTATCTCTGGC
GGTGTTGACATAAATACCACTGGCGGTGATACTGAGCACATCAGAATTCTAAGGAAATACGA
TGAAAAAAATGTTCCTTTCTGCCGTATTGCTTCTGTCGGCTGCCGCCCAAACCGTGTGGGCG
GATACGGTGTTTTCCTGTAAAACGGACAACAACAAATACATAGAAGTCCAAAAAATCAACCG
CAATCTTTACGAATATTCGTTCGGCAGTGCGGCAAAAAAAGAAATTGCCATACGCAACAGCA
AAGCTGACCTGTTGGGGCGTTCCGACAGGTGGCAAGGTATGGGCAGCGGTCGTTGGGCAACG
ATGAAATTCCAAAACGGCGAATTTATGTACACCATATGGACAGGCTTCGATTCCGTGACTCA
TACGGAAAGCAGCGGTGTCGTTGTGGAGCGTAGGGGCAAGGAAGTCGCACGGGTCGGCTGTA
CGCCGAAAACCGCGCAGGCGAATTTCAACGATGACGATTTTTCCGGGATCCTGCAGGATGAC
GATGACAAACACCATCATCACCATCATTAGAGCTTGGCGTAATCATGGTCATAGCTGTTTCC
TGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTA
AAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCT
TTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGG
CGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTC
GGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGG
GATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGC
CGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCT
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CAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGC
TCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCC
TTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCG
TTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCC
GGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCAC
TGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGC
CTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACC
TTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTT
TTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCT
TTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGA
TTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTA
AAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCT
CAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACG
ATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACC
GGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTG
CAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCG
CCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTC
GTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCA
TGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCC
GCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGT
AAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGC
GACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTA
AAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTT
GAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCA
CCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCG
ACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGG
TTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTC
CGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATTATTATCATGACATTA
ACCTATAAAAATAGGCGTATCACGAGGCCCTTTCGTC 
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Appendix III- Sequencing result for the single cysteine α 
mutants 
 
As can be seen from the figure below, the point mutations at both residue 55 and 91 were 
unsuccessful. The figure below shows the sequencing results translated back into single 
letter amino acid code. 
 
